<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006266.pub2" GROUP_ID="ADDICTN" ID="085506020911062810" MERGED_FROM="" MODIFIED="2011-02-18 12:47:14 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;" NOTES_MODIFIED="2011-02-18 12:47:14 +0100" NOTES_MODIFIED_BY="Laura Amato" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2011-02-18 12:47:14 +0100" MODIFIED_BY="Laura Amato">
<TITLE MODIFIED="2011-02-17 11:12:45 +0100" MODIFIED_BY="[Empty name]">Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses</TITLE>
<CONTACT>
<PERSON ID="13377" ROLE="AUTHOR">
<PREFIX>dr</PREFIX>
<FIRST_NAME>Federica</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vigna-Taglianti</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION>epidemiology consultant</POSITION>
<EMAIL_1>federica.vignataglianti@oed.piemonte.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>University of Piemonte Orientale "A. Avogadro"</ORGANISATION>
<ADDRESS_1>via Solaroli 17</ADDRESS_1>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP>28100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 011 40188305</PHONE_1>
<PHONE_2/>
<FAX_1>+39 011 40188301</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-03-09 19:33:35 +0100" MODIFIED_BY="Federica Vigna-Taglianti">
<PERSON ID="17491" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maurizio</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Leone</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>maurizio.leone@maggioreosp.novara.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>SCDU Neurologia</DEPARTMENT>
<ORGANISATION>Aziena Ospedaliero-Universitaria "Maggiore della Carità"</ORGANISATION>
<ADDRESS_1>C Mazzini 18</ADDRESS_1>
<ADDRESS_2/>
<CITY>28100 Novara</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0321 3733 218</PHONE_1>
<PHONE_2>+39 0321 3733 964</PHONE_2>
<FAX_1>+39 0321 3733 298</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13377" ROLE="AUTHOR">
<PREFIX>dr</PREFIX>
<FIRST_NAME>Federica</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vigna-Taglianti</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION>epidemiology consultant</POSITION>
<EMAIL_1>federica.vignataglianti@oed.piemonte.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>University of Piemonte Orientale "A. Avogadro"</ORGANISATION>
<ADDRESS_1>via Solaroli 17</ADDRESS_1>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP>28100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 011 40188305</PHONE_1>
<PHONE_2/>
<FAX_1>+39 011 40188301</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6BF7904E82E26AA20003EB8A5056D0A9" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>GianCarlo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Avanzi</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medical Sciences</DEPARTMENT>
<ORGANISATION>University of Piemonte Orientale "A. Avogadro"</ORGANISATION>
<ADDRESS_1>via Solaroli 17</ADDRESS_1>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP>28100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>0321-3733848</PHONE_1>
<PHONE_2/>
<FAX_1>0321-3733841</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="CD1FC54C82E26AA2008044A2CA06F016" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Romeo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brambilla</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Public Health</DEPARTMENT>
<ORGANISATION>University of Turin</ORGANISATION>
<ADDRESS_1>via Santena 5bis</ADDRESS_1>
<ADDRESS_2/>
<CITY>Turin</CITY>
<ZIP>10126</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>011-40188308</PHONE_1>
<PHONE_2/>
<FAX_1>011-40188301</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6227" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Fabrizio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Faggiano</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>fabrizio.faggiano@med.unipmn.it</EMAIL_1>
<EMAIL_2>fabrizio.faggiano@med.unipmn.it</EMAIL_2>
<URL/>
<MOBILE_PHONE>+ 39 335 480633</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical and Experimental Medicine</DEPARTMENT>
<ORGANISATION>University of Piemonte Orientale "A. Avogadro"</ORGANISATION>
<ADDRESS_1>via Solaroli 17</ADDRESS_1>
<ADDRESS_2/>
<CITY>Novara</CITY>
<ZIP>28100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0321 660661</PHONE_1>
<PHONE_2>+39 011 40188308</PHONE_2>
<FAX_1>+39 0321 660682</FAX_1>
<FAX_2>+39 011 40188301</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-02-18 11:15:55 +0100" MODIFIED_BY="Laura Amato">
<UP_TO_DATE>
<DATE DAY="18" MONTH="2" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2011-02-18 12:47:14 +0100" MODIFIED_BY="Laura Amato">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-18 12:47:14 +0100" MODIFIED_BY="Laura Amato">
<DATE DAY="18" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>The authors amended the review following the suggestions given by Mike Clarke</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-01-11 09:40:41 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-11 09:40:41 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-11 09:40:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>changed status from protocol to review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Regione Piemonte, Ricerca Sanitaria Finalizzata 2006</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<SUMMARY MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<TITLE MODIFIED="2011-02-03 13:11:42 +0100" MODIFIED_BY="[Empty name]">Gamma-hydroxybutyrate for treating symptoms associated with alcohol withdrawal and preventing relapses for people who are dependent on alcohol</TITLE>
<SUMMARY_BODY MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Excessive long term alcohol consumption can lead to dependence on alcohol. This means that when a person stops drinking suddenly he or she experiences withdrawal symptoms. The main goals for clinical management of alcohol withdrawal are to minimize the severity of symptoms and facilitate entry into a treatment program, so that the person can achieve and maintain abstinence from alcohol. Symptoms of withdrawal range from tremor, nausea, anxiety, restlessness and insomnia to more severe effects such as seizures, hallucinations, agitation and delirium. Progression to coma and cardiac arrest is possible. Medications that are intended to help people who are dependent on alcohol to withdraw from it include benzodiazepines, anticonvulsants and gamma-hydroxybutyrate (GHB). GHB was first available as a health food and body-building supplement, but reports of adverse events led to its withdrawal for that purpose.</P>
<P>Thirteen randomised controlled trials involving 648 participants were included in this review. Eleven of these were conducted in Italy. However, there is not enough reliable evidence from the research that has been done to date to be confident of a difference between GHB and placebo, or to determine reliably if GHB is more or less effective than other drugs for the treatment of alcohol withdrawl or the prevention of relapses.</P>
<P>Six trials with a total of 286 participants evaluated the effectiveness of GHB in reducing withdrawal syndrome. These compared the drug with a variety of other interventions, making it impossible to use them all in a single analysis. One study suggests that GHB might reduce withdrawal symptoms more than a placebo, but this is based on a very small number of patients. No strong differences were observed between GHB and benzodiazepines or Clomethiazole. In the other comparisons, the differences were not statistically significant.</P>
<P>Seven trials involving 362 participants tested the use of GHB to treat alcohol dependence or prevent relapses if a person was already detoxified (mid-term outcomes). These included several different comparisons, so each analysis was able to include only one or two trials; and the trials were generally small (range 17 to 98 participants). GHB did appear to be better than Naltrexone and Disulfiram in maintaining abstinence and preventing craving, based on two trials and one trial respectively for these comparisons. The most consistently reported side effect of GHB was dizziness and vertigo, with this being more common at higher doses. The findings of this review should be considered alongside concerns that have been raised about GHB regarding the risk of developing addiction, and the misuse or abuse of the drug, suggesting to use GHB only under strict medical surveillance.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<ABS_BACKGROUND MODIFIED="2011-02-03 10:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>Chronic excessive alcohol consumption may lead to dependence, and to alcohol withdrawal syndrome (AWS) in case of abrupt drinking cessation. Gamma-hydroxybutyric acid (GHB) can prevent and suppress withdrawal symptoms, and improve the medium-term abstinence rate. However, clear estimates of its beneficial and harmful effects have not been yet established.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>To evaluate the efficacy and safety of GHB for the treatment of AWS and the prevention of relapse.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>We searched the Cochrane Drugs and Alcohol Group's Register of Trials (October 2008), PubMed, EMBASE, CINAHL (January 2005 to October 2008), EconLIT (1969 to February 2008), and reference lists of retrieved articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-02-04 08:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCT) and Controlled Prospective Studies (CPS) evaluating the efficacy and the safety of GHB versus placebo or other pharmacological treatments.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-02-04 08:13:31 +0100" MODIFIED_BY="[Empty name]">
<P>Three authors independently extracted data and assessed the methodological quality of the studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Thirteen RCTs were included, 11 of which had been conducted in Italy.</P>
<P>For alcohol withdrawal syndrome, comparing GHB 50mg versus placebo, results from 1 study (23 participants) favour GHB for withdrawal symptoms: MD -12.1 (95% CI -15.9 to -8.29), but tolerated side effects were more frequent in the GHB group: RR 16.2 (95% CI 1.04 to 254.9; based on 7 of 11 patients in the GHB group developing transitory vertigo compared to none in the placebo group). In the comparison of GHB 50mg versus Clomethiazole, results from 1 study (21 participants) favour GHB for withdrawal symptoms: MD -3.40 (95% CI -5.09 to -1.71). For GHB 100mg versus Clomethiazole, results from 1 study (98 participants) favour Clomethiazole for side effects: RR 1.84 (95% CI 1.19 to 2.85).</P>
<P>At mid-term, comparing GHB 50mg/day with placebo, 1 study (71 participants, 3 months follow-up) favour GHB for abstinence rate (RR 5.35, 95% CI 1.28 to 22.4), controlled drinking (RR 2.13, 95% CI 1.07 to 5.54), relapses (RR 0.36, 95% CI 0.21 to 0.63), and number of daily drinks (MD -4.60, 95% CI -6.18 to -3.02). On abstinence, GHB performed better than Naltrexone (NTX) (2 studies, 64 participants) (RR 2.59, 95% CI 1.35 to 4.98 at 3 months) and than Disulfiram (1 study, 59 participants) (RR 1.66, 95% CI 0.99 to 2.80 at 12 months, slightly significant). The combination of GHB and NTX was better than NTX for abstinence (RR 12.3, 95% CI 1.79 to 83.9 at 3 months; 1 study, 35 participants). The combination of NTX, GHB and Escitalopram was better than Escitalopram alone for abstinence (RR 2.02 95% CI 1.03 to 3.94 at 3 months; RR 4.58, 95% CI 1.28 to 16.5 at 6 months; 1 study, 23 participants). For Alcohol Craving Scale, results favour GHB over placebo (MD -4.50, 95% CI -5.81 to -3.19 at 3 months; 1 study, 71 participants) and over Disulfiram at 12 months (MD -1.40, 95% CI -1.86 to -0.94, from 1 study with 41 participants).</P>
<P>All other comparisons and outcomes did not show significant differences.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>There is insufficient randomised evidence to be confident of a difference between GHB and placebo, or to determine reliably if GHB is more or less effective than other drugs for the treatment of alcohol withdrawl or the prevention of relapses. The small amount of randomised evidence available suggests that GHB 50mg may be more effective than placebo in the treatment of AWS, and in preventing relapses and craving in previously detoxified alcoholics during the first 3 months of follow-up. This review does not provide evidence in favour or against GHB compared to benzodiazepines and Clomethiazole for treatment of AWS; but, again based on a small amount of randomised evidence, GHB appears better than NTX and Disulfiram in maintaining abstinence and preventing craving in the medium term (3 to 12 months). The review does not provide evidence of a difference in side effects between GHB and benzodiazepines, NTX or Disulfiram. These findings should be considered alongside concerns that have been raised about GHB regarding the risk of developing addiction, and the misuse or abuse of the drug, suggesting to use GHB only under strict medical surveillance.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<BACKGROUND MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<CONDITION MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Chronic excessive alcohol consumption may lead to dependence, and hence to the alcohol withdrawal syndrome (AWS) in the event of abrupt reduction or cessation of drinking. AWS is a life-threatening condition. Its severity ranges from a moderate form characterized by tremor, nausea, anxiety, restlessness, insomnia to a more severe form with seizures, hallucinations, agitation and delirium. Progression to coma, cardiac arrest and death is also possible (<LINK REF="REF-Pieninkeroinen-1992" TYPE="REFERENCE">Pieninkeroinen 1992</LINK>; <LINK REF="REF-Morton-1994" TYPE="REFERENCE">Morton 1994</LINK>; <LINK REF="REF-Schuckit-1995" TYPE="REFERENCE">Schuckit 1995</LINK>). All the signs and symptoms of AWS arise from alcohol-induced adaptations in the central nervous system (CNS). Alcohol usually acts in the brain like a depressant drug. During prolonged intoxication, the CNS adapts to these effects and alcohol tolerance ensues. The amount of GABA receptors decreases, whereas the amount of NMDA receptors increases (<LINK REF="REF-Tan-1997" TYPE="REFERENCE">Tan 1997</LINK>).</P>
<P>The main goals of the clinical management of AWS are to minimize the severity of symptoms, prevent its more severe manifestations (such as seizure and delirium) and facilitate entry into a treatment program to achieve and maintain abstinence from alcohol (<LINK REF="REF-O_x0027_Connor-1998" TYPE="REFERENCE">O'Connor 1998</LINK>).<BR/>Withdrawal from alcohol may require pharmacological management, depending on the amount of drinking, the presence of symptoms, and the setting of detoxification (<LINK REF="REF-SIGN-2003" TYPE="REFERENCE">SIGN 2003</LINK>). Approximately, three-quarters of patients can be detoxified successfully as out-patients without medication (<LINK REF="REF-SIGN-2003" TYPE="REFERENCE">SIGN 2003</LINK>), but more intensive support is generally required for patients at risk or already presenting symptoms of withdrawal, for whom in-patient detoxification is recommended. Different classes of drugs have been used to prevent and treat AWS. These include benzodiazepines, neuroleptics, antiepileptics and others (<LINK REF="REF-Hillbom-2003" TYPE="REFERENCE">Hillbom 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-02-04 08:16:42 +0100" MODIFIED_BY="[Empty name]">
<P>Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid, a metabolite of gamma-amino-butyric acid (GABA). Its neuropharmacological and neurophysiological effects (<LINK REF="REF-Gessa-2000" TYPE="REFERENCE">Gessa 2000</LINK>) include the modulation of some neurotransmitters such as dopamine, serotonin, acetylcholine and opioids. Similarity of the effects of GHB and alcohol on the CNS was first described in the 1970s and subsequently confirmed (<LINK REF="REF-Frau-1995" TYPE="REFERENCE">Frau 1995</LINK>; <LINK REF="REF-Colombo-1995" TYPE="REFERENCE">Colombo 1995</LINK>; <LINK REF="REF-Colombo-1998" TYPE="REFERENCE">Colombo 1998</LINK>; <LINK REF="REF-Agabio-1998" TYPE="REFERENCE">Agabio 1998</LINK>). Its alcohol-mimicking effects represent a rationale for using GHB in alcohol addiction treatment and in craving (<LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>) and clinical trials (<LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>; <LINK REF="STD-Addolorato-1998" TYPE="STUDY">Addolorato 1998</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>) have shown that GHB can prevent and suppress withdrawal symptoms, and improve abstinence rate in the medium term.</P>
</INTERVENTION>
<THEORY MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>GHB was used in Europe for decades without reports of severe side effects and incidents of abuse. When it became widely available in the US, as a health food and body-building supplement during the 1980s, reports of adverse events increased to the point that the Food and Drug Administration (<LINK REF="REF-FDA-2006" TYPE="REFERENCE">FDA 2006</LINK>) ordered its removal from the market in 1990.These adverse effects ranged from mild hypothermia, dizziness, nausea, vomiting, weakness, loss of peripheral vision, confusion, agitation, hallucination, decreased respiratory effort, unconsciousness and coma.Some deaths have been reported in relation to GHB ingestion, usually when mixed with other drugs (<LINK REF="REF-Nicholson-2001" TYPE="REFERENCE">Nicholson 2001</LINK>; <LINK REF="REF-Caldicott-2004" TYPE="REFERENCE">Caldicott 2004</LINK>). One death has been ascribed to GHB alone (<LINK REF="REF-CDC-1997" TYPE="REFERENCE">CDC 1997</LINK>).<BR/>
</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-02-04 08:19:14 +0100" MODIFIED_BY="[Empty name]">
<P>Clear estimates of the beneficial and harmful effects of GHB, and the balance between these, have not been yet established.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-02-04 08:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of GHB for the treatment of AWS and the prevention of relapse, and more specifically:<BR/>
</P>
<UL>
<LI>to compare the efficacy of GHB with placebo or other drugs;</LI>
<LI>to identify the most effective GHB dosage and schedules;</LI>
<LI>to estimate the frequency of side effects.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<SELECTION_CRITERIA MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<CRIT_STUDIES MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Randomized controlled trials (RCT), controlled clinical trials (CCT), and controlled prospective studies (CPS) evaluating the efficacy and the safety of GHB in treating AWS and preventing mid-term relapses, in comparison with placebo or other pharmacological treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-02-04 08:21:19 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients diagnosed in accordance with appropriate standardized criteria (e.g., criteria of Diagnostic and Statistical Manual of Mental Disorders (<LINK REF="REF-DSM-IV_x002d_R-1994" TYPE="REFERENCE">DSM IV-R 1994</LINK>) or equivalent) or as defined by the authors of the original research, who are receiving therapy to prevent or to treat AWS. All patients are eligible, regardless of age, gender, outpatient or inpatient setting, and history of previous detoxification treatments.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<SUBSECTION>
<HEADING LEVEL="4">Experimental intervention:</HEADING>
<P>Gamma-hydroxybutyric acid (GHB) at any dosage. Dosage classification is intended as mg/kg/day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control intervention:</HEADING>
<P>Placebo, any other pharmacological treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons that are expected:</HEADING>
<UL>
<LI>GHB vs. placebo for the treatment of AWS;</LI>
<LI>GHB vs. placebo for the prevention of mid-term relapses;</LI>
<LI>GHB vs. other drugs for the treatment of AWS;</LI>
<LI>GHB vs. other drugs for the prevention of mid-term relapses;</LI>
<LI>GHB combined with other drugs vs. placebo for the treatment of AWS;</LI>
<LI>GHB combined with other drugs vs. placebo for the prevention of mid-term relapses;</LI>
<LI>GHB combined with other drugs vs. other drugs for the treatment of AWS;</LI>
<LI>GHB combined with other drugs vs. other drugs for the prevention of mid-term relapses.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Outcomes were categorized as measures of global severity, severity of single symptoms and signs, and other short-term and mid-term efficacy outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="4">Short-term outcomes:</HEADING>
<P>Short-term outcomes were those evaluated in the first month of administration of GHB for treating AWS.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome:</HEADING>
<UL>
<LI>Global severity of overall alcohol withdrawal syndrome as measured using a prespecified scale, including Clinical Institute Withdrawal Assessment for Alcohol [CIWA-Ar], and others.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes:</HEADING>
<UL>
<LI>Severity of single symptoms and signs, measured with either qualitative or quantitative scales, including:</LI>
</UL>
<UL>
<UL>
<LI>Tremor;</LI>
<LI>Anxiety;</LI>
<LI>Agitation;</LI>
<LI>Depression;</LI>
<LI>Paroxysmal sweat;</LI>
<LI>Hyperhydrosis.</LI>
</UL>
</UL>
<UL>
<LI>Side effects</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mid-term outcomes:</HEADING>
<P>Mid-term outcomes were those evaluated after the first month of administration of GHB for preventing relapses.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes:</HEADING>
<UL>
<LI>Drop-out rate;</LI>
<LI>Abstinence rate;</LI>
<LI>Relapse to heavy drinking;</LI>
<LI>Craving, as measured in prespecified scales (including Alcohol Craving scale, LCCR-1, and others).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes:</HEADING>
<UL>
<LI>Length of stay in treatment;</LI>
<LI>Controlled drinking;</LI>
<LI>Number of daily drinks;</LI>
<LI>Number of heavy drinking days;</LI>
<LI>Side effects.</LI>
</UL>
<P>Relapse to heavy drinking is defined as 5 or more drinks on one occasion for men and 4 or more drinks on one occasion for women (<LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>).</P>
<P>Controlled drinking is defined as drinking less than 40g alcohol per day for men and less than 20g per day for women (<LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-02-04 08:25:19 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-02-04 08:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>The following electronic databases were searched:<BR/>
</P>
<UL>
<LI>MEDLINE (1950 to September 2008);</LI>
<LI>EMBASE (1988 to September 2008);</LI>
<LI>PsycInfo (1967 to September 2008);</LI>
<LI>CINAHL - Cumulative Index to Nursing and Allied Health Literature (1982 to September 2008);</LI>
<LI>The Cochrane Library (update September 2008).</LI>
</UL>
<P>We used a search strategy based on MEDLINE but revised appropriately for each database to take account of differences in controlled vocabulary and syntax rules. No language, publication or time restrictions were applied. Details of the search strategies can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-02-04 08:25:19 +0100" MODIFIED_BY="[Empty name]">
<P>Editorials, reviews, commentaries, letters to the editor were included in the set. Review articles, as well included and excluded studies cited in the review were checked to identify other relevant studies. Relevant editorials, commentaries, and letters were reviewed to identify useful articles. The authors of all included and excluded studies (n=29) were contacted to identify other potentially relevant studies. Seven authors sent published references or papers.</P>
<P>Three pharmaceutical companies distribute GHB: 1. Laboratorio Farmaceutico C.T. S.r.l., Sanremo, Italy; 2. Jazz Pharmaceuticals, Palo Alto, California, USA; and 3. UCB Pharma Ltd, Brussels (Belgium). Only Laboratorio Farmaceutico C.T. supplies GHB for the treatment of alcohol withdrawal and dependence. The other two companies supply GHB for the treatment of narcolepsy. We contacted all three companies to obtain published and unpublished trials. Laboratorio Farmaceutico C.T. provided information on two ongoing trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<STUDY_SELECTION MODIFIED="2011-02-04 15:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (FVT and RB) checked the abstracts for relevance. Three authors (FVT, MAL and RB) blindly reviewed whole reports and assessed trials for inclusion, abstracted the outcome data and evaluated the quality of the trials. Disagreements were resolved by discussion with a fourth author (FF).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>The following information were extracted:</P>
<UL>
<LI>Total number of patients allocated to each treatment group;</LI>
<LI>Demographic characteristics;</LI>
<LI>Setting (out- or in-patients);</LI>
<LI>Whether medication was started immediately after the onset of withdrawal or not;</LI>
<LI>Factors related to the alcohol withdrawal episode (severity of symptoms, time since the last drink);</LI>
<LI>Risk factors (previous detoxification or withdrawal episodes, years of alcohol use, mixed abuse of drugs);</LI>
<LI>Dose and duration of GHB therapy;</LI>
<LI>Dose and duration of other therapies;</LI>
<LI>Adverse effects;</LI>
<LI>Deaths.</LI>
</UL>
<P>We e-mails four authors of included studies to ask for data or supplementary information. All four replied and one provided the requested data, which was used in our analysis.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>The risk of bias assessment  for RCTs, CCTs and CPSs in this review was performed using the criteria recommended by the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and by completing the risk of bias tables in RevMan 5 software. This is achieved by answering a pre-specified question about the adequacy of the study in relation to the relevant item, such that a judgement of "Yes" indicates low risk of bias, "No" indicates high risk of bias, and "Unclear" indicates unclear or unknown risk of bias. To make these judgments, we used the criteria indicated by the Handbook adapted to the addiction field.</P>
<P>In particular, the following criteria were used to evaluate risk of bias:</P>
<OL>
<LI>Sequence generation (avoidance of selection bias);</LI>
<LI>Allocation concealment (avoidance of selection bias);</LI>
<LI>Completeness of outcome data (avoidance of attrition bias);</LI>
<LI>Selective reporting (avoidance of reporting bias);</LI>
<LI>Other possible bias, such as similarity of patients in the groups (avoidance of selection bias);</LI>
<LI>Blinding of patients, providers and assessors of subjective outcomes (avoidance of performance bias and detection bias) .</LI>
</OL>
<P>Inclusion of all patients in the analysis and drop out rate were used to evaluate completeness of outcome data. A mention of the study protocol in the paper was used to evaluate the possibility of selective reporting. Similarity of patients in the groups at the starting of the trial and methods used to increase the strength of the statistical analysis were used to check for other possible biases.</P>
<P>Blinding was considered separately for patients, providers and assessors of subjective outcomes. These were considered the most important potential biases for our review, because objective outcomes were limited to retention in treatment.</P>
<P>Two review authors independently assessed the internal validity of the included studies. Any disagreement between the review authors was resolved by discussion, including input from a third independent reviewer if required. Our assessment of risk of bias was not blinded to the authors, institution or journal of the original research.</P>
<P>There were too few studies in the meta-analyses to support sensitivity analysis. This will be done in the future updates of the review, if possible.</P>
<P>Results of our risk of bias evaluation are shown in the Risk of bias tables and figures (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-02-04 15:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>The primary analysis was intention-to-treat and included all randomised patients, analysed in the treatment group to which they were allocated, irrespective of which treatment they actually received.</P>
<P>A standardized effect size was calculated for each study, based on the outcomes reported. Dichotomous outcomes were expressed as relative risks with 95% confidence intervals. Continuous outcomes were expressed as mean difference or, where this was not possible, as standardized mean difference.</P>
<P>To allow clinical evaluation of the overall safety of the treatment, data on side-effects were summarized in two additional tables, for GHB 50mg/day (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), and for GHB 100mg/day (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Side-effects rates were calculated as the number of patients declaring the side-effect out of the total number of patients receiving GHB in the studies reporting side-effects. Only data from patients receiving GHB alone were used. Moreover, to provide an unbiased measure of tolerated side effects (those not causing the treatment to be abandoned), the three studies mentioning only severe side effects were excluded from the overall number of patients used to calculate the rates.</P>
<P>Thestrength of the evidence was classified in four categories according to the GRADE assessment:</P>
<UL>
<LI>
<B>++++ High:</B> Further research is very unlikely to change our confidence in the estimate of effect.</LI>
<LI>
<B>+++ Moderate:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</LI>
<LI>
<B>++ Low:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</LI>
<LI>
<B>+ Very low:</B> We are very uncertain about the estimate.</LI>
</UL>
<P>The results of the GRADE assessment are provided in the Summary of findings tables but because of the high number of comparisons and outcomes, these are included for the most relevant outcomes only.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-02-04 08:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were the unit of randomisation as well as unit of analysis in all included studies. Therefore, there is no concern about unit of analysis issues for this review.</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-02-04 08:32:16 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical heterogeneity was assessed by reviewing the differences across trials in the characteristics of recruited patients and treatment protocols. Exclusion criteria have been summarized for each study in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Statistical heterogeneity was assessed using a Chi-squared test (p-value threshold for heterogeneity of 0.05). The I<SUP>2</SUP> statistic was also calculated (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
<P>In the comparison between GHB and diazepam, which includes two studies, we present the pooled results even though heterogeneity was statistically significant for many of the meta-analyses. These results have to be interpreted with particular caution, therefore.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-02-04 08:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>Given the low number of studies in each comparison and meta-analysis, we did not assess publication bias by the use of a funnel plot. However, we will do so in future updates, if a sufficient number of studies are available for inclusion in the meta-analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Where possible, the relative risk and its 95% confidence intervals were calculated, using a fixed effects model. For continuous outcomes, a standardized mean difference (SMD) was calculated to summarise results across studies which had measured the same outcome in different ways.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>To incorporate quality assessment in the review process, we intended to plot intervention effects stratified by risk of bias and if we had found differences in results among studies at different risk of bias, we would have performed sensitivity analysis excluding studies with high risk of bias. However, none of our meta-analyses of main outcomes include more than two studies at the moment and so we did not perform sensitivity analysis for any outcome.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<STUDY_DESCRIPTION MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>The characteristics of the included and excluded studies are described in the relevant tables.</P>
<SEARCH_RESULTS MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>Our search strategy, including handsearching of the reference lists and examination of the abstracts from conferences on alcohol, identified a total of 645 articles. Of these, 411 were excluded on the basis of the title. The abstract of 234 reports were evaluated by two reviewers independently (FVT and RB) and 116 of these were not relevant for this review and were excluded; 43 were reviews, 31 were other material (letters, commentaries, etc), and 26 reports (22 studies) were excluded with a specific reason for exclusion (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). This left 18 reports (13 studies) for inclusion (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Among the 13 included studies, 6 evaluated the effects of GHB on withdrawal symptoms in the short-term (<LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>; <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>; <LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>; <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>), and 7 evaluated the effects of GHB in preventing relapses and maintaining abstinence in the mid-term (<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>; <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>; <LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>). Two studies are ongoing (<LINK REF="STD-Lesch-2000a" TYPE="STUDY">Lesch 2000a</LINK>; <LINK REF="STD-Lesch-2000b" TYPE="STUDY">Lesch 2000b</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-02-18 11:41:34 +0100" MODIFIED_BY="Laura Amato">
<P>A total of 13 studies (18 reports) were included. All included studies were RCTs. All, except one (<LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>), presented data that could be used in our meta-analyses. The number of patients in the studies with suitable data varied from 17 to 35 in 4 trials (<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>; <LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>), 40-60 in 5 trials (<LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>), and 82-98 in 3 trials (<LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>; <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>).</P>
<P>
<B>Patients</B>
</P>
<P>The studies included a total of 648 patients. From 10 studies providing this information, 81% of patients were men and the mean age of the participants was 43.5 years. Mean duration of alcohol dependence was 11.4 years (based on information from 6 studies). The exclusion criteria applied to select patients for each study are described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>
<B>Setting </B>
</P>
<P>Six studies were conducted in an inpatient setting (<LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>; <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>; <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>; <LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>), and 7 recruited outpatients (<LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>; <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>;<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>;<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>).</P>
<P>
<B>Countries in which the studies were conducted:</B>
</P>
<P>Most of the studies were done in Italy (11 studies). There was one study from Germany and one from Austria.<BR/>
</P>
<P>
<B>Comparison</B>
</P>
<P>Six studies (<LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>; <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>; <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>; <LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>) evaluated the effects of GHB on withdrawal syndrome. Of these, five compared two intervention groups and one compared three groups (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>).These six studies allowed five comparisons.</P>
<P>Seven studies (<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>; <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>; <LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>) evaluated the effects of GHB on mid-term relapses. Of these, four studies were two group comparisons (<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>), two had three intervention groups (<LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>) and one compared four interventions (<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>).</P>
<P>The comparisons available for our meta-analyses are:</P>
<OL>
<LI>GHB 50mg vs Placebo for AWS, one study (<LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>);</LI>
<LI>GHB 50mg vs Diazepam for AWS, three studies (<LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>);</LI>
<LI>GHB 50mg vs Clomethiazole for AWS, two studies (<LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>);</LI>
<LI>GHB 100mg vs Clomethiazole for AWS, one study (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>).</LI>
<LI>GHB 50mg vs GHB100 for AWS, one study (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>);</LI>
<LI>GHB 50mg vs Placebo for maintaining abstinence, two studies (<LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>);</LI>
<LI>GHB 50mg vs Naltrexone for maintaining abstinence, three studies (<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>);</LI>
<LI>GHB 50mg vs Disulfiram for maintaining abstinence, one study (<LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>);</LI>
<LI>GHB 50 mg + Naltrexone vs Naltrexone for maintaining abstinence, one study (<LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>);</LI>
<LI>GHB 50mg + Disulfiram vs Disulfiram + Placebo for maintaining abstinence, one study (<LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>);</LI>
<LI>GHB 75mg + Escitalopram vs Escitalopram for maintaining abstinence, one study (<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>);</LI>
<LI>GHB 75mg + Escitalopram vs Naltrexone + Escitalopram, for maintaining abstinence, one study (<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>);</LI>
<LI>GHB 75mg + Naltrexone + Escitalopram vs Escitalopram, for maintaining abstinence, one study (<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>).</LI>
</OL>
<P>Details on the interventions compared in these studies are shown in the Characteristics of Included Studies table (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>
<B>Alcohol dependence diagnosis</B>
</P>
<P>The diagnosis criteria used in the 13 studies were:</P>
<UL>
<LI>DSM-IV (8 studies);</LI>
<LI>DSM-III (3 studies);</LI>
<LI>definition of the authors (2 studies).</LI>
</UL>
<P>
<B>Follow-up</B>
</P>
<P>Studies assessing the effects of GHB on withdrawal syndrome:</P>
<UL>
<LI>7 hours (2 studies);</LI>
<LI>8 days (1 study);</LI>
<LI>18 days (3 studies);</LI>
<LI>21 days (1 study).</LI>
</UL>
<P>Studies assessing the effects of GHB on mid-term relapses:</P>
<UL>
<LI>1-2 months (1 study);</LI>
<LI>3 months (5 studies);</LI>
<LI>6 months (2 studies);</LI>
<LI>12 months (1 study).</LI>
</UL>
<P>
<B>Outcomes</B>
</P>
<P>Studies assessing the effects of GHB on withdrawal syndrome evaluated the following outcomes:</P>
<UL>
<LI>Drop-outs (4 studies):</LI>
<UL>
<LI>at 7 hours (1 study);</LI>
<LI>at 8 days (1 study);</LI>
<LI>at 18 days (2 studies).</LI>
</UL>
<LI>CIWA-Ar score (4 studies).</LI>
</UL>
<UL>
<LI>CIWA-Ar subscores (3 studies):</LI>
<UL>
<LI>Tremor (3 studies);</LI>
<LI>Paroxysmal sweat (2 studies);</LI>
<LI>Anxiety (3 studies);</LI>
<LI>Agitation (2 studies);</LI>
<LI>Hyperhydrosis (1 study).</LI>
</UL>
<LI>Withdrawal score (1 study).</LI>
</UL>
<UL>
<LI>4-points withdrawal scale (1 study).</LI>
</UL>
<UL>
<LI>STAI y1 score for anxiety (2 studies).</LI>
</UL>
<UL>
<LI>Depression (2 studies):</LI>
<UL>
<LI>SDS Zung test score (2 studies).</LI>
</UL>
<LI>Side effects (3 studies).</LI>
</UL>
<P>Studies assessing the effectiveness of GHB in preventing mid-term relapses evaluated the following outcomes:</P>
<UL>
<LI>Drop-outs (7 studies):</LI>
</UL>
<UL>
<UL>
<LI>at 3 months (5 studies);</LI>
<LI>at 6 months (2 studies);</LI>
<LI>at 12 months (1 study).</LI>
</UL>
<LI>Average stay in program (1 study).</LI>
</UL>
<UL>
<LI>Abstinence (7 studies):</LI>
<UL>
<LI>at 3 months (4 studies);</LI>
<LI>at 6 months (2 studies);</LI>
<LI>at 12 months (1 study).</LI>
</UL>
<LI>Controlled drinking at 3 months (2 studies):</LI>
</UL>
<UL>
<UL>
<LI>at 3 months (1 study);</LI>
<LI>at 12 months (1 study).</LI>
</UL>
<LI>Relapse to heavy drinking (5 studies):</LI>
<UL>
<LI>at 3 months (3 studies);</LI>
<LI>at 6 months (1 study);</LI>
<LI>at 12 months (1 study).</LI>
</UL>
<LI>Number of daily drinks (2 studies):</LI>
<UL>
<LI>at 3 months (1 study);</LI>
<LI>at 12 months (1 study).</LI>
</UL>
<LI>Alcohol craving scale at 12 months (1 study).</LI>
</UL>
<UL>
<LI>Craving score at 1, 2 and 3 months (1 study).</LI>
</UL>
<UL>
<LI>Side effects (5 studies).</LI>
</UL>
<P>Note: This information on outcomes does not take into account variables such as comparison groups; therefore the number of studies included in each meta-analysis can be different from the numbers presented above.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-02-04 12:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-two studies (26 reports) were excluded. Three were RCTs, one was a CCT, and 18 were observational studies. Among RCTs, one (<LINK REF="STD-Ceccanti-1995" TYPE="STUDY">Ceccanti 1995</LINK>) was excluded because of a failure in the randomisation, whilst the other two (<LINK REF="STD-Caputo-2006" TYPE="STUDY">Caputo 2006</LINK>; <LINK REF="STD-Lenzenhuber-1999" TYPE="STUDY">Lenzenhuber 1999</LINK>) were excluded because of the population of patients. The CCT by <LINK REF="STD-Balducci-1993" TYPE="STUDY">Balducci 1993</LINK> did not control for confounding factors at the analysis stage. Among observational studies, sixteen (<LINK REF="STD-Addolorato-1996" TYPE="STUDY">Addolorato 1996</LINK>; <LINK REF="REF-Addolorato-1998" TYPE="REFERENCE">Addolorato 1998</LINK>; <LINK REF="STD-Avanzi-1996" TYPE="STUDY">Avanzi 1996</LINK>; <LINK REF="STD-Baldelli-1993" TYPE="STUDY">Baldelli 1993</LINK>; <LINK REF="STD-Cibin-1995" TYPE="STUDY">Cibin 1995</LINK>; <LINK REF="STD-De-Rosa-1997" TYPE="STUDY">De Rosa 1997</LINK>; <LINK REF="STD-Korninger-2003" TYPE="STUDY">Korninger 2003</LINK>; <LINK REF="STD-Leder-1993" TYPE="STUDY">Leder 1993</LINK>; <LINK REF="STD-Liboni-1995" TYPE="STUDY">Liboni 1995</LINK>; <LINK REF="STD-Manzato-1995" TYPE="STUDY">Manzato 1995</LINK>; <LINK REF="STD-Marcelli-1996" TYPE="STUDY">Marcelli 1996</LINK>; <LINK REF="STD-Maremmani-1998" TYPE="STUDY">Maremmani 1998</LINK>; <LINK REF="STD-Maremmani-2001" TYPE="STUDY">Maremmani 2001</LINK>; <LINK REF="STD-Montesano-1997" TYPE="STUDY">Montesano 1997</LINK>; <LINK REF="STD-Mosti-1995" TYPE="STUDY">Mosti 1995</LINK>; <LINK REF="STD-Vendramin-1995" TYPE="STUDY">Vendramin 1995</LINK>) did not have a control group, one (<LINK REF="STD-Vittadini-1993" TYPE="STUDY">Vittadini 1993</LINK>) used an inappropriate control group, and one (<LINK REF="STD-Strepparola-1995" TYPE="STUDY">Strepparola 1995</LINK>) did not control for confounding factors at the analysis stage.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>The results of our risk of bias evaluation are summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2009-10-12 16:58:35 +0200" MODIFIED_BY="[Empty name]">
<P>Three studies (23%) were judged of low risk of bias as regards the randomisation procedure and the allocation concealment (<LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>; <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>). All the other studies were of unclear risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-02-04 08:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>Five studies (38%) adopted adequate blinding procedures as regards patients, providers and outcome assessors (low risk of bias) (<LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK>; <LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>; <LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>; <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>; <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>), two were of moderate risk of bias (<LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>; <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>), whilst the remaining six were open randomised trials (high risk of bias).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-10-12 17:35:20 +0200" MODIFIED_BY="[Empty name]">
<P>All studies apart from two (87%) (<LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>; <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>) reported attrition rates (low risk of bias). </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>Only one study (8%) (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>) mentioned the study protocol and study protocol violations, suggesting a low risk of selective reporting. Data on two studies came from conference abstracts (<LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>; <LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>), and one (<LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK>) did not report data useful for the meta-analysis, suggesting a high risk of selective reporting. The other studies were of unclear risk of selective reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-10-12 17:35:35 +0200" MODIFIED_BY="[Empty name]">
<P>Only one study (8%) (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>) described in detail other possible sources of bias, suggesting low risk of bias. All the other studies were of unclear risk of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>
<B>Withdrawal syndrome</B>
</P>
<P>
<I>
<B>1. GHB 50mg vs placebo</B>
</I>
</P>
<P>One study evaluated the effects of GHB vs placebo in reducing withdrawal symptoms (<LINK REF="STD-Gallimberti-1989" TYPE="STUDY">Gallimberti 1989</LINK>). It evaluated the short-term effect (7 hours), comparing 11 patients in the intervention group with 12 in the placebo group. None of the patients left the treatment, see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. The study shows an increasing effectiveness of GHB on symptoms compared to placebo with increasing time from the administration of the treatment. After 1 hour, the MD was -4.6 (95% CI -8.12 to -1.08), after 2 hours it was -7.1 (95% CI -9.8 to -4.4); and at 3 hours the MD was -10.5 (95% CI -15.8 to -5.2). At 5 hours, the MD reached -12.1 (95% CI -15.9 to -8.29); this value did not change at 7 hours. All differences were statistically significant and in favour of GHB (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Seven (63%) patients receiving GHB developed transitory vertigo, whilst none of the placebo patients developed any side-effect (RR 16.2, 95% CI 1.04 to 254.9), see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
<P>
<I>
<B>2. GHB 50mg vs diazepam</B>
</I>
</P>
<P>Many of the meta-analyses of the two studies available for this comparison have a high degree of heterogeneity. Therefore, the results should be interpreted with caution.</P>
<P>Two studies compared the effects of GHB versus diazepam in reducing withdrawal symptoms in the short-term (<LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>, <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK>). The study by <LINK REF="STD-Nava-2007" TYPE="STUDY">Nava 2007</LINK> did not have any drop-outs, whilst the drop-out rate in the study by <LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK> was lower in the GHB group, but this was not statistically significant (RR 0.50, 95% CI 0.17 to 1.48), see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>. The meta-analyses on CIWA-Ar score did not show any statistically significant difference between the two treatments in the evaluation day per day (day 2 to day 21), apart from a slight statistically significant difference in favour of GHB at days 18-21 (1 study, MD -1.33, 95% CI -2.66 to 0.00), see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>. When looking at the CIWA-Ar sub scores, a statistically significant difference in favour of GHB was found on the tremor sub score at all observation points (day 2 to day 21, 2 studies), see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>. For the paroxysmal sweats sub score, a statistically significant difference emerged in favour of GHB at day 5 (2 studies, MD -0.43, 95% CI -0.66 to -0.20), at days 10-14 (2 studies, MD -0.60, 95% CI -0.86 to -0.34), and at days 18-21 (2 studies, MD -0.24, 95% CI -0.48 to -0.01), see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>. The anxiety sub score was more favourabe for GHB compared to diazepam at day 3 (2 studies, MD -0.51, 95% CI -0.78 to -0.24), at days 4-5 (2 studies, MD -0.29, 95% CI -0.52 to -0.05), and at days 10-14 (2 studies, MD -0.52, 95% CI -0.77 to -0.27), whilst the difference between the two treatments was lost at 18-21 days (2 studies), see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>. For the agitation sub score, there was a statistically significant difference in favour of GHB at day 3 (2 studies, MD -0.23, 95% CI -0.40 to -0.06), at days 4-5 (2 studies, MD -0.35, 95% CI -0.54 to -0.16), and at days 10-14 (2 studies, MD -0.31, 95% CI -0.51 to -0.11), see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>.</P>
<P>The STAI-y1 score and the SDS Zung test score were evaluated by one study (<LINK REF="STD-Addolorato-1999a" TYPE="STUDY">Addolorato 1999a</LINK>), and between day 2 and day 21, there were no statistically significant differences between the two treatments, see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> and <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>. Fewer patients developed tolerated side-effects in the GHB group, but the result was not statistically significant (RR 0.53, 95% CI 0.20 to 1.38), see <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>.</P>
<P>The study by <LINK REF="STD-Ceccanti-1996" TYPE="STUDY">Ceccanti 1996</LINK> compared GHB versus a BDZ (oxazepam), but did not provide data that could be used in the meta-analysis. In the study, there were no statistically significant differences between the two treatments for the CIWA-Ar score or the anxiety and depression tests.</P>
<P>
<I>
<B>3. GHB 50mg vs Clomethiazole</B>
</I>
</P>
<P>Two studies compared the effects of GHB 50 mg/day versus Clomethiazole on withdrawal symptoms in the short-term (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>, <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>). In the study by <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>, the drop-out rate was lower in the GHB group, but the difference was not statistically significant (RR 0.17, 95% CI 0.02 to 1.31), see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>. The study by <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK> evaluated only the effect on a 4-points withdrawal score at 7 hours, and was in favour of GHB (MD -3.40, 95% CI -5.09 to -1.71), see <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>. For all other outcomes evaluated by <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK> at days 2 and 8 (CIWA-Ar score, subscores of tremor, hyperhidrosis, and anxiety, and side-effects), there was no statistically significant difference between GHB and Clomethiazole (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).<BR/>
</P>
<P>
<I>
<B>4. GHB 100mg vs Clomethiazole</B>
</I>
</P>
<P>The study by <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK> also evaluated the effect of a higher dose of GHB (100 mg/day) versus Clomethiazole. The drop-out rate was lower in the GHB group, but the difference was not statistically significant (RR 0.69, 95% CI 0.21 to 2.21), see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>. For all the outcomes related to withdrawal at days 2 and 8 (CIWA-Ar, sub scores of tremor, hyperhidrosis, and anxiety), the difference between the two treatments was not statistically significant (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). On the contrary, a statistically significant higher rate of tolerated side-effects was observed in the GHB group (RR 1.84, 95% CI 1.19 to 2.85), see <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>.1. The rate of side-effects causing abandon was not different between the two groups, see <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>.2.<BR/>
</P>
<P>
<I>
<B>5. GHB 50 mg vs GHB 100mg</B>
</I>
</P>
<P>Comparing GHB at the standard dosage (50mg/day) with GHB at the high dose (100mg/day), no statistically significant differences were found, apart from side effects (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>). The drop-out rate was lower with GHB 50mg, but the difference was not statistically significant (RR 0.24, 95% CI 0.03 to 2.05), see <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>. For all the outcomes related to withdrawal symptoms at days 2 and 8 (CIWA-Ar, subscores of tremor, hyperhydrosis, and anxiety), the difference between the two doses was not statistically significant (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). As noted, there was a statistically significant difference in tolerated side-effects, in favour of the lower dose (GHB 50mg) (RR 0.62, 95% CI 0.42 to 0.92), see <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.1. There was no significant difference between the doses for side-effects causing abandon (RR 0.62, 95% CI 0.32 to 7.66), see <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.2.</P>
<P>
<B>Prevention of mid-term relapses</B>
</P>
<P>
<I>
<B>6. GHB 50mg vs placebo</B>
</I>
</P>
<P>Two studies compared GHB versus placebo for maintaining abstinence in the mid-term: <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK> at 3 months and <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK> at 6 months follow-up, with no statistically significant difference in drop-out rate at 3 months (RR 0.83, 95% CI 0.28 to 2.52) and at 6 months (RR 0.89, 95% CI 0.16 to 4.93), respectively (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.1 and <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.2). However, the average stay in program was significantly longer in the GHB group (MD 8.30, 95% CI 0.40 to 16.2), see <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>. Abstinence at 3 months was significantly higher in the GHB group (RR 5.35, 95% CI 1.28 to 22.4) in <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK> (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>.1), but the difference was not statistically significant at 6 months in <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK> (RR 1.33, 95 CI 0.58 to 3.07), see <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>.2. Patients receiving GHB more frequently drank in a controlled way (RR 2.13, 95% CI 1.07 to 5.54), see <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK> , and had fewer relapses to heavy drinking by 3 months (RR 0.36, 95% CI 0.21 to 0.63) in <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK> (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.1), at 6 months (RR 0.44, 95% CI 0.05 to 4.02, non significant) in <LINK REF="STD-Di-Bello-1995" TYPE="STUDY">Di Bello 1995</LINK> (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>.2). At 3 months follow-up in <LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>, the mean number of daily drinks was significantly lower in the GHB group (MD -4.60, 95% CI -6.18 to -3.02), see <LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>. The craving score was evaluated by one study at 1, 2 and 3 months follow-up (<LINK REF="STD-Gallimberti-1992" TYPE="STUDY">Gallimberti 1992</LINK>), finding a statistically significant difference in favour of GHB at each of these time points, with the effect increasing over time, moving from a MD of -3.00 (95% CI -4.19 to -1.81) at 1 month to -4.50 (95% CI -5.81 to -3.19) at 3 months (<LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>). On the contrary, tolerated side effects favoured placebo, but the difference was not statistically significant (RR 1.91, 95% CI 0.63 to 5.82), see <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>.</P>
<P>
<I>
<B>7. GHB 50mg vs Naltrexone (NTX)</B>
</I>
</P>
<P>Three studies compared GHB and Naltrexone (NTX) for maintaining abstinence, two at 3 months (<LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>) and one at 12 months (<LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>). The drop-out rate was not significantly different between the two drugs, at either 3 months (RR 0.68, 95% CI 0.26 to 1.75), see <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.1 or at 12 months (RR 0.96, 95% CI 0.15 to 6.37), see <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>.2. The abstinence rate at 3 months was significantly better for GHB (RR 2.59, 95% CI 1.35 to 4.98); see <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>.1, but there was no significant difference at 12 months in <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK> (RR 1.34, 95% CI 0.83 to 2.16), see <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>.2. The effect on the relapses to heavy drinking non-significantly favoured NTX at 3 months(RR 3.23, 95% CI 0.57 to 18.3) in the meta-analysis of <LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK> and <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK> (<LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>.1), but non-significantly favoured GHB at 12 months in <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK> (RR 0.55, 95% CI 0.18 to 1.67), see <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>.2. The number of daily drinks at 12 months was not also different in the two groups in this trial (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>), and nor was the effect on controlled drinking (RR 0.77, 95% CI 0.23 to 2.57), see <LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK>. On the contrary, the Alcohol Craving Scale at 12 months was significantly in favour of GHB in <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK> (MD -1.90, 95% CI -2.45 to -1.35), see <LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK>. There were fewer side effects with GHB, but the result was not statistically significant for either side-effects causing abandon (RR 0.62, 95% CI 0.18 to 2.10), see <LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK>.1 or tolerated side-effects (RR 0.34, 95% CI 0.10 to 1.17), see <LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK>.2.</P>
<P>
<I>
<B>8. GHB 50mg vs Disulfiram</B>
</I>
</P>
<P>One study (<LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>) compared GHB and Disulfiram for abstinence at 12 months of follow-up. The drop-out rate was non-significantly lower in the GHB group (RR 0.25, 95% CI 0.06 to 1.04), see <LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>. Abstinence at 12 months was more common among patients allocated GHB (RR 1.66, 95% CI 0.99 to 2.80, non significant), see <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>. Relapses to heavy drinking were non-significantly higher in the GHB group (RR 1.48, 95% CI 0.36 to 6.03), see <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>, and the number of daily drinks was non-significantly lower in the GHB group (MD -0.30, 95% CI -1.10 to 0.50), see <LINK REF="CMP-008.04" TYPE="ANALYSIS">Analysis 8.4</LINK>. The effect on controlled drinking favoured Disulfiram (RR 0.63, 95% CI 0.21 to 1.93, non significant), see <LINK REF="CMP-008.05" TYPE="ANALYSIS">Analysis 8.5</LINK>. The difference on the Alcohol Craving Scale was statistically significant in favour of GHB (MD -1.40, 95% CI -1.86 to -0.94), see <LINK REF="CMP-008.06" TYPE="ANALYSIS">Analysis 8.6</LINK>. There were fewer side-effects rate with GHB, but this was not statistically significant (RR 0.55, 95% CI 0.11 to 2.79), see <LINK REF="CMP-008.07" TYPE="ANALYSIS">Analysis 8.7</LINK>.</P>
<P>
<I>
<B>9. GHB 50mg + NTX vs NTX</B>
</I>
</P>
<P>The same study (<LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>) compared the combination of GHB and NTX versus NTX alone for maintaining abstinence at 3 months. The proportion of patients who dropped out rate was similar in both groups (RR 0.71, 95% CI 0.19 to 2.71), see <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>. Abstinence at 3 months was significantly in favour of the combination of drugs (RR 12.3, 95% CI 1.79 to 83.9), see <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>. Relapses to heavy drinking were non-significantly less common in the combination group (RR 0.32, 95% CI 0.01 to 7.26), see <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>. Side effects appeared to be higher in the combination group, both for side-effects causing abandonment of treatment (RR 2.83, 95% CI 0.33 to 24.7), see <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>.1, and for tolerated side-effects (RR 1.89, 95% CI 0.56 to 6.38), see <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>.2.</P>
<P>
<I>
<B>10. GHB 50mg + Disulfiram vs Disulfiram + placebo</B>
</I>
</P>
<P>One study (<LINK REF="STD-Ferri-1991" TYPE="STUDY">Ferri 1991</LINK>) evaluated the effects of the combination of GHB and Disulfiram versus Disulfiram plus placebo on abstinence at 3 months follow-up. There was little data available for this study, and only the drop-out rate could be analysed in this review. This was non-significantly in favour of the combination of GHB and Disulfiram (RR 0.20, 95% CI 0.03 to 1.56), see <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>.</P>
<P>
<I>
<B>11. GHB 75mg + Escitalopram vs Escitalopram</B>
</I>
</P>
<P>One study (<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>) compared the combination of GHB 75mg and Escitalopram versus Escitalopram alone for maintaining abstinence at 3 and 6 months follow-up. Abstinence was more common for GHB 75mg + escitalopram at both 3 months (RR 1.65, 95% CI 0.80 to 3.41) and 6 months (RR 2.75, 95% CI 0.70 to 10.9), but neither of these results was statistically significant (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>).</P>
<P>
<I>
<B>12. GHB 75mg + Escitalopram vs NTX + Escitalopram</B>
</I>
</P>
<P>
<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK> also evaluated the combination of GHB 75mg and Escitalopram versus NTX and Escitalopram for maintaining abstinence at 3 and 6 months. It was the only study to do so. There was no significant difference in abstinence at 3 months (RR 1.29, 95% CI 0.72 to 2.29) or 6 months follow-up (RR 1.50, 95% CI 0.56 to 4.00), see <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>.</P>
<P>
<I>
<B>13. NTX + GHB 75mg + Escitalopram vs Escitalopram</B>
</I>
</P>
<P>This study (<LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>) also compared the combination of NTX, GHB 75mg and Escitalopram versus Escitalopram for maintaining abstinence. Abstinence was found to be significantly in favour of the combination of NTX, GHB and Escitalopram, at both 3 months (RR 2.02, 95% CI 1.03 to 3.94) and at 6 months follow-up (RR 4.58, 95% CI 1.28 to 16.5), see <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>.</P>
<P>
<B>Overall rate of side-effects</B>
</P>
<P>Combining the data from all studies that reported this, the number of patients developing side effects from GHB was low (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).For GHB 50mg, the most frequent side effect was vertigo or dizziness, which was developed by nearly 20% of patients. Diarrhoea, headache, rhinitis, and nausea affected around 0.6% to 2.5% of patients receiving GHB 50mg. Some of the side-effects (vertigo/dizziness, headache, and sense of drunkenness) led to the abandonment of the treatment in 0.4% to 3.2% of patients. The single patient who developed a sense of drunkenness left the treatment, and 18% to 25% of patients developing vertigo/dizziness or headache left the treatment.<BR/>
</P>
<P>Among patients receiving GHB 100mg per day, 53% developed vertigo, 9.4% diarrhoea, 6.2% nausea, 9.4% rhinitis, and 3.1% seizure (one case). However, none of these patients left the treatment because of adverse effects.<BR/>Only three studies mentioned the possibility that patients develop a craving for GHB (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>, <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>). The studies by <LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK> and <LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK> did not observe any case of GHB craving among the participants, whilst the study by <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK> observed two cases (10% of the patients in the GHB group).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>This systematic review includes 13 randomised trials, providing data regarding 648 alcoholic patients, of whom 337 received GHB alone or in combination with other treatments. Six trials included 286 patients with different severity levels of alcohol withdrawal syndrome (AWS) and evaluated the effects of GHB in treating overt AWS (short-term outcomes). Seven trials included 362 alcoholic patients for whom GHB was tested as a treatment for alcohol dependence or to prevent relapses if the person had already detoxified (mid-term outcomes). We did not find any eligible studies in which GHB was used to prevent AWS. However, although several hundred patients are available for this review, most results should be interpreted with caution because only small numbers of patients could be included in each of the several comparisons that we are able to analyse.</P>
<SUMMARY_OF_RESULTS MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>There is insufficient randomised evidence to be confident that the effects of GHB and placebo are different, or to determine reliably if GHB is more or less effective than other drugs for the treatment of alcohol withdrawl or the prevention of relapses. As regards short-term effects, results from the single trial comparing GHB to placebo (23 patients) suggest that GHB 50mg/Kg/day might be superior to placebo in reducing withdrawal symptoms. Comparing GHB 50mg with diazepam, the CIWA-Ar sub-scores for tremor, anxiety and agitation were more often lower for GHB, but the difference was usually not statistically significant. No significant differences were found between the drugs for side effects or number of dropouts. Comparing GHB 50mg with Clomethiazole, a significant difference in favour of GHB was observed only for 4-points withdrawal scale in one study of 21 patients, whereas CIWA-Ar score, sub-scores and side effects were not found to be different between the two treatments in one high quality study. We did not find a difference between GHB 100mg and Clomethiazole on beneficial outcomes, but side effects were in favour of Clomethiazole. There was no evidence of an important difference between daily doses of GHB 50mg vs 100mg on any outcome relating to alcohol, but the higher doses caused significantly more side effects.</P>
<P>As regards mid-term effects, compared to placebo, GHB 50mg increased the number of patients who were abstinent or had controlled drinking, and reduced the number of patients relapsing, the number of daily drinks and craving scores at 3 months in one trial (71 patients). However, these benefits were not apparent at six months in another study (17 patients). GHB appears to be superior to both NTX and Disulfiram in reducing craving and increasing abstinent patients, but it had no influence on the number of relapses to heavy drinking or on the number of daily drinks. The combination of GHB and NTX showed a positive effect on abstinence compared to NTX alone but is counterbalanced by a possible increase of the adverse effects. The combination of NTX, GHB and Escitalopram was found to improve abstinence rate at 3 and 6 months compared to Escitalopram alone.</P>
<P>Two additional statistical concerns have to be considered when interpreting the results. The first is related to the fact that many of the meta-analyses for the two trials of GHB versus diazepam had a high degree of heterogeneity, and therefore the pooled estimate might not reflect the real effect. The second statistical concern arises from the large number of comparisons and outcomes, which could have produced some statistically significant effects by chance alone (<LINK REF="REF-Bender-2008" TYPE="REFERENCE">Bender 2008</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>Most trials were from a single country (Italy, n=11), and sample sizes were generally very small (range 17-98 patients). Moreover, the comparisons were varied, with GHB compared to placebo or one of several other drugs, outcomes were heterogeneous in type and timing, and recent trials studied new comparisons without re-testing the previous ones. The studies used a long list of inclusion or exclusion criteria for patients. These factors could reduce the reliability of results of the studies and, therefore, the findings of this review.</P>
<P>Information on specific side-effects was rarely collected with appropriate checklists and patients known to be at higher risk of side effects, such as those with delirium or seizures, severe liver impairment, or previous withdrawals complicated by seizures, and polydrug abusers, were generally excluded. The most consistently reported side effect was dizziness/vertigo, which was more frequent in the GHB than in the placebo group and was found to be dose dependent in the one randomised trial that directly compared different doses. A prevalence of about 20% is confirmed by data from more than 1000 patients in observational studies (<LINK REF="REF-Begh_x00e8_-2000" TYPE="REFERENCE">Beghè 2000</LINK>). In the trials comparing GHB with other drugs, these showed a favourable safety profile for GHB, although the difference was significant only in comparison to NTX.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>The methodological quality of the studies is difficult to determine because of the lack of adequate descriptions of the randomisation procedure and other possible sources of bias in the reports (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Moreover, half of the studies were open (ie without blinding of participants or providers), which increases the risk of bias for the subjective outcomes used to compare the studies. Only the study (<LINK REF="STD-Nimmerrichter-2002" TYPE="STUDY">Nimmerrichter 2002</LINK>) appears to be of good quality.</P>
<P>Mostly due to the low number of enrolled patients and the inclusion of only one study in most meta-analyses, the overall quality of the evidence, as synthesized in the summary of findings tables, is generally low.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>Concern has been raised regarding toxicity and possible dependency from GHB and the possibility of its misuse or abuse (<LINK REF="REF-Nicholson-2001" TYPE="REFERENCE">Nicholson 2001</LINK>). However, most of these problems depend on different settings of use, doses and modalities of administration more than on other features which apply to GHB in the question for this review. GHB is licensed and approved for the use in alcoholics only in Italy, under the same limitations as BZD, and in Austria. It was banned from the retail market in the USA in 1990, and it is an illegal drug in many other countries. However, in the USA and elsewhere in the European Union, it is approved for the treatment of narcolepsy with cataplexy (<LINK REF="REF-EMCDDA-2002" TYPE="REFERENCE">EMCDDA 2002</LINK>). In many countries, GHB is currently available over the internet or on the "black market" and is used for its purported anabolic effect or for weight loss or sleep induction. It is also used as an illicit recreational drug because of its euphorigenic potential, mostly by mixing it with other illicit substances (<LINK REF="REF-Maremmani-2007" TYPE="REFERENCE">Maremmani 2007</LINK>, <LINK REF="REF-Nicholson-2001" TYPE="REFERENCE">Nicholson 2001</LINK>). In the USA, GHB was characterized by the media as a drug facilitating sexual assault (<LINK REF="REF-Nicholson-2001" TYPE="REFERENCE">Nicholson 2001</LINK>). Tolerance to GHB has not been systematically studied in randomised trials, but craving and abuse has been described in 2-39% of patients (<LINK REF="REF-Begh_x00e8_-2000" TYPE="REFERENCE">Beghè 2000</LINK>, <LINK REF="REF-Gallimberti-2000" TYPE="REFERENCE">Gallimberti 2000</LINK>; <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>; <LINK REF="REF-Caputo-2011" TYPE="REFERENCE">Caputo 2011</LINK>), mainly in those with a sustained full remission from heroin or cocaine dependence (<LINK REF="REF-Caputo-2008" TYPE="REFERENCE">Caputo 2008</LINK>). However, the need to increase the dose should not be confounded with the need to fractionate the dose, given its short half-life (2 hours) (<LINK REF="REF-Johnson-2005" TYPE="REFERENCE">Johnson 2005</LINK>). In the trials included in this review and in observational studies, more than 1000 alcoholics patients have been treated with GHB and withdrawal symptoms have not been described (<LINK REF="REF-Begh_x00e8_-2000" TYPE="REFERENCE">Beghè 2000</LINK>), although single cases have been reported elsewhere (<LINK REF="REF-Addolorato-1997" TYPE="REFERENCE">Addolorato 1997</LINK>; <LINK REF="REF-Addolorato-1999b" TYPE="REFERENCE">Addolorato 1999b</LINK>; <LINK REF="REF-Addolorato-2000" TYPE="REFERENCE">Addolorato 2000</LINK>). When GHB is used as illegal drug, several cases of dependence based on the development of withdrawal symptoms have been described (<LINK REF="REF-Wojtowicz-2008" TYPE="REFERENCE">Wojtowicz 2008</LINK>); and when the dose taken was known, it was always higher than 20 g/day (<LINK REF="REF-Craig-2000" TYPE="REFERENCE">Craig 2000</LINK>), five-fold the therapeutic dose (3-4 g/day). Toxicity from GHB is well documented with some death associated with its use (<LINK REF="REF-Nicholson-2001" TYPE="REFERENCE">Nicholson 2001</LINK>; <LINK REF="REF-Caldicott-2004" TYPE="REFERENCE">Caldicott 2004</LINK>; <LINK REF="REF-CDC-1997" TYPE="REFERENCE">CDC 1997</LINK>), mostly in combination with other drugs.</P>
<P>In conclusion, problems with GHB abuse appear to be confined primarily to polydrug abusers, and when the drug is used outside of the medical context. When GHB is administered under continuous medical surveillance, is kept at or under 50-100 mg/Kg/day and with supervision by a designated family member, cases of abuse and withdrawal are rare.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<IMPLICATIONS_PRACTICE MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>There is insufficient randomised evidence to be confident of a difference between GHB and placebo, or to determine reliably if GHB is more or less effective than other drugs for the treatment of alcohol withdrawal or the prevention of relapses. Based on a single small trial, it appears that GHB might be more effective than placebo in the treatment of AWS, but randomised trials have not shown it to be better than BZD and Clomethiazole.</P>
<P>Based on other small trials, GHB appears more effective than placebo in preventing relapses and craving and maintaining abstinence in previously detoxified alcoholics, and more effective than NTX and Disulfiram in preventing craving and maintaining abstinence, at three months of follow-up.</P>
<P>The side effects of GHB 50mg/Kg/day are limited and manageable, and have not been shown to be different from those with BZD, NTX or Disulfiram. However potential abuse must be considered and the drug must be administered only in the context of medical surveillance.</P>
<P>Since abuse and toxicity are more frequent in polydrug abusers or previous abusers, GHB should not be used for these patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<P>The evidence supporting the results of this review is weak, mainly due to the small number of patients in the included trials. However, because of ethical problems in conducting controlled trials for a condition with a high mortality ratio and an established therapy, new trials comparing GHB with placebo are unlikely. Larger trials comparing GHB to other drugs are warranted, especially because GHB is the sole drug to treat AWS that has also anti-craving effect.</P>
<P>Future trials need to be more consistent in regard to the measurement of standard outcomes, using common scales and time points.</P>
<P>The efficacy and safety of GHB should be evaluated in comparative trials against other drugs, whereas add-on trials are not a priority at the moment.</P>
<P>Non-responders to GHB should be identified, and dose-finding studies are needed to understand the maximum therapeutic dose and the optimal dose schedule.</P>
<P>The effects of GHB for preventing AWS should be evaluated in unintended detoxifications that arise following major health problems, such as accidents, surgery, etc.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-02-17 15:46:14 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Federica Mathis for the help in the search of the literature, and Alessandro Lanszweert for the translation of the German documents. We especially thank Mike Clarke for his careful review and suggestions on the manuscript.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-04-20 15:58:33 +0200" MODIFIED_BY="[Empty name]">
<P>MA Leone, F Vigna-Taglianti, GC Avanzi, R Brambilla, and F Faggiano have no conflict of interest</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-04-20 15:58:00 +0200" MODIFIED_BY="[Empty name]">
<P>MAL, GA and FF conceptualised the review; FV-T and RB performed the literature searches and organised papers collection. FV-T, RB and MAL reviewed the papers. FV-T, RB and MAL abstracted data from the papers for meta-analysis. MAL, GA and FF wrote introduction, discussion and conclusions sections. FV-T and RB wrote abstract, methods, description of studies, methodological quality of included studies and results sections. All authors provided comments to the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-02-25 17:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>The title has been changed.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-04-20 16:58:53 +0200" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-02-04 11:20:46 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-04-08 11:07:54 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-04-08 11:07:54 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addolorato-1999a" MODIFIED="2009-04-02 11:21:51 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 1999a" YEAR="1999">
<REFERENCE MODIFIED="2009-04-02 11:21:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Balducci G, Capristo E, Attilia ML, Taggi F, Gasbarrini G, et al</AU>
<TI>Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine</TI>
<SO>Alcohol Clin Exp Res</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>10</NO>
<PG>1596-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caputo-2003" MODIFIED="2009-04-02 11:22:26 +0200" MODIFIED_BY="[Empty name]" NAME="Caputo 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-02 11:22:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caputo F, Addolorato G, Lorenzini F, Domenicali, Greco G, de RE A, et al</AU>
<TI>Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2003</YR>
<VL>70</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caputo-2007" MODIFIED="2009-04-02 11:22:49 +0200" MODIFIED_BY="[Empty name]" NAME="Caputo 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-04-02 11:22:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, et al</AU>
<TI>Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study</TI>
<SO>Eur Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>12</NO>
<PG>781-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceccanti-1996" MODIFIED="2009-04-02 11:24:26 +0200" MODIFIED_BY="[Empty name]" NAME="Ceccanti 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-02 11:24:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ceccanti M, Attilia M, Ceccanti B, Sebastiani G, Cavalieri G, Devito R, et al</AU>
<TI>Efficacy of therapeutic protocols for the treatment of alcohol withdrawal syndrome (AWS)</TI>
<TO>Efficacia di vari protocolli terapeutici nel trattamento della Sindrome da Astinenza Alcolica (SAA)</TO>
<SO>Alcologia</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>suppl2</NO>
<PG>72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:23:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Ceccanti M, Attilia M, Ceccanti B, Sebastiani G, Cavalieri G, Devito R, et al</AU>
<TI>Efficacy of various therapeutic protocols for the tratment of alcohol withdrawal (AW). The GHB in the treatment of alcohol dependence. State of the art</TI>
<TO>Efficacia di vari protocolli terapeutici nel trattamento della sindrome di astinenza alcolica (SAA). Il sale sodico dell'acido 4-idrossibutirrico (GHB) nel trattamento dell'alcol-dipendenza. Stato dell'arte.</TO>
<SO>Relazioni, comunicazioni e posters presentati al XIV Congresso della Società Italiana di Alcologia, Castel S.Pietro 10-12 Ottobre 1996</SO>
<YR>1996</YR>
<PG>21-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Bello-1995" MODIFIED="2009-04-02 14:22:59 +0200" MODIFIED_BY="[Empty name]" NAME="Di Bello 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:24:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Di Bello MG, Gambassi F, Mugnai L, Masini E, Mannaioni PF</AU>
<TI>Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol dependent patients</TI>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>2</NO>
<PG>111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 14:22:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moncini M, Masini E, Gambassi F, Mannaioni PF</AU>
<TI>Gamma-hydroxybutyric acid and alcohol-related syndromes</TI>
<SO>Alcohol</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>285-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Elsing-1996" NAME="Elsing 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Elsing C, Schimanski U, Stremmel W</AU>
<TI>Randomized controlled trial for the treatment of alcohol withdrawal syndrome: clomethiazole vs. gamma-hydroxybutyric acid</TI>
<SO>Eur J Clin Investig</SO>
<YR>1996</YR>
<VL>26S</VL>
<PG>A17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ferri-1991" MODIFIED="2009-04-02 11:25:08 +0200" MODIFIED_BY="[Empty name]" NAME="Ferri 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-04-02 11:25:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ferri M</AU>
<TI>Association between GHB and disulfiram for the treatment of alcohol dependence</TI>
<TO>L'associazione GHB-Disulfiram nel trattamento della dipendenza alcolica</TO>
<SO>Primo Congresso Nazionale SITD, Roma 25-27 Ottobre 1991</SO>
<YR>October 1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallimberti-1989" MODIFIED="2009-04-02 11:25:41 +0200" MODIFIED_BY="[Empty name]" NAME="Gallimberti 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-04-02 11:25:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallimberti L, Canton G, Gentile N, Ferri M, Cibin M, Ferrara SD, et al</AU>
<TI>Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>787-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallimberti-1992" MODIFIED="2009-04-02 11:26:13 +0200" MODIFIED_BY="[Empty name]" NAME="Gallimberti 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-04-02 11:25:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallimberti L, Ferri M, Ferrara S, Fadda F, Gessa GL</AU>
<TI>Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study</TI>
<SO>Alcoholism Clin Exp Res</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>673-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:26:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gessa GL, Gallimberti L</AU>
<TI>Gamma-hydroxybutyric acid in the treatment of alcohol dependence</TI>
<SO>Neuropharmacol Alcohol</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>suppl1</NO>
<PG>303-4A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nava-2006" MODIFIED="2009-04-02 11:26:04 +0200" MODIFIED_BY="[Empty name]" NAME="Nava 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-02 11:26:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nava F, Premi S, Manzato E, Lucchini A</AU>
<TI>Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions</TI>
<SO>J Psychoactive Drugs</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>3</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nava-2007" MODIFIED="2009-04-02 11:26:22 +0200" MODIFIED_BY="[Empty name]" NAME="Nava 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-04-02 11:26:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL</AU>
<TI>Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs diazepam</TI>
<SO>Am J Drug Alcohol Abuse</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>379-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nimmerrichter-2002" MODIFIED="2010-04-08 11:07:54 +0200" MODIFIED_BY="[Empty name]" NAME="Nimmerrichter 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-02 11:26:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lesch OM, Walter H, Grunhut C, Gutierrez K, Benda N, Semler B, et al</AU>
<TI>GHB efficacy in the therapy of alcoholism: clinical evidence</TI>
<SO>Fundamental Clin Pharmacology</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>21S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-08 11:07:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nimmerrichter AA, Beckmann E, Gazso E, Mader R, Marx B, Plech A, et al</AU>
<TI>Double blind controlled trial of GHB in two dosages and clomethiazole in the treatment of alcohol withdrawal syndrome</TI>
<SO>Alcohol Clin Exp Res</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>suppl</NO>
<PG>32A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-08 11:07:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM</AU>
<TI>Double blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal</TI>
<SO>Alcohol Alcohol</SO>
<YR>2002</YR>
<VL>37</VL>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stella-2008" MODIFIED="2009-04-02 11:27:14 +0200" MODIFIED_BY="[Empty name]" NAME="Stella 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-04-02 11:27:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stella L, Addolorato G, Rinaldi B, Capuano A, Berrino L, Rossi F, et al</AU>
<TI>An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients</TI>
<SO>Pharmacological Research</SO>
<YR>2008</YR>
<VL>57</VL>
<PG>312-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-04-02 11:32:38 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addolorato-1996" MODIFIED="2009-04-02 11:27:51 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-02 11:27:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, et al</AU>
<TI>An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects</TI>
<SO>Alcohol Alcohol</SO>
<YR>1996</YR>
<VL>4</VL>
<PG>341-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:27:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Stefanini GF, Casella G, Marsigli L, Caputo F, Gasbarrini G, and Study Group</AU>
<TI>Evaluation of the therapeutic efficacy of gamma-hydroxybutyric acid in the medium-term treatment of alcoholic outpatients</TI>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>3</NO>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:27:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Stefanini GF, Gasbarrini G</AU>
<TI>Manageability and tolerability of gamma-hydroxybutyric acid in the medium term outpatient treatment of alcoholism</TI>
<SO>Alcohol Clin Exp Res</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>2</NO>
<PG>380-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Addolorato-1998" MODIFIED="2009-04-02 11:28:17 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-04-02 11:28:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Cibin M, Caprista E, Beghè F, Gessa GL, Stefanini GF, et al</AU>
<TI>Maintaining abstinence from alcohol with gamma-hydroxybutyric acid</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:28:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Cibin M, Caputo F, Capristo E, Gessa GL, Stefanini GF, et al</AU>
<TI>Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients</TI>
<SO>Drug Alcohol Dep</SO>
<YR>1998</YR>
<VL>53</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Avanzi-1996" MODIFIED="2009-04-02 11:28:31 +0200" MODIFIED_BY="[Empty name]" NAME="Avanzi 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-02 11:28:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Avanzi M, Bonomini M, Federici F, Spotti R, Bonfà F</AU>
<TI>Utility of the association GHB and disulfiram in the treatment of alcohol dependence</TI>
<TO>Utilità dell'associazione GHB e disulfiram nel trattamento della dipendenza da alcol</TO>
<SO>Alcologia</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>suppl2</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldelli-1993" MODIFIED="2009-04-02 11:29:00 +0200" MODIFIED_BY="[Empty name]" NAME="Baldelli 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-04-02 11:29:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baldelli C, De Luca AM, Conte M, Spedo C, Carabini P, Amato L, et al</AU>
<TI>Use of GHB for the treatment of opiate and alcohol withdrawal syndrome</TI>
<TO>Impiego dell'acido gamma-idrossibutirrico (GHB) nel trattamento contemporaneo della sindrome di astinenza da alcol e oppioidi</TO>
<SO>Atti dell'XI Congresso Nazionale SIA, Bari 14-16 Ottobre</SO>
<YR>1993</YR>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balducci-1993" MODIFIED="2009-04-02 11:29:21 +0200" MODIFIED_BY="[Empty name]" NAME="Balducci 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-04-02 11:29:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Balducci G, Attilia ML, Cavalieri G, Romeo M, Santini P, Devito R, et al</AU>
<TI>Alcohol dependence and GHB: valuation of the anti craving efficacy in chronic alcoholism</TI>
<TO>Dipendenza alcolica e GHB: valutazione dell'efficacia anticraving in corso di alcolismo cronico</TO>
<SO>Atti dell'XI Congresso Nazionale SIA, Bari 14-16 Ottobre</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caputo-2006" MODIFIED="2009-04-02 11:29:41 +0200" MODIFIED_BY="[Empty name]" NAME="Caputo 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-02 11:29:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Caputo F, Stoppo M, Vignoli T, Lorenzini F, Del Re A, Andreone P, et al, Alcoholism Treatment Study Group</AU>
<TI>Gamma-idroxybutyric GHB acid plus naltrexone in the treatment of non-responder alcoholics to GHB therapy. an open randomized comparative study</TI>
<SO>Alcohol Clin Experim Res</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>suppl 6</NO>
<PG>107A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceccanti-1995" MODIFIED="2009-04-02 11:29:56 +0200" MODIFIED_BY="[Empty name]" NAME="Ceccanti 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:29:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ceccanti M, Attilia ML, Blum K, Cavaleri G, Franzese A, Sasso GF, et al</AU>
<TI>Gamma-hydroxybutyric acid versus benzodiazepines: a clinical study in chronic alcoholics</TI>
<SO>Acta Toxicol Ther</SO>
<YR>1995</YR>
<VL>XVI</VL>
<NO>4</NO>
<PG>231-242</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cibin-1995" MODIFIED="2009-04-02 11:30:06 +0200" MODIFIED_BY="[Empty name]" NAME="Cibin 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:30:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cibin M, Zavan V</AU>
<TI>GHB and multimodal treatment of alcohol dependence: a clinical experience</TI>
<TO>GHB e trattamento multimodale dell'alcoldipendenza: una esperienza clinica</TO>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>suppl2</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Rosa-1997" MODIFIED="2009-04-02 11:30:18 +0200" MODIFIED_BY="[Empty name]" NAME="De Rosa 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-04-02 11:30:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Rosa MGL, Pierini C, Leali G, Marchesi GF</AU>
<TI>GHB and multimodal treatment in alcohol dependents with prevalent psychiatric comorbidity</TI>
<TO>GHB e trattamento multimodale in alcol-dipendenti a prevalente comorbilità psichiatrica</TO>
<SO>Alcologia</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>suppl2</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korninger-2003" MODIFIED="2009-04-02 11:30:26 +0200" MODIFIED_BY="[Empty name]" NAME="Korninger 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-02 11:30:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korninger C, Roller RE, Lesch OM</AU>
<TI>Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital</TI>
<SO>Acta Med Austriaca</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>83-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leder-1993" MODIFIED="2009-04-02 11:30:34 +0200" MODIFIED_BY="[Empty name]" NAME="Leder 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-04-02 11:30:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Leder F, Galimberti G, Strepparola G, Lucchini A</AU>
<TI>Use of GHB in the treatment of chronic alcoholism: results on 22 subjects</TI>
<TO>Impiego dell'acido gamma-idrossibutirrico (GHB) nel trattamento dell'alcolismo cronico: i risultati su 22 soggetti</TO>
<SO>Atti dell'XI Congresso Nazionale SIA, Bari 14-16 Ottobre</SO>
<YR>1993</YR>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenzenhuber-1999" NAME="Lenzenhuber 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lenzenhuber E, Muller C, Rommelspacher H, Spies C</AU>
<TI>Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts</TI>
<SO>Anaesthesist</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>2</NO>
<PG>89-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liboni-1995" MODIFIED="2009-04-02 11:30:47 +0200" MODIFIED_BY="[Empty name]" NAME="Liboni 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:30:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liboni W, Cipolla U, Oddenino E, Pasquero G</AU>
<TI>Outpatient experience of treatment with GHB for alcohol dependence</TI>
<TO>Esperienza ambulatoriale di trattamento con acido gamma idrossibutirrico della dipendenza alcolica</TO>
<SO>Gazz Med Ital - Arch Sci Med</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>1</NO>
<PG>9-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manzato-1995" MODIFIED="2009-04-02 11:30:56 +0200" MODIFIED_BY="[Empty name]" NAME="Manzato 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:30:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Manzato E, Cantiero D, Faccini M</AU>
<TI>Day hospital treatment with GHB for alcohol dependence</TI>
<TO>Il GHB nel trattamento della dipendenza alcolica in pazienti ambulatoriali (day hospital)</TO>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>suppl2</NO>
<PG>59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcelli-1996" MODIFIED="2009-04-02 11:31:10 +0200" MODIFIED_BY="[Empty name]" NAME="Marcelli 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-04-02 11:31:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marcelli G, Cenci M, Casacchia M</AU>
<TI>The control of the craving using GHB in outpatient setting in the alcohol treatment centre of psychiatric clinic of the University of l'Aquila</TI>
<TO>Il controllo ambulatoriale del craving con GHB nel centro alcologico della clinica psichiatrica universitaria di L'Aquila</TO>
<SO>Alcologia</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>suppl2</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maremmani-1998" NAME="Maremmani 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maremmani I, Balestri C, Lamanna F, Tagliamonte A</AU>
<TI>Efficacy of split doses of GHB as anticraving in the treatment of alcohol dependence, preliminary results</TI>
<SO>Alcoholism</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>1-2</NO>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maremmani-2001" MODIFIED="2009-04-02 11:31:38 +0200" MODIFIED_BY="[Empty name]" NAME="Maremmani 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-02 11:31:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maremmani I, Lamanna F, Tagliamonte A</AU>
<TI>Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics</TI>
<SO>J Psychoactive Drugs</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>2</NO>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:31:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Maremmani I, Raimondi F, Castrogiovanni P</AU>
<TI>The GHB in the treatment of alcoholism: from abstinence to craving</TI>
<SO>New Trends Exp Clin Psychiatry</SO>
<YR>1996</YR>
<VL>XII</VL>
<NO>3</NO>
<PG>189-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montesano-1997" MODIFIED="2009-04-02 11:31:27 +0200" MODIFIED_BY="[Empty name]" NAME="Montesano 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-04-02 11:31:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Montesano F, Montesano S, Mellace V, Battaglia E</AU>
<TI>Our experience in the rational use of GHB in alcoholists</TI>
<TO>L'uso razionale dell'acido gammaidrossibutirrico (GHB) nei soggetti alcolisti secondo la nostra esperienza</TO>
<SO>Alcologia</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>suppl2</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mosti-1995" MODIFIED="2009-04-02 11:31:47 +0200" MODIFIED_BY="[Empty name]" NAME="Mosti 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:31:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mosti A, Zurla R</AU>
<TI>The GHB in territorial clinical practice: preliminary analysis of 100 cases</TI>
<TO>L'acido 4-idrossibutirrico (GHB) nella pratica clinica territoriale: analisi preliminare di 100 casi</TO>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>suppl2</NO>
<PG>63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strepparola-1995" MODIFIED="2009-04-02 11:32:04 +0200" MODIFIED_BY="[Empty name]" NAME="Strepparola 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:32:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Strepparola G, Alietti M, Mascherpa M, Galimberti G, Tosi M, Leder F, et al</AU>
<TI>Is possible to treat craving? Our experince with GHB</TI>
<TO>E' possibile il trattamento del craving? La nostra esperienza con l'acido gamma-idrossibutirrico</TO>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>suppl2</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vendramin-1995" MODIFIED="2009-04-02 11:32:22 +0200" MODIFIED_BY="[Empty name]" NAME="Vendramin 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-02 11:32:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vendramin A, Bertuola C</AU>
<TI>Contribute of the use of GHB alone or with SSRI for the treatment of alcoholism associated with psychopathological disorders. Benfits for a psychotherapeutic integrate approach</TI>
<TO>Contributo del GHB da solo o in associazione con SSRI nel trattamento dell'alcolismo correlato a disturbi psicopatologici. Benefici per l'approccio psicoterapeutico integrato</TO>
<SO>Alcologia</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>suppl2</NO>
<PG>75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vittadini-1993" MODIFIED="2009-04-02 11:32:38 +0200" MODIFIED_BY="[Empty name]" NAME="Vittadini 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-04-02 11:32:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vittadini G, Gabanelli P, Giorgi I</AU>
<TI>Effects of a brief therapy with GHB on absinence, one, three, six months follow up study</TI>
<TO>Studio degli effetti di una terapia a breve termine con GHB sull'astinenza in un follow-up a uno, tre, sei mesi.</TO>
<SO>Atti dell'XI Congresso Nazionale SIA, Bari 14-16 Ottobre</SO>
<YR>1993</YR>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-10-10 16:13:32 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Lesch-2000a" MODIFIED="2009-10-10 16:13:19 +0200" MODIFIED_BY="[Empty name]" NAME="Lesch 2000a" YEAR="2000">
<REFERENCE MODIFIED="2009-04-02 11:32:50 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;study protocol&lt;/p&gt;" NOTES_MODIFIED="2009-04-02 11:32:50 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lesh OM</AU>
<TI>Double-blind, double-dummy evaluation of the efficacy of GHB versus benzodiazepine in the acute withdrawal detoxification (GATE 1)</TI>
<SO>(GATE 1)</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:33:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rotondo C, Prastaro A, Attilia ML, Ceccanti M</AU>
<TI>Detoxification and alcohol abstinence. The role of GHB</TI>
<TO>Disintossicazione e astinenza dall'alcol. Il ruolo del GHB</TO>
<SO>Mission (FeDerSerD)</SO>
<YR>2007</YR>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lesch-2000b" MODIFIED="2009-10-10 16:13:32 +0200" MODIFIED_BY="[Empty name]" NAME="Lesch 2000b" YEAR="2000">
<REFERENCE MODIFIED="2009-04-02 11:33:34 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;study protocol&lt;/p&gt;" NOTES_MODIFIED="2009-04-02 11:33:34 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lesh OM</AU>
<TI>Multinational, multicentre, double-blind, placebo-controlled evaluation of the efficacy of GHB in the long-term maintenance of abstinence in alcoholic patients after the initial weaning phase, stratified by Lesch's taxonomy (GATE 2)</TI>
<SO>GATE 2</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-02 11:33:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rotondo C, Prastaro A, Attilia ML, Ceccanti M</AU>
<TI>Detoxification and alcohol withdrawal. The role of GHB</TI>
<TO>Disintossicazione e astinenza dall'alcol. Il ruolo del GHB</TO>
<SO>Mission (FeDerSerD)</SO>
<YR>2007</YR>
<PG>13-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-02-04 11:20:46 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-02-04 11:20:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Addolorato-1997" MODIFIED="2009-04-02 11:33:54 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 1997" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Caputo F, Stefanini GF, Gasbarrini G</AU>
<TI>Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug.</TI>
<SO>Addiction</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>1035-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Addolorato-1998" MODIFIED="2009-04-02 11:34:20 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 1998" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Cibin M, Capristo E, Beghè F, Gessa GL, Stefanini GF, et al</AU>
<TI>Maintaining abstinence from alcohol with gamma-hydroxybutyric acid</TI>
<SO>The Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Addolorato-1999b" MODIFIED="2009-04-02 11:34:38 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Caputo F, Capristo E, Bernardi M, Stefanini GF, Gasbarrini G</AU>
<TI>A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration</TI>
<SO>Clin Neuropharmacol</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>60-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Addolorato-2000" MODIFIED="2009-04-02 11:34:44 +0200" MODIFIED_BY="[Empty name]" NAME="Addolorato 2000" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Caputo F, Capristo E, Stefanini F, Gasbarrini G</AU>
<TI>Gamma-hydroxybutyric acid Efficacy, potential abuse, and dependence in the treatment of alcohol addiction</TI>
<SO>Alcohol</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agabio-1998" MODIFIED="2009-04-02 11:35:00 +0200" MODIFIED_BY="[Empty name]" NAME="Agabio 1998" TYPE="JOURNAL_ARTICLE">
<AU>Agabio R, Colombo G, Loche A, Lobina C, Pani ML, Reali R, et al</AU>
<TI>Gamma-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism</TI>
<SO>Alcohol Alcohol</SO>
<YR>1998</YR>
<VL>33</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begh_x00e8_-2000" MODIFIED="2009-04-02 11:35:21 +0200" MODIFIED_BY="[Empty name]" NAME="Beghè 2000" TYPE="JOURNAL_ARTICLE">
<AU>Beghè F, Carpanini MT</AU>
<TI>Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients</TI>
<SO>Alcohol</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>223-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bender-2008" MODIFIED="2011-02-04 11:20:46 +0100" MODIFIED_BY="[Empty name]" NAME="Bender 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bender R, Bunce C, Clarke M, Gates S, Lange S, Pace NL, Thorlund K</AU>
<TI>Attention should be given to multiplicity issues in systematic reviews</TI>
<SO>J Clin Epidemiol</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>9</NO>
<PG>857-865</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caldicott-2004" MODIFIED="2009-04-02 11:35:29 +0200" MODIFIED_BY="[Empty name]" NAME="Caldicott 2004" TYPE="JOURNAL_ARTICLE">
<AU>Caldicott DGE, Chow F, Burns BJ, Felgate P, Byard RW</AU>
<TI>Fatalities associated with use of gamma-hydroxybutyrate and its analogues in Australasia</TI>
<SO>MJA</SO>
<YR>2004</YR>
<VL>181</VL>
<PG>310-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caputo-2008" MODIFIED="2009-04-02 11:35:14 +0200" MODIFIED_BY="[Empty name]" NAME="Caputo 2008" TYPE="OTHER">
<AU>Caputo F, Francini S, Stoppo M, Lorenzini F, Vignoli T, Del Re A, et al</AU>
<TI>Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study</TI>
<SO>J Psychopharmacol</SO>
<YR>2008</YR>
<VL>[Epub ahead of print]</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caputo-2011" MODIFIED="2011-02-04 10:40:00 +0100" MODIFIED_BY="[Empty name]" NAME="Caputo 2011" TYPE="JOURNAL_ARTICLE">
<AU>Caputo F, Francini S, Brambilla R, Taglianti FV, Stoppo M, Del Re A, Leggio L, Addolorato G, Zoli G, Bernardi M</AU>
<TI>Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity</TI>
<SO>Eur Neuropsychopharmacol</SO>
<YR>2011 Jan 26</YR>
<VL>doi: 10.1016/j.euroneuro.2010.12.005 </VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-1997" MODIFIED="2009-04-02 11:35:36 +0200" MODIFIED_BY="[Empty name]" NAME="CDC 1997" TYPE="JOURNAL_ARTICLE">
<AU>Center for Disease Control and Prevention</AU>
<TI>Gamma-hydroxybutyrate use-New York and Texas, 1995-96</TI>
<SO>Morb Mortal Wkly Rep</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>281-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colombo-1995" MODIFIED="2009-04-02 11:35:44 +0200" MODIFIED_BY="[Empty name]" NAME="Colombo 1995" TYPE="JOURNAL_ARTICLE">
<AU>Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL</AU>
<TI>Symmetrical generalization between the discriminative stimulus effects of gamma-hydroxybutyric acid and ethanol: occurrence within narrow dose ranges</TI>
<SO>Physiol Behav</SO>
<YR>1995</YR>
<VL>57</VL>
<PG>105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colombo-1998" NAME="Colombo 1998" TYPE="JOURNAL_ARTICLE">
<AU>Colombo G, Agabio R, Diaz G, Reali R, Gessa GL</AU>
<TI>Gamma-hydroxybutyric acid (GHB) intake in ethanol-preferring (sP) and -nonpreferrig (sNP) rats</TI>
<SO>Physiol Behav</SO>
<YR>1998</YR>
<VL>64</VL>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Craig-2000" NAME="Craig 2000" TYPE="JOURNAL_ARTICLE">
<AU>Craig K, Gomez HF, McManus JL, Bania T</AU>
<TI>Severe gamma-hydroxybutyrate withdrawal: a case report and literature review.</TI>
<SO>J Emerg Med</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>6-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM-IV_x002d_R-1994" NAME="DSM IV-R 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders. IV Edition</SO>
<YR>1994</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMCDDA-2002" MODIFIED="2008-12-29 11:06:29 +0100" MODIFIED_BY="[Empty name]" NAME="EMCDDA 2002" TYPE="OTHER">
<AU>European Monitoring Centre for Drugs and Drug Addiction</AU>
<TI>Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs</TI>
<SO>www.emcdda.europa.eu/html.cfm/index33345EN.html</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2006" MODIFIED="2009-04-02 11:36:04 +0200" MODIFIED_BY="[Empty name]" NAME="FDA 2006" TYPE="OTHER">
<TI>US Food and Drug Administration</TI>
<SO>US Department of Health and Human Services</SO>
<PG>http//www.fda.gov</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frau-1995" MODIFIED="2009-04-02 11:36:12 +0200" MODIFIED_BY="[Empty name]" NAME="Frau 1995" TYPE="JOURNAL_ARTICLE">
<AU>Frau M, Colombo G, Marchese G, Stefanini E, Gessa GL</AU>
<TI>Different affinity of cortical GHB binding site in sardinian alcohol-preferring (sP) and -nonpreferring (sNP) rats</TI>
<SO>Alcohol Alcohol</SO>
<YR>1995</YR>
<VL>30</VL>
<PG>133-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallimberti-2000" MODIFIED="2009-04-02 11:40:40 +0200" MODIFIED_BY="[Empty name]" NAME="Gallimberti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gallimberti L, Spella MR, Soncini CA, Sessa GL</AU>
<TI>Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence</TI>
<SO>Alcohol</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gessa-2000" MODIFIED="2009-04-02 11:36:23 +0200" MODIFIED_BY="[Empty name]" NAME="Gessa 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gessa GL, Agabio R, Carai M, Lobina C, Pani M, Reali R, et al</AU>
<TI>Mechanism of the anti-alcohol effect of gamma-hydroxybutyric acid (GHB)</TI>
<SO>Alcohol</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-10-08 12:55:59 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008</YR>
<VL>Available from www.cochrane-handbook.org</VL>
<NO>.</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillbom-2003" NAME="Hillbom 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hillbom M, Pieninkeroinen I, Leone M</AU>
<TI>Seizures in Alcohol-Dependent Patients. Epidemiology, Pathophysiology and Management</TI>
<SO>CNS Drugs</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>1013-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2005" MODIFIED="2009-04-02 11:40:51 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Swift R, Addolorato G, Ciraulo D, Myrick H</AU>
<TI>Safety and efficacy of GABAergic medications for treating alcoholism</TI>
<SO>Alcohol Clin Exp Res</SO>
<YR>2005</YR>
<VL>29</VL>
<PG>248-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maremmani-2007" NAME="Maremmani 2007" TYPE="JOURNAL_ARTICLE">
<AU>Maremmani I, Pacini M</AU>
<TI>Use of sodium gamma-hydroxybutyrate (GHB) i n alcoholic heroin addicts and polydrug-abusers</TI>
<SO>Heroin Addict Relat Clin Probl</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>55-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morton-1994" NAME="Morton 1994" TYPE="JOURNAL_ARTICLE">
<AU>Morton A, Laird LK, Crane DF, Partovi N, Frye LH</AU>
<TI>A prediction model for identifying alcohol withdrawal seizures</TI>
<SO>Am J Drug Alcohol Abuse</SO>
<YR>1994</YR>
<VL>20</VL>
<PG>75-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-2001" NAME="Nicholson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Nicholson KL, Balster RL</AU>
<TI>GHB: a new and novel drug of abuse</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2001</YR>
<VL>63</VL>
<PG>1-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connor-1998" NAME="O'Connor 1998" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor PG, Schottenfeld RS</AU>
<TI>Patients with alcohol problems</TI>
<SO>N Engl J Med</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>592-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pieninkeroinen-1992" MODIFIED="2009-04-02 11:41:25 +0200" MODIFIED_BY="[Empty name]" NAME="Pieninkeroinen 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pieninkeroinen IP, Telakivi TM, Hillbom ME</AU>
<TI>Outcome in subjects with alcohol-provoked seizures</TI>
<SO>Alcohol Clin Exp Res</SO>
<YR>1992</YR>
<VL>16</VL>
<PG>955-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schuckit-1995" NAME="Schuckit 1995" TYPE="BOOK_SECTION">
<AU>Schuckit MA</AU>
<TI>Alcoholism acute treatment</TI>
<SO>Drug and alcohol abuse. A clinical guide to diagnosis and treatment</SO>
<YR>1995</YR>
<PG>97-117</PG>
<EN>IV</EN>
<ED>MA Schuckit</ED>
<PB>Plenum Medical Book Co</PB>
<CY>New York-London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2003" MODIFIED="2008-12-29 10:18:51 +0100" MODIFIED_BY="[Empty name]" NAME="SIGN 2003" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network</AU>
<TI>The management of harmful drinking and alcohol dependence in primary care. A national clinical guideline</TI>
<SO>www.sign.ac.uk</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-1997" NAME="Tan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tan CY, Weaver DF</AU>
<TI>Molecular pathogenesis of alcohol withdrawal seizures: the modified lipid-protein interaction mechanism</TI>
<SO>Seizure</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>255-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2004" MODIFIED="2009-10-30 13:56:48 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2004" TYPE="BOOK">
<AU>WHO</AU>
<TI>WHO Global Status Report on Alcohol</TI>
<SO>www.who.int</SO>
<YR>2004</YR>
<PB>Department of Mental Health and Substance Abuse, WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2009-10-30 13:56:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wojtowicz-2008" NAME="Wojtowicz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wojtowicz JM, Yarema MC, Wax PM</AU>
<TI>Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review</TI>
<SO>CJEM</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Addolorato-1999a">
<CHAR_METHODS MODIFIED="2009-02-27 15:05:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Single blind.<BR/>The 60 enrolled subjects fulfilling the inclusion criteria were randomly divided into the two groups of treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-04 11:00:44 +0100" MODIFIED_BY="[Empty name]">
<P>60 subjects were randomly assigned to the experimental groups, out of 145 subjects affected by current alcoholism and consecutively enrolled from March 1996 until December 1998. Inclusion criteria: age 18-65 years; a daily alcohol consumption over 80 gr ethanol/day during the last 24 hours; a diagnosis of alcohol abuse and/o dependence according to DSM IV criteria.<BR/>Exclusion criteria: delirium tremens; alcoholic hallucinosis; severe psychiatric diseases; epilepsy; severe cardiac failure; diabetes mellitus; severe liver impairment; hepatic encephalopathy; kidney failure; neoplastic diseases; patients without cooperating relatives; polydrug abusers; Mini Mental State Examination score &lt;10. Only the subjects with a CIWA-Ar score &gt;= 10 points (moderate or severe AWS) were finally enrolled in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Two experimental conditions:<BR/>- GHB group (n=30): subjects were treated with oral doses of GHB of 50 mg/kg body weight fractioned in three daily doses for 10 days.<BR/>- diazepam group (n=30): subjects were treated with decreasing oral doses of diazepam. A total of 0.5 to 0.75 mg/kg body weight of diazepam were administered by dividing into six administrations/day for 6 days. A dose reduction of at least 25% daily was therefore tapered up to day 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>After a 12-hours fast, venous blood samples were drawn on days 1 and 10 in order to perform routine blood examinations, including AST, ALT, GGT, MCV parameters.<BR/>All the subjects were given a questionnaire that extracted information on level of education, economic and social status, and contained two different self-rating psychometric test, for current anxiety (State Anxiety Inventory) and for depression (SDS Zung). Psychological tests were administered 15 min before drug administration from day 1 (baseline) to day 18.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Caputo-2003">
<CHAR_METHODS MODIFIED="2009-05-05 08:01:35 +0200" MODIFIED_BY="[Empty name]">
<P>RCT. Open randomised study.<BR/>The 35 patients were randomly assigned to the two groups of treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>35 recently detoxified alcohol dependent outpatients were randomly assigned to two experimental groups. Alcohol dependence was defined according to the DSM-IV criteria. Exclusion criteria: severe liver, kidney, hearth or lung disease, epilepsy or epileptiform convulsion, polydrug addiction, psychiatric co-morbidity, previous treatment of withdrawal syndrome with GHB during the detoxification period and previous treatment with either NTX or GHB for maintaining alcohol abstinence.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Two experimental conditions:<BR/>- GHB group (n=18): patients were treated with oral doses of GHB (50 mg/kg body weight) for 3 months.<BR/>- Naltrexone group (n=17): patients were treated with oral doses of NTX (5 mg/day) for 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 17:48:46 +0200" MODIFIED_BY="[Empty name]">
<P>Each subject was checked as an outpatient every week for 12 weeks. Craving level was evaluated by administration of the Alcohol Craving Scale (ACS) at the time of admission to the study and at the end of the 3 months of treatment. The abstinence from alcohol, the amount of alcohol intake, recorded as daily drinks and number of relapses in heavy drinking were evaluated on the basis of the participant's self evaluation, the interview of a family member and the determination of blood alcohol concentrations and alcohol in the saliva at the end of every week of treatment. Laboratory parameters (AST, ALT, GGT, MCV) were also tested on admission and at the end of the study.</P>
<P>Relapse in heavy drinking was defined as five or more drinks on one occasion for men and four or more drinks on one occasion for women.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-04 11:00:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caputo-2007">
<CHAR_METHODS MODIFIED="2010-01-04 11:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Open randomised study.<BR/>The 55 patients were randomly assigned to the three groups of treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-05 08:02:04 +0200" MODIFIED_BY="[Empty name]">
<P>55 alcoholics consecutively admitted over a period of 24 months to the centres involved in the research in Bologna and Cosenza, were randomly allocated to three experimental groups.<BR/>Inclusion criteria were:<BR/>- alcohol dependence as defined according to the DSM-IV-R criteria<BR/>- completion of a detoxification treatment<BR/>- maintenance of abstinence from alcohol for 7 days.<BR/>Exclusion criteria were: severe liver, kidney, heart or lung disease, epilepsy, withdrawal seizures, polydrug addiction, psychiatric co-morbidity according to DSM-IV-R criteria, and previous treatment with either NTX or GHB.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>After providing their informed consent, the patients were randomly allocated to three groups: <BR/>- GHB (n=20): 50mg/kg fractioned in three daily doses for 3 months<BR/>- GHB + NTX (n=18): 50mg/kg of GHB fractioned in three daily doses for 3 months + 50mg/kg/day of NTX for 3 months<BR/>- NTX (n=17): 50mg/kg/day of NTX for 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 17:49:36 +0200" MODIFIED_BY="[Empty name]">
<P>Four physicians (three internists and one psychiatrist) checked every outpatient weekly for 3 months, recording abstinence from alcohol, amount of daily alcohol intake, and relapse in heavy drinking. These parameters were assessed on the basis of participant self-evaluation, the interview of a family member and the determination of alcohol concentrations in blood and saliva. At admission to the study and at the end of treatment, they also evaluated craving, by administration of the Alcohol Craving Scale, and laboratory parameters of alcohol abuse (AST, ALT, GGT, MCV).</P>
<P>Relapse in heavy drinking was defined as five or more drinks on one occasion for men and four or more drinks on one occasion for women.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-14 15:40:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Ceccanti-1996">
<CHAR_METHODS MODIFIED="2009-10-08 15:08:05 +0200" MODIFIED_BY="[Empty name]">
<P>RCTs. Unclear blinding.<BR/>GHB vs oxazepam.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-04 11:01:10 +0100" MODIFIED_BY="[Empty name]">
<P>42 male patients, hospitalised in the Alcohol Unit at the University of Roma La Sapienza, were included at random in the study, selected from a population of alcoholics. Inclusion criteria: age 18-65 years, daily alcohol consumption over 80g/ethanol/day during the last 24 hours, diagnosis included among DSM III R (303.90-305.00-303.00), Mini Mental State Examination score&gt;=8, CIWA-Ar &gt;=10.<BR/>Exclusion criteria: delirium tremens, alcoholic hallucinosis, psychiatric diseases, epilepsy, severe cardiac failure, diabetes mellitus, severe liver impairment, hepatic encephalopathy, kidney failure, severe neoplastic or degenerative disease, no cooperating relatives, abusers of other legal and illegal drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients were randomly assigned to two experimental conditions:<BR/>- GHB (n=not specified): 50mg/kg in three administrations per day; <BR/>- oxazepam (n=not specified): 80-120 mg fractioned in three administrations per day.<BR/>The treatments were administered from day 1 through day 10, followed by wash-out through day 18.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>STAI Y1 (State Anxiety Interview Y1) test for the assessment of the anxiety state level was performed each day from day 1 to day 5, at day 10 and at day 18, between 9 and 10 am.<BR/>SDS Zung test (Self reported Depression Scale by Zung) for the assessment of depression and CIWA-Ar test were performed as STAI Y1 test. <BR/>At day 1, 10 and 18 venous blood was drawn and markers of alcohol intake were tested (AST, ALT, AST/ALT, GGT, MCV, CDT).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-09 18:40:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Bello-1995">
<CHAR_METHODS MODIFIED="2009-03-26 11:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Double blind.<BR/>Patients were randomly assigned to the two experimental groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 patients out of 182 alcohol-dependent subjects admitted to the Toxicological Unit of the Department of Pharmacology in Florence from June 1992 to December 1993 entered the experimental study. Patients had severe alcohol dependence, according to the DSM-IV criteria, with an average ethanol intake of 150 ml ethanol per day. Patients admitted to the experimental study were previously detoxified with an inpatient protocol. Patients were excluded if they had severe neurological or psychiatric illnesses.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-08 12:45:21 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to two groups:<BR/>- GHB (n=9): sodium salt of GHB dissolved in a brown cherry syrup, at a concentration of 175 mg/ml, mean daily dose 50 mg/kg<BR/>- placebo (n=8):<BR/>They received the detoxification treatment in the hospital, and thereafter randomly assigned to the groups and monitored as outpatients for 6 months. They were treated in a double-blind manner, with solutions A and B, and checked every two weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 18:40:24 +0200" MODIFIED_BY="[Empty name]">
<P>Medical and psychological examinations were carried out every week for 6 months. The intensity of alcohol craving was assessed with a questionnaire, the Alcohol Craving Scale, devised and validated in Italy. The questionnaire contained 14 items, 11 of which required a positive or negative answer, corresponding to 0 or 1 points, respectively, whereas the last 3 items were in multiple-choice form, with 1 point assigned to an answer if present. The minimum craving score was 0 and the maximum score was 14 points.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-26 11:23:45 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Elsing-1996">
<CHAR_METHODS MODIFIED="2009-10-08 15:14:03 +0200" MODIFIED_BY="[Empty name]">
<P>RCT. Patients were randomly assigned to the two experimental groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 patients with severe alcohol withdrawal syndrome were included in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-08 11:04:24 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to two groups:<BR/>- GHB (n=11): 30 mg/kg BW followed by 15 mg/kg BW i.v.<BR/>- Clomethiazole (n=10): 250 mg every 4 hours as a mixture</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Four major withdrawal syndromes were evaluated: tremors, sweating, nausea, restlessness. Each symptom was scored on a 4 point scale, and the sum gave the total score of symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-04 11:02:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferri-1991">
<CHAR_METHODS MODIFIED="2009-03-26 11:34:23 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Double blind.<BR/>Patients were randomly assigned to the two experimental groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 alcohol dependent patients were included in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-04 11:02:04 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to two groups:<BR/>- Disulfiram + GHB (n=20)<BR/>- Disulfiram + placebo (n=20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Alcohol Craving Scale was completed for the patients at 1, 2 and 3 months follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-27 16:04:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-05 08:02:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallimberti-1989">
<CHAR_METHODS MODIFIED="2009-03-26 11:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Double blind.<BR/>Patients were randomly allocated to the two experimental groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>23 patients were included in the study; they were alcoholics who met the DSM-III R criteria of alcohol withdrawal syndrome. Patients were excluded if they had convulsions, delirium tremens, or concurrent severe illness, or if they abused other drugs, or were receiving antiepileptic treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>On admission, patients were clinically examined and randomly allocated to one of two groups:<BR/>- GHB group (n=11): patients received one dose of 50 mg/kg body weight dissolved in a black cherry syrup<BR/>- control group (n=12): patients received a corresponding volume of syrup alone.<BR/>The patients did not know whether they were receiving GHB or vehicle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-05 08:02:58 +0200" MODIFIED_BY="[Empty name]">
<P>Clinical evaluations were done by the same investigator who was blind to treatment group.<BR/>On the morning after admission, each patient was examined 30 minutes before the dose of GHB was given, and 1-2-3-5 and 7 hours later. Six main withdrawal symptoms were evaluated, i.e. tremors, sweating, nausea, depression, anxiety, and restlessness. Each symptom was scored on a 4-point scale (0=not present, 1=mild, 2=moderate, 3=severe). The sum of these points gave the total score of symptoms for each patient, the maximum being 18 points. The total score was used as an index of severity of withdrawal. Blood pressure and heart rate were also recorded every day. Routine laboratory tests were carried out on admission and were repeated if there were any abnormalities.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-27 15:43:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Gallimberti-1992">
<CHAR_METHODS MODIFIED="2009-03-26 11:35:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT. Double blind.<BR/>Patients were randomly assigned to the two experimental groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>82 alcoholic patients entered the study sequentially over a 1-year period. Patients included in the study had a 5-year or more history of alcoholism defined according to the DSM III-R criteria, and an average daily ethanol intake in excess of 150 g for the past 2 years or more. Exclusion criteria were a major psychiatric disorder other than alcohol dependence, cirrhosis of the liver, pregnancy, renal or heart failure, epilepsy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-04 11:02:24 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to two groups, studied for 3 months:<BR/>- GHB (n=41): patients received 50 mg/kg of GHB dissolved in a black cherry syrup, divided into three daily doses.<BR/>- placebo (n=41): patients received a placebo syrup with the same organoleptic characteristics as the active medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-04 11:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>Within 8 hours of admission to the day-hospital, each subject underwent a full physical examination by a physician of the team and routine laboratory tests, including SGT, MCV and acholuria. Each subject was also examined for depression (Hamilton Depression scale), anxiety (Spielberg's State and Trait Anxiety Scale), and severity of alcoholism (Veterans Alcoholism Screening Test).<BR/>Patients received the first medical interview and treatment in the day-hospital; thereafter they were followed up as outpatients and seen every day for the first 3 days and then at weekly intervals. At the weekly visit subjects provided a urine sample for measurement of alcohol concentration and were interviewed by one of the physicians (blinded to treatment) about their alcohol intake and the intensity of craving. A self-reported alcohol intake was recorded as the mean number of standard drinks consumed per day and the percentage of days of abstinence. Intensity of craving was assessed with a questionnaire derived, with modifications, from Stunkard and Messick's questionnaire to measure dietary restraint, disinhibition, and hunger. The questionnaire contained 11 items, each of which required a yes or no answer, corresponding to 1 or 0 points, respectively, with a maximum craving score of 11 points.<BR/>At the end of the 3rd month, subjects were categorized in three groups:<BR/>- abstinence group<BR/>- controlled drinking group: less than 40g alcohol per day<BR/>- excessive drinking group: more than 40g alcohol per day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-18 11:41:35 +0100" MODIFIED_BY="Laura Amato"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-04 11:02:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nava-2006">
<CHAR_METHODS MODIFIED="2009-05-05 08:03:29 +0200" MODIFIED_BY="[Empty name]">
<P>RCT. Open randomised study.<BR/>The 86 alcohol dependent outpatients fulfilling the inclusion criteria were randomised to study conditions. The randomisation assignments were generated via computer software.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-05 08:03:36 +0200" MODIFIED_BY="[Empty name]">
<P>86 alcohol dependent outpatients, out of 114 recruited through advertisements, words-of-mouth, and local press release in the Lombardia Region from September 2001 to September 2002, were randomised to study conditions. To be included in the research participants were required to meet the following inclusion criteria: DSM-IV TR diagnosis for alcohol dependence, complete abstinence for at least 14 days, free of any withdrawal syndrome, age 18 years or older. Exclusion criteria: pregnancy, nursing, or refusal to use a reliable method of birth control in woman, psychiatric comorbidity as evaluated by DSM-IV TR criteria, polydrug addiction, HIV antibodies, serious physical illness, previous pharmacological treatment for alcohol abuse, current use of any psychotropic medication, homelessness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-04 11:02:40 +0100" MODIFIED_BY="[Empty name]">
<P>Three experimental conditions:<BR/>- GHB group (n=28): patients received three daily oral doses of GHB (50 mg/kg body weight tid)<BR/>- NTX group (n=27): patients received an oral daily dose of NTX (50 mg)<BR/>- Disulfiram group (n=31): patients received an oral daily dose of Disulfiram (200 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 17:55:34 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were followed for 12 months: once a week they were examined for vital signs, adverse events, self-reported drinking, and breath alcohol concentration. The amount of alcohol intake, abstinence from alcohol, and the number of relapses to heavy drinking were evaluated on the basis of the participant's self report and an interview with a family member or friend. Self-reported drinking or abstinence was confirmed by determinations of breath alcohol concentration. A visual analogic scale (range: 0-10) was used to measure craving for alcohol. Patients were asked to indicate their peak craving for alcohol at any time during the past day. Alcohol craving was measured at admission and at 12 months. Laboratory parameters of alcohol abuse (AST, ALT, GGT, MCV) were tested for at admission and at 12 months.</P>
<P>The following definitions were used to categorize the outcomes:</P>
<P>- abstinence: no alcohol intake</P>
<P>- not abstinence: less than five drinks on one occasion for men and less than four drinks on one occasion for women</P>
<P>- relapse to heavy drinking: five or more drinks on one occasion for men and four or more drinks on one occasion for women</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-26 11:39:12 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-04 11:03:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nava-2007">
<CHAR_METHODS MODIFIED="2009-05-05 08:04:04 +0200" MODIFIED_BY="[Empty name]">
<P>RCT. Open randomised study.<BR/>The 42 alcohol dependent inpatients meeting the inclusion criteria were randomly assigned to the study conditions. The randomisation assignment was generated via computer software.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-05 08:04:07 +0200" MODIFIED_BY="[Empty name]">
<P>42 alcohol dependent inpatients, out of 55 screened patients in Lombardia Region were randomised to study conditions (11 excluded and 2 refused). To be included in the research, participants were required to met the following criteria:<BR/>- DSM IV TR diagnosis for alcohol dependence<BR/>- age 18 years or older<BR/>- no pregnancy<BR/>- no axis I psychiatric or other drug dependence disorders<BR/>- no HIV antibodies<BR/>- no serious physical illness (TB, hepatitis or cyrrhosis, renal or cardiovascular illness, unstable diabetes)<BR/>-severe alcohol withdrawal syndrome (at least 20 points on the CIWA-Ar scale).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Two experimental conditions:<BR/>- GHB group (n=21): patients received 50 mg/kg/day of GHB fractioned in four daily doses.<BR/>- diazepam group (n=21): patients received 0.5 mg/kg/day of diazepam fractioned in four daily doses.<BR/>Starting from the first week of treatment and only if the CIWA-Ar score was &lt;5, both medications were gradually tapered according to clinical response.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-04 11:03:17 +0100" MODIFIED_BY="[Empty name]">
<P>At admission and also during the study period, alcohol abstinence was checked by a breath analyser at least once every day. Illegal drugs were also monitored every week by urine analysis using an immunoassay technique.<BR/>All patients were followed for three weeks. Every day during the course of the study, the alcohol withdrawal syndrome was evaluated before the first daily medication dose using the CIWA-Ar.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-26 12:06:37 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-04-08 11:05:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nimmerrichter-2002">
<CHAR_METHODS MODIFIED="2009-05-05 08:04:31 +0200" MODIFIED_BY="[Empty name]">
<P>RCT. Double blind.<BR/>Participants were randomised to one of the three treatments by means of a computerized randomisation schedule.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-04 11:03:47 +0100" MODIFIED_BY="[Empty name]">
<P>98 out of 967 patients admitted to the Anton-Proksch Institute in Vienna were considered potential participants according to the inclusion and exclusion criteria and accepted the involvement in the study (3 refused).<BR/>Inclusion criteria: - at least three DSM-IV and ICD-10 criteria for the diagnosis of alcohol dependence (the MALT was applied to confirm the diagnosis)<BR/>- severe alcohol dependence and withdrawal syndrome (at least 20 points on the CIWA-Ar scale with at least 12 points scored on items 4 (tremor), 5 (sweating) and 11 (nervousness/ anxiety).<BR/>- GGT&gt;1.3 times the upper normal range and/or MCV&gt;95 fl and/or CDT&gt;2.5%.<BR/>Exclusion criteria:<BR/>- illness such as decompensated liver cirrhosis, acute pancreatitis, reduced respiratory function, acute pulmonary or bronchial disease, myocardial infarction during the preceding months and cardiac arythmia - dementia, schizophrenia<BR/>- polysubstance misuse or dependence or use of benzodiazepines and hypno-sedatives<BR/>- suspected sleep apnoea syndrome<BR/>- an allergy to either of the study drugs<BR/>- epileptic seizures, except those forms occurring exclusively during alcohol withdrawal.<BR/>A history of delirium associated with alcohol withdrawal was not a reason for exclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-08 11:05:19 +0200" MODIFIED_BY="[Empty name]">
<P>Three experimental conditions:<BR/>- GHB50 group (n=33): patients received 50 mg of GHB/kg body weight<BR/>- GHB100 group (n=32): patients received 100 mg of GHB/kg body weight<BR/>- Clomethiazole (n=33): patients received 1000 mg of Clomethiazole.<BR/>All medications were administered four times a day with double doses in the evening. On day 6 participants received only half the daily dose, with the other half of the dose being substituted by placebo. On days 7 and 8 only placebo was given. Placebo was administered either as capsules of identical shape, size, taset and colour, or as a syrup.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-05 08:04:58 +0200" MODIFIED_BY="[Empty name]">
<P>At admission and during the study period, alcohol abstinence was checked by a breath analyser at least once every day by specially appointed research personnel responsible for administering the tests and supervising intake of the study medication.<BR/>The withdrawal syndrome was measured on the CIWA-Ar scale, eight times on day 2 and once on days 3-5.<BR/>On days 1 and 8 clinical and biological parameters, including electrocardiogram, CDT, MCV, GGT, ASAT, ALAT were measured. Side effects of the study treatment were determined by open questions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-27 16:30:20 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-04 11:04:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stella-2008">
<CHAR_METHODS MODIFIED="2009-05-05 08:05:21 +0200" MODIFIED_BY="[Empty name]">
<P>RCT. Open randomised study.<BR/>Patients were randomised into four groups; they were aware of the medication they would receive.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 alcohol-dependent patients attending the Public Addiction Unit, ASL Napoli 4 were enrolled and detoxified with metadoxine and diazepam. Alcohol dependence was defined according to the DSM-IV criteria. Exclusion criteria were: pregnant or breast-feeding women, sever liver, kidney, heart or lung disease, poly-drug addiction, any associated major psychiatric disorder, or previous treatment with NTX, GHB, or SSRI to maintain alcohol abstinence.<BR/>Only patients (n=47) who completed detoxification were included in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-04 11:04:22 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into four groups:<BR/>- escitalopram 20 mg/day (n=11).<BR/>- NTX 50 mg/day and escitalopram 20 mg/day (n=12).<BR/>- GHB 75 mg/kg body weight/day divided into 5 daily doses and 20 mg/day of Escitalopram (n=12).<BR/>- NTX 50 mg/day and GHB75 mg/kg body weight/day divided into 5 doses and Escitalopram 20 mg/day (n=12).<BR/>Treatment lasted for 6 months. All patients received psychological support consisting of formal counselling and supportive behavioural therapy provided by a psychologist. Medication and its administration were entrusted to a family member.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-09 18:43:14 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were monitored by means of monthly blood tests, complete blood count, leukocyte count, liver tests (ALT, AST, gamma-GT) and mean erythrocyte cell volume (MCV).<BR/>Tests for alcohol in urine were carried out twice a week. A test was considered positive if alcohol exceeded 1g/L. Assessment visits were planned immediately before the study and 1,2,3,4,5 and 6 months after treatment onset. At each control visit, the amount of alcohol intake was evaluated according to the number of drinks consumed per day and the number of drinking days a week. Craving for alcohol was evaluated with the Italian version of the Obsessive Compulsive Drinking Scale. Relapse into heavy drinking was evaluated from the participant's self-evaluation, an interview of a family member, and with toxicological tests. Anxiety and panic attacks were assessed according to the DSM-IV. Insomnia was classified according to the American Sleep Disorders Association. Pain was self-assessed with two measures of the Italian version of the McGill Pain Questionnaire. Depression was evaluated with Hamiltons Depression Scale.</P>
<P>Relapse into heavy drinking was defined as 5 or more drinks on one occasion for men and 4 or more drinks on one occasion for women.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-27 15:28:08 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-01-04 11:04:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-04-06 11:24:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addolorato-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-06 11:24:26 +0200" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study, without control group. In the analysis, patients are divided in two groups (A=abstinent, B=non abstinent) and the results are analysed retrospectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:21:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addolorato-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:21:55 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study, without control group. In a second phase of the study patients are divided in two groups receiving 3 doses vs 6 doses/day, based on their abstinence status.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:22:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Avanzi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:22:04 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:22:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baldelli-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-04 11:04:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balducci-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-04 11:04:28 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded because of lack of control of confounding at the analysis stage. CCT. Unclear criteria of selection and allocation of patients to treatment. No control for confounding variables at the analysis stage. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-08 11:22:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caputo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-08 11:22:01 +0200" MODIFIED_BY="[Empty name]">
<P>Excluded because of selection of patients. RCT. After a month of GHB treatment, patients who continued to drink (not abstinent) were randomly allocated to two treatment groups (GHB vs GHB+NTX). Population of patients selected, based on their abstinence status (patients resistant to GHB).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-05 08:05:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ceccanti-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-05 08:05:48 +0200" MODIFIED_BY="[Empty name]">
<P>Excluded as randomisation failed. RCT. Some evidence of failure in randomisation. Inadequate control for confounding factors at the analysis stage. Number of patients in the groups were not reported. Patients who relapsed were excluded from the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:22:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cibin-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:22:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Rosa-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:22:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korninger-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study, without control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leder-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:05 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-08 11:21:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lenzenhuber-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-08 11:21:47 +0200" MODIFIED_BY="[Empty name]">
<P>Excluded because of selection of patients. RCT. After surgical treatment for gastroenteric cancer, alcohol dependent patients developing withdrawal syndrome were admitted to intensive clinical management unit and randomly assigned to GHB or flunitrazepam. Population of patients selected, based on their withdrawal syndrome status after surgical treatment for cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liboni-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:18 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study, without control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manzato-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcelli-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:32 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maremmani-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maremmani-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study, without control group. A second phase of the study concerns the evaluation of 3 doses vs 6 doses/day but the results are analysed retrospectively, without control of confounding factors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montesano-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:23:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mosti-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-08 12:10:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strepparola-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-08 12:10:21 +0200" MODIFIED_BY="[Empty name]">
<P>Excluded as lack of control of confounding at the analysis stage. Observational study: CPS. No control for confounding variables at the analysis stage. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-14 15:24:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vendramin-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-14 15:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study without control group. Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-08 12:11:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vittadini-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-08 12:11:35 +0200" MODIFIED_BY="[Empty name]">
<P>Excluded as study design not in the inclusion criteria: observational study with a control group selected from a population previously treated (historical control group). Data published as abstract of a conference.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-01-04 11:04:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-01-14 15:35:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lesch-2000a">
<CHAR_STUDY_NAME MODIFIED="2009-01-14 15:35:05 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, double-dummy evaluation of the efficacy of GHB versus benzodiazepine in the acute alcohol detoxification (GATE 1).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-01-14 15:35:03 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, double-dummy study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>208 consenting in- or out-patients, reporting to specialized alcoholic treatment centres. All patients should have been classified as alcohol-dependent, according to ICD-10 and DSM-IV and stratified by the Lesch typology; they should be willing to undergo an alcohol detoxification procedure, and should be prepared to remain alcohol-abstinent after the end of the detoxification programme.<BR/>Inclusion criteria: age 21-75 years, alcohol dependency according to the CAGE instrument, DSM-IV, ICD10, MALT.<BR/>Exclusion criteria: history of epilepsy or epileptic seizures not properly controlled, dependence from narcotics or BDZ, renal failure, heart failure, hepatic encephalopathy stage II-IV, severe psychiatric disorder, treatment with clonidine, haloperidol, or bromocriptine, hypersensitivity to GHB or BDZ.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- GHB group: GHB 10ml (dosed at 175mg/ml) in three doses/day for the first 5 days, then 5ml in three doses/day for 2 days, and finally 2.5ml in three doses/day for the last 2 days. The patient will receive also three to four dummy BDZ tablets per day. <BR/>- oxazepam group: oxazepam in tablets of 60+60+90 mg per day in days 1-5; then 30 mg/day in days 6-7, and 15 mg/day in day 8-10. In addition each patient will receive GHB-matching placebo suspension. <BR/>In both cases, the treatment period shall be followed by a 10-day untreated follow-up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Withdrawal symptoms intensity, as monitored by the CIWA-Ar scale, and subscores of tremor, hyperhydrosis and nervousness/anxiety.<BR/>Abstinence rate during the 10-day detoxification period, monitored daily with a breath analyser.<BR/>Frequency, nature and severity of adverse clinical events.<BR/>Cognitive disturbances, FAIR test and Benton Test, controlled by MWT.<BR/>Post-treatment craving.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>15 October 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. O.M. Lesch<BR/>University Psichiatric Clinic <BR/>Wahringer Gurtel 18-20<BR/>A-1090 Wien (Austria)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-04 11:04:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lesch-2000b">
<CHAR_STUDY_NAME MODIFIED="2010-01-04 11:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Multinational, Multicentre, double-blind, placebo-controlled evaluation of the efficacy of GHB in the long-term maintenance of abstinence in alcoholic patients after the initial weaning phase, stratified by Lesch's taxonomy (GATE 2)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-01-14 15:35:29 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>320 patients, defined as alcohol dependent according to the ICD 10 and DSM-IV and screened by the CAGE and MALT instruments. Each participating centre will randomise not less than one (8 patients) and not more than four (32 patients) blocks, assigned by either treatment by a computer-generated stratified randomisation list.<BR/>Inclusion criteria: age 21-75 years, alcohol dependency according to the CAGE instrument, DSM-IV, ICD10, MALT, having successfully undergone a detoxification program, encompassing a 10-day treatment period and a subsequent 10-day untreated follow-up.<BR/>Exclusion criteria: history of epilepsy or epileptic seizures not properly controlled, dependence from narcotics or BDZ, renal failure, heart failure, hepatic encephalopathy stage II-IV, severe psychiatric disorder, treatment with clonidine, disulfiram, haloperidol, bromocriptine, serotonine re-uptake inhibitors or other serotoninergic agents, hypersensitivity to GHB or BDZ.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>- GHB 17.5ml (dosed at 175mg/ml) split in three doses/day during 6 months, followed by a 6 month untreated follow-up.<BR/>- matching placebo suspension, to be taken by the same route and with the same schedule as the test medication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion of drop-out patients.<BR/>CAD during treatment period and the whole observation period.<BR/>Proportion of abstinent patients at the end of the 6-month treatment period and at the end of the observation period.<BR/>Time to the first relapse.<BR/>Time course of craving intensity and frequency by LCRR.<BR/>Time course of biological markers of alcohol abuse.<BR/>Sobriety during visits by alcohol breathing analyzer.<BR/>Changes in dependence severity, drinking behaviour and problems and social environment by ASI.<BR/>Frequency, nature and severity of adverse clinical events, including mortality and morbidity.<BR/>Changes in vital signs, safety haematology and clinical chemistry.<BR/>Risk of onset of dependence from the medication, by modified LCRR and additional questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>15 October 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. O.M. Lesch<BR/>University Psichiatric Clinic <BR/>Wahringer Gurtel 18-20<BR/>A-1090 Wien (Austria)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-04-08 11:04:51 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-05-05 08:05:33 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:33:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>"All the subjects were randomly divided into two groups of treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:00:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>"Thirty-five recently detoxified alcohol dependent outpatients were randomly enrolled in two groups over a period of 12 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:57:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>"The patients were randomly allocated to three groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:10:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>"Patients were randomly allocated to two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:15:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>"The patients were randomly divided into two groups, A and B"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:20:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>"We treated in a randomised, prospective study.."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 16:09:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>"Randomized double-blind trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:45:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>"Patients were randomly allocated to one of four groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>"Each subject was randomly to the drug or placebo group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:03:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"A total of 86 patients were randomised to study conditions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:03:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"Those who returned the following day in alcohol withdrawal were randomly assigned to either diazepam or GHB." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:05:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>"Participants were randomised to one of the three treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:05:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>"Patients were randomised into four groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-05-05 08:05:09 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:15:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:45:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:58:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:20:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:20:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:52:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:53:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:48:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:58:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:03:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"The randomisation assignments were generated via computer software."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:04:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"The randomisation assignment was generated via computer software."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:05:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>"by means of a computerized randomised schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 15:40:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-10-08 15:33:32 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-01-04 11:02:55 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-12 17:09:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>Attrition at 18 days:<BR/>- GHB group: 13.3%<BR/>- diazepam group: 26.6%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-08 14:57:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>Attrition at 3 months: <BR/>- GHB group: 22.3%<BR/>- NTX group: 23.6%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-08 15:04:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>Attrition at 3 months: <BR/>- GHB group: 10%<BR/>- GHB + NTX group: 16.7%<BR/>- NTX group: 23.5%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-26 11:28:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>Attrition at 18 days: not reported. <BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-26 11:23:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>Attrition at 6 months:<BR/>- GHB group: 22.2%<BR/>- placebo group: 25%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-27 15:25:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>No patients left the treatment<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-04 11:02:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>Attrition at 3 months:<BR/>- Disulfiram + GHB: 5%<BR/>- Disulfiram + placebo: 25%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-27 15:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>No patients left the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-27 15:54:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>Attrition at 3 months: <BR/>- GHB group: 12.2%<BR/>- placebo group: 14.6%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-04 11:02:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"All patients who relapsed were re-evaluated and excluded from the study." However, since the author provided complete data, these were included in the meta-analyses according to ITT approach.</P>
<P>Attrition (re-calculated applying ITT approach):<BR/>- GHB group: 7.1%<BR/>- NTX group: 7.4%<BR/>- Disulfiram group: 29%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-26 12:05:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"All subjects completed the study without drop-out"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-27 16:17:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>Attrition.<BR/>- GHB50 group: 3%<BR/>- GHB100 group: 12.5%<BR/>- clomethiazole 18%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-27 15:33:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>No patients left the treatment. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-05-05 08:04:24 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:52:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:52:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:52:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:28:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>Data on patients allocated to groups not reported. No data available for inclusion in the meta-analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:21:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>"the procedures followed were in accordance with the Guidelines of the Ethical Committee of the University of Florence and approved by the responsible Institutional Committee for Human Experimentation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:54:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:54:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:54:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:54:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>study protocol not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 08:04:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"The study was approved by the local ethic committee"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:10:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>"The study design followed the Guidelines of the Plinius Major Society (1994) and was approved by the Ethics Committee of the Vienna University Clinic."</P>
<P>Protocol violations are declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>"This study received Ethics Committee approval"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-01-04 11:02:17 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 13:06:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>"The two groups of patients were well matched in terms of age, gender, demographic characteristics, alcohol consumption, and duration of addiction. Total CIWA-Ar, STAI-y1, and SDS Zung tests score also did not differ between groups at baseline."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:49:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>"At the time of the admission to the study, the two groups did not differ in terms of demographic data, education, employment, marital status, duration of alcohol addiction, time of abstinence, alcohol craving scale and alcohol dependence degree"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 14:59:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>"The three groups did not differ in terms of demographic data, education, employment, marital status, duration of alcohol addiction, ACS, and degree of alcohol dependence"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:29:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>Similarity of groups not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:25:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>Similarity of groups not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:53:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>Data from abstract of a conference.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>"The two groups did not differ as regards socio-demographic variables".</P>
<P>Data from a paragraph of a book chapter.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 13:05:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>"The mean scores of the two groups before treatment were similar in the GHB group and in the control group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 13:08:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>"The two groups did not differ in age, initial S-GT, and E-MCV, and did not differ for severity of alcoholism, alcohol intake, anxiety and depression score"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 11:59:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"At the time of admission to the study the three groups did not differ in terms of demographic data, alcohol use and laboratory parameters of ethanol abuse"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 12:06:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"The two groups of patients were well matched in terms of demographic characteristics, living situation and alcohol use"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-06 16:08:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>Power calculations for sample size were illustrated.</P>
<P>"21 patients were discovered to have had major protocol violation. However, the analysis was conducted (ITT) on all patients who received at least one dose of the trial medication, and had at least one post-baseline assessment on the primary efficacy variable. There were no significant differences between the GHB groups and the CLO group in the proportion of male and female participants, age or weight. There were no differences between groups in Lesch typology, MALT, CIWA-Ar score and subscores."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-26 13:11:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>"Upon admission to the trial, the four groups did not differ in terms of demographic data, education, employment, marital status, and duration of alcohol addiction"; "Baseline measurements were similar in the four groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-04-08 11:04:35 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of patients?</NAME>
<DESCRIPTION>
<P>Were the patients blinded to their allocation to the treatment?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 14:52:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>"The whole study was performed on a single-blind design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 14:58:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>"Patients were aware of the drug they would receive"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:01:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>"open randomised comparative study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:08:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>"The study was conducted according to an experimental comparative randomised blinded study design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:09:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 11:04:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>"Patients received either GHB i.v. or Clomethiazole as a mixture"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:24:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:26:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>"The patients did not know whether they were receiving GHB or vehicle"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:27:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>"Randomized double-blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:27:55 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"open randomised study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:30:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"an open study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:31:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>"double-blind, double-dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:32:00 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>"Patients were aware of the medication they would receive"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-04-08 11:04:51 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of providers?</NAME>
<DESCRIPTION>
<P>Were the providers blinded to the allocation of patients to the intervention arms?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 14:57:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>"The whole study was performed on a single-blind design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:00:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>"We performed an open randomised 3-month study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:01:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>"open randomised comparative study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:08:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>"The study was conducted according to an experimental comparative randomised blinded study design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:11:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>"Double-blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 11:04:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>"GHB i.v. or Clomethiazole"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:24:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:26:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>"Randomised double-blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:27:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>"Physicians who performed treatments and medical interviews were unaware of the treatment administered"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:27:53 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"open randomised study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:30:11 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"an open study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:31:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>"double-blind, double-dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:32:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>"Open randomised study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-01-04 11:01:54 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of subjective outcomes?</NAME>
<DESCRIPTION>
<P>Were the people appointed of the collection of subjective ouctomes blinded to the patients' allocation to intervention arms?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 14:52:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Addolorato-1999a">
<DESCRIPTION>
<P>"investigators who performed CIWA-Ar, STAI, and Zung tests at the different times of treatment did not know which drug was being administered to the patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:00:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caputo-2003">
<DESCRIPTION>
<P>Open randomised study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:01:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caputo-2007">
<DESCRIPTION>
<P>"open randomised comparative study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:08:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ceccanti-1996">
<DESCRIPTION>
<P>"The study was conducted according to an experimental comparative randomised blinded study design"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:11:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Bello-1995">
<DESCRIPTION>
<P>"Double-blind study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 11:01:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>Open randomised study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:24:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferri-1991">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:26:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1989">
<DESCRIPTION>
<P>"Clinical evaluation were done by the same investigator who was blinded to treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:26:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallimberti-1992">
<DESCRIPTION>
<P>"Physicians who performed treatments and medical interviews were unaware of the treatment administered"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:27:52 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2006">
<DESCRIPTION>
<P>"open randomised study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:30:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nava-2007">
<DESCRIPTION>
<P>"an open study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:31:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerrichter-2002">
<DESCRIPTION>
<P>"double-blind, double-dummy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 15:32:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stella-2008">
<DESCRIPTION>
<P>"Open randomised study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-02-17 17:09:09 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-02-17 17:09:09 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-02-17 17:09:09 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs placebo be used for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to placebo for alcohol withdrawal </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with alcohol withdrawal </P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>withdrawal score - 7 hours</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean withdrawal score - 7 hours in the intervention groups was<BR/>
<B>12.1 lower</B>
<BR/>(14.65 to 9.55 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>23<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>side-effects - tolerated side-effects</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 16.25 </B>
<BR/>(1.04 to 254.98)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>23<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
<BR/>(1 to 255)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> very low sample size</P>
<P>
<SUP>2</SUP> evidence available only from 1 study</P>
<P>
<SUP>3</SUP> medium risk in control population estimated as 1 per 1000</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-03-10 14:22:48 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:22:48 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs diazepam be used for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to diazepam for alcohol withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with alcohol withdrawal</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>diazepam</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>diazepam</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>CIWA-Ar score - day 5</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean CIWA-Ar score - day 5 in the intervention groups was<BR/>
<B>0.73 lower</B>
<BR/>(2.23 lower to 0.77 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> single blind</P>
<P>
<SUP>2</SUP> low sample size</P>
<P>
<SUP>3</SUP> evidence available only from 1 study</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2010-03-10 14:23:21 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:23:21 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs clomethiazole be used for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to clomethiazole for alcohol withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with alcohol withdrawal</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>clomethiazole</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>clomethiazole</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 points withdrawal scale - 7 hours</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean 4 points withdrawal scale - 7 hours in the intervention groups was<BR/>
<B>3.4 lower</B>
<BR/>(5.09 to 1.71 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>21<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>CIWA-Ar score - day 8</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean CIWA-Ar score - day 8 in the intervention groups was<BR/>
<B>1.1 lower</B>
<BR/>(3.1 lower to 0.9 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>59<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>side-effects - side-effects causing abandon</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.33 </B>
<BR/>(0.01 to 7.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>66<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(0 to 237)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> not blinded</P>
<P>
<SUP>2</SUP> very low sample size</P>
<P>
<SUP>3</SUP> evidence available only from 1 study</P>
<P>
<SUP>4</SUP> low sample size</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2010-03-10 14:23:59 +0100" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:23:59 +0100" MODIFIED_BY="[Empty name]">GHB 100mg vs clomethiazole be used for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 100mg compared to clomethiazole for alcohol withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with alcohol withdrawal</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 100mg</P>
<P>
<B>Comparison: </B>clomethiazole</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>clomethiazole</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 100mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>CIWA-Ar score - day 8</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean CIWA-Ar score - day 8 in the intervention groups was<BR/>
<B>0.4 lower</B>
<BR/>(2.86 lower to 2.06 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>55<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>side-effects - side-effects causing abandon</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.03 </B>
<BR/>(0.07 to 15.79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>65<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>31 per 1000</B>
<BR/>(2 to 474)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> low sample size</P>
<P>
<SUP>2</SUP> evidence available only from 1 study</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2010-03-10 14:24:32 +0100" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:24:32 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs GHB 100 mg be used for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to GHB 100 mg for treatment of alcohol withdrawal and prevention of relapses</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with alcohol withdrawal</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>GHB 100 mg</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 100 mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>CIWA-Ar score - day 8</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean CIWA-Ar score - day 8 in the intervention groups was<BR/>
<B>0.7 lower</B>
<BR/>(2.24 lower to 0.84 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>60<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>side-effects - side-effects causing abandon</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.32 </B>
<BR/>(0.01 to 7.66)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>65<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>31 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
<BR/>(0 to 237)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> evidence available only from 1 study</P>
<P>
<SUP>2</SUP> low sample size</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2010-03-10 14:25:02 +0100" MODIFIED_BY="[Empty name]" NO="6" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:25:02 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs placebo be used in alcohol dependent patients</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to placebo for alcohol dependent patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> alcohol dependent patients</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>abstinence - 6 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.33 </B>
<BR/>(0.58 to 3.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>17<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>665 per 1000</B>
<BR/>(290 to 1535)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>relapse to heavy drinking - 6 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.44 </B>
<BR/>(0.05 to 4.02)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>17<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>(13 to 1005)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>craving score - 3 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean craving score - 3 months in the intervention groups was<BR/>
<B>4.5 lower</B>
<BR/>(5.81 to 3.19 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>71<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> very low sample size</P>
<P>
<SUP>2</SUP> evidence available only from 1 study</P>
<P>
<SUP>3</SUP> low sample size</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2010-03-10 14:25:45 +0100" MODIFIED_BY="[Empty name]" NO="7" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:25:45 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs NTX be used in alcohol dependent patients</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to NTX for alcohol dependent patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> alcohol dependent patients</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>NTX</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>NTX</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>abstinence - 12 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.34 </B>
<BR/>(0.83 to 2.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>55<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>482 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>646 per 1000</B>
<BR/>(400 to 1041)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>relapses to heavy drinking - 12 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.55 </B>
<BR/>(0.18 to 1.67)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>55<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>259 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
<BR/>(47 to 433)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Alcohol Craving Scale - 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Alcohol Craving Scale - 12 months in the intervention groups was<BR/>
<B>1.9 lower</B>
<BR/>(2.45 to 1.35 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>side-effects - side-effects causing abandon</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.62 </B>
<BR/>(0.18 to 2.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>127<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>74 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
<BR/>(13 to 155)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> open randomized studies, not blinded</P>
<P>
<SUP>2</SUP> low sample size</P>
<P>
<SUP>3</SUP> evidence available only from 1 study</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2010-03-10 14:26:30 +0100" MODIFIED_BY="[Empty name]" NO="8" READONLY="YES">
<TITLE MODIFIED="2010-03-10 14:26:30 +0100" MODIFIED_BY="[Empty name]">GHB 50mg vs disulfiram be used in alcohol dependent patients</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>GHB 50mg compared to disulfiram for alcohol dependent patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> alcohol dependent patients</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> GHB 50mg</P>
<P>
<B>Comparison: </B>disulfiram</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>disulfiram</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>GHB 50mg</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>abstinence - 12 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.66 </B>
<BR/>(0.99 to 2.8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>59<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>387 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>642 per 1000</B>
<BR/>(383 to 1084)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>relapses to heavy drinking - 12 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.48 </B>
<BR/>(0.36 to 6.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>59<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>144 per 1000</B>
<BR/>(35 to 585)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Alcohol Craving Scale - 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Alcohol Craving Scale - 12 months in the intervention groups was<BR/>
<B>1.4 lower</B>
<BR/>(1.86 to 0.94 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>41<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>side-effects - side-effects causing abandon</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.55 </B>
<BR/>(0.11 to 2.79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>59<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>129 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
<BR/>(14 to 360)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> open randomized study</P>
<P>
<SUP>2</SUP> low sample size</P>
<P>
<SUP>3</SUP> evidence available only from 1 study</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-03-10 14:22:33 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-03-10 14:22:33 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-02-25 17:42:38 +0100" MODIFIED_BY="[Empty name]">Exclusion criteria</TITLE>
<TABLE COLS="10" ROWS="14">
<TR>
<TH>
<P>study</P>
</TH>
<TH ALIGN="CENTER">
<P>severe psychiatric diseases</P>
</TH>
<TH ALIGN="CENTER">
<P>seizures, epilepsy</P>
</TH>
<TH ALIGN="CENTER">
<P>delirium, allucinations</P>
</TH>
<TH ALIGN="CENTER">
<P>cardiovascular, pulmonary, renal diseases</P>
</TH>
<TH ALIGN="CENTER">
<P>liver disease, hepatic encephalopathy</P>
</TH>
<TH ALIGN="CENTER">
<P>diabetes mellitus</P>
</TH>
<TH ALIGN="CENTER">
<P>drugs abuse, addiction</P>
</TH>
<TH>
<P>previous treatment</P>
</TH>
<TH ALIGN="CENTER">
<P>homeless, no relatives</P>
</TH>
</TR>
<TR>
<TD>
<P>Addolorato 1999</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>Caputo 2003</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Caputo 2007</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ceccanti 1996</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>Di Bello 1995</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Elsing 1996*</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ferri 1991*</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gallimberti 1989</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gallimberti 1992</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nava 2006</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nava 2007</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Nimmerrichter 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Stella 2008</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* not reported</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-02-25 16:23:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-02-25 16:23:32 +0100" MODIFIED_BY="[Empty name]">Side effects (GHB 50mg)*</TITLE>
<TABLE COLS="9" ROWS="9">
<TR>
<TH>
<P>side-effect</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>%</P>
</TH>
<TH>
<P>n causing abandon</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>%</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>% causing abandon</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>patients developing tolerated adverse effect when receiving GHB 50mg</P>
</TD>
<TD>
<P>total number of patients receiving GHB 50mg**</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>patients leaving the treatment because of side effect</P>
</TD>
<TD>
<P>total number of patients receiving GHB 50mg***</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>patients developing any adverse effect when receiving GHB 50mg</P>
</TD>
<TD>
<P>n/N</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>2.5%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>dizziness or vertigo</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>19.6%</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>3.2%</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>18.4%</P>
</TD>
</TR>
<TR>
<TD>
<P>headache</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>1.9%</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>0.4%</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>25.0%</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>0.6%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>rhinitis</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>1.3%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>sense of drunkenness</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>0.4%</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>tiredness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>158</P>
</TD>
<TD>
<P>0.6%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>218</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*associations of drugs are not considered</P>
<P>**only patients receiving GHB in the studies reporting tolerated side-effects were considered</P>
<P>***patients receiving GHB in the studies reporting any side-effects were considered</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-02-25 16:00:34 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Side effects (GHB 100mg)</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TH>
<P>side-effect</P>
</TH>
<TH>
<P>n</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>%</P>
</TH>
<TH>
<P>n causing abandon</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>% causing abandon</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>patients developing adverse effect when receiving GHB 100mg</P>
</TD>
<TD>
<P>total number of patients receiving GHB 100mg</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>patients leaving the treatment because of side effect</P>
</TD>
<TD>
<P>patients developing adverse effect when receiving GHB 100mg</P>
</TD>
<TD>
<P>n/N</P>
</TD>
</TR>
<TR>
<TD>
<P>diarrhoea</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>9.4%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>nausea</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>6.2%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>rhinitis</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>9.4%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>seizure</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>3.1%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>vertigo</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>53.1%</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-17 11:01:18 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-04-06 16:42:57 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>GHB 50mg vs placebo: withdrawal syndrome</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-04-06 16:42:57 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="96.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>7 hours</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="16.301943214056035" CI_END="-7.817116864502592" CI_START="-10.714990738350593" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.266053801426592" ESTIMABLE="YES" I2="75.46304788651774" I2_Q="75.46304788651774" ID="CMP-001.02" MODIFIED="2009-04-03 14:38:44 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0026396550058022106" P_Q="0.0026396550058022106" P_Z="4.857979403404151E-36" Q="16.301943214056035" RANDOM="NO" SCALE="16.688084653665005" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="55" TOTAL_2="60" UNITS="" WEIGHT="500.0" Z="12.534107777086207">
<NAME>withdrawal score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.081026381998067" CI_START="-8.118973618001935" DF="0" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.01040522524687639" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="2.562063632066507">
<NAME>1 hour</NAME>
<CONT_DATA CI_END="-1.081026381998067" CI_START="-8.118973618001935" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="11.8" ORDER="2" SD_1="3.9" SD_2="4.7" SE="1.795427694467423" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.402310742883464" CI_START="-9.797689257116538" DF="0" EFFECT_SIZE="-7.1000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="2.490769487132681E-7" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="5.158394078756286">
<NAME>2 hours</NAME>
<CONT_DATA CI_END="-4.402310742883464" CI_START="-9.797689257116538" EFFECT_SIZE="-7.1000000000000005" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="11.3" ORDER="3" SD_1="3.1" SD_2="3.5" SE="1.3763973615819296" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-5.2095272627804325" CI_START="-15.790472737219567" DF="0" EFFECT_SIZE="-10.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="1.0026898552398407E-4" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="3.8899400601554346">
<NAME>3 hours</NAME>
<CONT_DATA CI_END="-5.2095272627804325" CI_START="-15.790472737219567" EFFECT_SIZE="-10.5" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="12.6" ORDER="4" SD_1="1.6" SD_2="9.2" SE="2.6992703840224315" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-8.28760019623042" CI_START="-15.91239980376958" DF="0" EFFECT_SIZE="-12.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="1.0" P_Z="4.951331113761888E-10" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="6.220639343619067">
<NAME>5 hours</NAME>
<CONT_DATA CI_END="-8.28760019623042" CI_START="-15.91239980376958" EFFECT_SIZE="-12.1" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="13.6" ORDER="5" SD_1="1.7" SD_2="6.5" SE="1.9451376830601494" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-9.548679643043009" CI_START="-14.65132035695699" DF="0" EFFECT_SIZE="-12.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" NO="5" P_CHI2="1.0" P_Z="1.4664239045771947E-20" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="9.295408218049369">
<NAME>7 hours</NAME>
<CONT_DATA CI_END="-9.548679643043009" CI_START="-14.65132035695699" EFFECT_SIZE="-12.1" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="14.7" ORDER="6" SD_1="1.3" SD_2="4.3" SE="1.301717979045268" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="254.9789385176515" CI_START="1.0356247521272017" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="16.25" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="2.406504308813074" LOG_CI_START="0.01520242181671177" LOG_EFFECT_SIZE="1.2108533653148932" METHOD="MH" MODIFIED="2009-04-03 14:38:44 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.04715732685818894" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="1.9848844677300435">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="254.9789385176515" CI_START="1.0356247521272017" DF="0" EFFECT_SIZE="16.25" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="2.406504308813074" LOG_CI_START="0.01520242181671177" LOG_EFFECT_SIZE="1.2108533653148932" NO="1" P_CHI2="1.0" P_Z="0.04715732685818894" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="1.9848844677300435">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="254.9789385176515" CI_START="1.0356247521272017" EFFECT_SIZE="16.25" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.406504308813074" LOG_CI_START="0.01520242181671177" LOG_EFFECT_SIZE="1.2108533653148932" ORDER="7" O_E="0.0" SE="1.404662565556911" STUDY_ID="STD-Gallimberti-1989" TOTAL_1="11" TOTAL_2="12" VAR="1.973076923076923" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-04-08 13:07:53 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>GHB 50mg vs diazepam: withdrawal syndrome</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.484647141878634" CI_START="0.16839018036545472" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.1716232465525867" LOG_CI_START="-0.773683237880549" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-04-03 14:40:29 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.21192518261045934" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.2482892257349891">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.484647141878634" CI_START="0.16839018036545472" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.1716232465525867" LOG_CI_START="-0.773683237880549" LOG_EFFECT_SIZE="-0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.21192518261045934" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.2482892257349891">
<NAME>18 days</NAME>
<DICH_DATA CI_END="1.484647141878634" CI_START="0.16839018036545472" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1716232465525867" LOG_CI_START="-0.773683237880549" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="30" TOTAL_2="30" VAR="0.30833333333333335" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.8906192147465815" CI_END="-0.3265518343109123" CI_START="-1.7573110620807508" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0419314481958315" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2009-04-03 14:40:29 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.864063530525155" P_Q="0.864063530525155" P_Z="0.00430862341202497" Q="1.8906192147465815" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="132" UNITS="" WEIGHT="600.0" Z="2.8546355993197268">
<NAME>CIWA-Ar score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.360577481418825" CI_START="-2.6805774814188252" DF="0" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.9009877684153502" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.12441364720511895">
<NAME>day 2</NAME>
<CONT_DATA CI_END="2.3605774814188245" CI_START="-2.680577481418825" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="8.43" MEAN_2="8.59" ORDER="10" SD_1="4.33" SD_2="4.53" SE="1.286032550241136" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.42304266596942286" CI_START="-3.3230426659694214" DF="0" EFFECT_SIZE="-1.4499999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.12919363398075434" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="1.5172893972023769">
<NAME>day 3</NAME>
<CONT_DATA CI_END="0.42304266596942286" CI_START="-3.3230426659694214" EFFECT_SIZE="-1.4499999999999993" ESTIMABLE="YES" MEAN_1="4.36" MEAN_2="5.81" ORDER="11" SD_1="3.53" SD_2="3.09" SE="0.9556515735716287" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.46531968529030676" CI_START="-4.545319685290307" DF="0" EFFECT_SIZE="-2.0400000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" NO="3" P_CHI2="1.0" P_Z="0.11050338143831662" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="1.5959346633235751">
<NAME>day 4</NAME>
<CONT_DATA CI_END="0.46531968529030676" CI_START="-4.545319685290307" EFFECT_SIZE="-2.0400000000000005" ESTIMABLE="YES" MEAN_1="3.82" MEAN_2="5.86" ORDER="12" SD_1="2.74" SD_2="5.44" SE="1.2782478173333536" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7679355366667344" CI_START="-2.2279355366667346" DF="0" EFFECT_SIZE="-0.73" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.04" NO="4" P_CHI2="1.0" P_Z="0.3394949115478003" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.9551637394877847">
<NAME>day 5</NAME>
<CONT_DATA CI_END="0.7679355366667344" CI_START="-2.2279355366667346" EFFECT_SIZE="-0.73" ESTIMABLE="YES" MEAN_1="3.27" MEAN_2="4.0" ORDER="13" SD_1="2.98" SD_2="2.31" SE="0.7642668684130212" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1228303406627371" CI_START="-2.2828303406627373" DF="0" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.05" NO="5" P_CHI2="1.0" P_Z="0.5044003701082429" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.6675821330449163">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="1.1228303406627371" CI_START="-2.2828303406627373" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" MEAN_1="2.59" MEAN_2="3.17" ORDER="14" SD_1="3.54" SD_2="2.45" SE="0.8688069546657212" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.00427074567286323" CI_START="-2.664270745672863" DF="0" EFFECT_SIZE="-1.3299999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.06" NO="6" P_CHI2="1.0" P_Z="0.05073782877246809" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="1.953690514381851">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="0.00427074567286323" CI_START="-2.664270745672863" EFFECT_SIZE="-1.3299999999999998" ESTIMABLE="YES" MEAN_1="1.55" MEAN_2="2.88" ORDER="15" SD_1="2.06" SD_2="2.57" SE="0.6807628896231872" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="33.430314066877" CI_END="-0.5921245757752298" CI_START="-0.7710212355851749" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6815729056802023" ESTIMABLE="YES" I2="67.09573240025621" I2_Q="79.91163150914676" ID="CMP-002.03" MODIFIED="2010-04-08 13:05:32 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.479772669313542E-4" P_Q="1.463146244725655E-4" P_Z="1.9679788469541043E-50" Q="24.89002530134107" RANDOM="NO" SCALE="3.54" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="282" TOTAL_2="258" UNITS="" WEIGHT="600.0" Z="14.934413525559298">
<NAME>CIWA-Ar subscore: tremor</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2837932934024907" CI_END="-0.0853662039142093" CI_START="-0.6319682737443275" DF="1" EFFECT_SIZE="-0.35866723882926843" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="0.5942257349235294" P_Z="0.010106523124120513" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.00000000000001" Z="2.572163221988069">
<NAME>day 2</NAME>
<CONT_DATA CI_END="-0.09565239258069014" CI_START="-0.6643476074193096" EFFECT_SIZE="-0.3799999999999999" ESTIMABLE="YES" MEAN_1="3.33" MEAN_2="3.71" ORDER="17" SD_1="0.48" SD_2="0.46" SE="0.1450779757496604" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="92.38115672473877"/>
<CONT_DATA CI_END="0.890140343450814" CI_START="-1.0901403434508143" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.5" ORDER="16" SD_1="1.9" SD_2="1.6" SE="0.505182927472604" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="7.6188432752612405"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3910105918322757" CI_END="-0.6599420906559621" CI_START="-0.9113657822420504" DF="1" EFFECT_SIZE="-0.7856539364490063" ESTIMABLE="YES" I2="58.17668046239471" ID="CMP-002.03.02" NO="2" P_CHI2="0.12203490036467401" P_Z="1.6992973936647926E-34" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="12.249071756429302">
<NAME>day 3</NAME>
<CONT_DATA CI_END="-0.6729798163797762" CI_START="-0.9270201836202234" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.04" MEAN_2="3.84" ORDER="19" SD_1="0.21" SD_2="0.21" SE="0.0648074069840786" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="97.95056234985805"/>
<CONT_DATA CI_END="0.7781300676553865" CI_START="-0.9781300676553867" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.0" ORDER="18" SD_1="1.6" SD_2="1.5" SE="0.448033777447935" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="2.049437650141952"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.328881954924749" CI_END="-0.04671146983395952" CI_START="-0.6216153124609252" DF="1" EFFECT_SIZE="-0.33416339114744237" ESTIMABLE="YES" I2="24.74877122877124" ID="CMP-002.03.03" NO="3" P_CHI2="0.2490043601096723" P_Z="0.022699080131324736" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="2.2784617636509">
<NAME>day 4</NAME>
<CONT_DATA CI_END="-0.09152241120802823" CI_START="-0.7084775887919716" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.19" MEAN_2="3.59" ORDER="21" SD_1="0.51" SD_2="0.51" SE="0.15738941696133374" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="86.83267822948848"/>
<CONT_DATA CI_END="0.8921665346007506" CI_START="-0.6921665346007504" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.5" ORDER="20" SD_1="1.5" SD_2="1.3" SE="0.40417402607867237" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="13.167321770511514"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.01599884923362159" CI_END="-0.055602340447364784" CI_START="-0.6376081379198253" DF="1" EFFECT_SIZE="-0.34660523918359504" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.04" NO="4" P_CHI2="0.8993467930393566" P_Z="0.019571799435568894" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.00000000000001" Z="2.334457108856832">
<NAME>day 5</NAME>
<CONT_DATA CI_END="0.47705871031117497" CI_START="-1.2770587103111748" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.9" ORDER="22" SD_1="1.7" SD_2="1.4" SE="0.4474871565137431" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="11.008731972658646"/>
<CONT_DATA CI_END="-0.03152241120802818" CI_START="-0.6484775887919716" EFFECT_SIZE="-0.33999999999999986" ESTIMABLE="YES" MEAN_1="3.19" MEAN_2="3.53" ORDER="23" SD_1="0.51" SD_2="0.51" SE="0.15738941696133374" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="88.99126802734136"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.2113860477004574" CI_END="-0.722939453992014" CI_START="-1.3037136652744405" DF="1" EFFECT_SIZE="-1.0133265596332273" ESTIMABLE="YES" I2="68.86079763857542" ID="CMP-002.03.05" NO="5" P_CHI2="0.07312756087597738" P_Z="7.950645210010958E-12" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="6.839434406267692">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="-0.7945317299280246" CI_START="-1.4054682700719756" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="1.48" ORDER="25" SD_1="0.5" SD_2="0.51" SE="0.15585402205421645" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="90.36961773702527"/>
<CONT_DATA CI_END="0.7357407979684826" CI_START="-1.1357407979684826" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.7" ORDER="24" SD_1="1.9" SD_2="1.4" SE="0.47742754731693365" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="9.630382262974738"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3092180284423365" CI_END="-0.5557024641891359" CI_START="-1.1202834166595546" DF="1" EFFECT_SIZE="-0.8379929404243452" ESTIMABLE="YES" I2="23.61852813852813" ID="CMP-002.03.06" NO="6" P_CHI2="0.2525364119343676" P_Z="5.946764803079073E-9" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="5.818247942456373">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="-0.5983886550438675" CI_START="-1.2016113449561323" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.05" MEAN_2="0.95" ORDER="27" SD_1="0.22" SD_2="0.67" SE="0.15388616695776258" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="87.59858808486906"/>
<CONT_DATA CI_END="0.40160544761333894" CI_START="-1.2016054476133387" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.2" ORDER="26" SD_1="1.3" SD_2="1.5" SE="0.40898988651643614" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="12.401411915130934"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="53.453359750013135" CI_END="-0.15830480452795637" CI_START="-0.35990769686528257" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.25910625069661947" ESTIMABLE="YES" I2="79.42131224034557" I2_Q="75.14272458280387" ID="CMP-002.04" MODIFIED="2010-04-08 13:06:09 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.4847142204565955E-7" P_Q="0.0011892141576851367" P_Z="4.7039137072670637E-7" Q="20.11483525881934" RANDOM="NO" SCALE="2.27" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="282" TOTAL_2="258" UNITS="" WEIGHT="600.0" Z="5.0380122392773385">
<NAME>CIWA-Ar subscore: paroxysmal sweats</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.42490428938321545" CI_END="0.4711650263548248" CI_START="-0.07386961125262878" DF="1" EFFECT_SIZE="0.19864770755109804" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.5145000069925756" P_Z="0.15309379199463619" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.4286884742617434">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.6565229813351848" CI_START="-0.6565229813351848" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.1" ORDER="28" SD_1="1.4" SD_2="0.9" SE="0.3349668598575047" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="17.230121853709225"/>
<CONT_DATA CI_END="0.5395421547208078" CI_START="-0.05954215472080737" EFFECT_SIZE="0.2400000000000002" ESTIMABLE="YES" MEAN_1="3.52" MEAN_2="3.28" ORDER="29" SD_1="0.51" SD_2="0.48" SE="0.15283043825476278" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="82.76987814629076"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.868630017246256" CI_END="0.019277501552984244" CI_START="-0.456656497977267" DF="1" EFFECT_SIZE="-0.21868949821214137" ESTIMABLE="YES" I2="88.72430129506627" ID="CMP-002.04.02" NO="2" P_CHI2="0.002901152250685657" P_Z="0.07167309691115732" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.00000000000001" Z="1.8011889913979116">
<NAME>day 3</NAME>
<CONT_DATA CI_END="0.8716232868749261" CI_START="-0.0716232868749262" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.8" ORDER="30" SD_1="1.1" SD_2="0.5" SE="0.2406285475626238" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="25.459096600946808"/>
<CONT_DATA CI_END="-0.15437449075876664" CI_START="-0.7056255092412328" EFFECT_SIZE="-0.4299999999999997" ESTIMABLE="YES" MEAN_1="3.66" MEAN_2="4.09" ORDER="31" SD_1="0.48" SD_2="0.43" SE="0.14062784388658767" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="74.5409033990532"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.3868718063037" CI_END="0.07649026095256431" CI_START="-0.4381145948284696" DF="1" EFFECT_SIZE="-0.18081216693795263" ESTIMABLE="YES" I2="86.46246982184482" ID="CMP-002.04.03" NO="3" P_CHI2="0.00657020051483348" P_Z="0.16841627083351307" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.377310498274129">
<NAME>day 4</NAME>
<CONT_DATA CI_END="0.8915646639315925" CI_START="-0.09156466393159246" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.6" ORDER="32" SD_1="1.1" SD_2="0.6" SE="0.2508029064865435" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="27.398479132755913"/>
<CONT_DATA CI_END="-0.09802497563729173" CI_START="-0.7019750243627081" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.83" MEAN_2="3.23" ORDER="33" SD_1="0.56" SD_2="0.43" SE="0.15407172108500392" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="72.60152086724408"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.247182344548115" CI_END="-0.2017464035121021" CI_START="-0.6574031718272373" DF="1" EFFECT_SIZE="-0.42957478766966967" ESTIMABLE="YES" I2="87.87464665843044" ID="CMP-002.04.04" NO="4" P_CHI2="0.004081567947254894" P_Z="2.1941156870700678E-4" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="99.99999999999999" Z="3.695549681450994">
<NAME>day 5</NAME>
<CONT_DATA CI_END="0.5272428493889186" CI_START="-0.32724284938891846" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.7" ORDER="34" SD_1="0.9" SD_2="0.6" SE="0.21798505113305938" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="28.435839504098656"/>
<CONT_DATA CI_END="-0.3706853121960938" CI_START="-0.9093146878039056" EFFECT_SIZE="-0.6399999999999997" ESTIMABLE="YES" MEAN_1="2.64" MEAN_2="3.28" ORDER="35" SD_1="0.43" SD_2="0.46" SE="0.13740797786501474" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="71.56416049590133"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.951766999311632" CI_END="-0.34028937653224545" CI_START="-0.8565639714910409" DF="1" EFFECT_SIZE="-0.5984266740116432" ESTIMABLE="YES" I2="66.12198726277495" ID="CMP-002.04.05" NO="5" P_CHI2="0.08578388302262252" P_Z="5.527908135630473E-6" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="4.543685627391844">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="0.1272428493889186" CI_START="-0.7272428493889185" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.7" ORDER="36" SD_1="0.9" SD_2="0.6" SE="0.21798505113305938" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="36.504962976246155"/>
<CONT_DATA CI_END="-0.4460478485190238" CI_START="-1.0939521514809762" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.71" MEAN_2="1.48" ORDER="37" SD_1="0.56" SD_2="0.51" SE="0.165284747085288" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="63.49503702375385"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.459169034400877" CI_END="-0.005182080637453318" CI_START="-0.477710923141596" DF="1" EFFECT_SIZE="-0.24144650188952468" ESTIMABLE="YES" I2="81.68219387055953" ID="CMP-002.04.06" NO="6" P_CHI2="0.019465988237825194" P_Z="0.045182371397348466" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="2.002952646821772">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="0.3111950689989271" CI_START="-0.3111950689989271" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.4" ORDER="38" SD_1="0.6" SD_2="0.5" SE="0.1587759119318488" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="57.64096458078515"/>
<CONT_DATA CI_END="-0.2069843939844192" CI_START="-0.933015606015581" EFFECT_SIZE="-0.5700000000000001" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.9" ORDER="39" SD_1="0.48" SD_2="0.7" SE="0.1852154472628077" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="42.35903541921485"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="37.28240963220381" CI_END="-0.22751309606604575" CI_START="-0.44169795662592326" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3346055263459845" ESTIMABLE="YES" I2="70.49546928828758" I2_Q="71.31215885196436" ID="CMP-002.05" MODIFIED="2010-04-08 13:06:32 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.03325177549074E-4" P_Q="0.0037541374571946617" P_Z="9.13580237741998E-10" Q="17.428986636529697" RANDOM="NO" SCALE="1.95" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="282" TOTAL_2="258" UNITS="" WEIGHT="600.0" Z="6.123820133242876">
<NAME>CIWA-Ar subscore: anxiety</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.195677371440308" CI_END="0.2848652085314899" CI_START="-0.616964228368725" DF="1" EFFECT_SIZE="-0.16604950991861753" ESTIMABLE="YES" I2="68.7077297308866" ID="CMP-002.05.01" NO="1" P_CHI2="0.07383322429515138" P_Z="0.4704436170530657" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="99.99999999999999" Z="0.7217574538477328">
<NAME>day 2</NAME>
<CONT_DATA CI_END="1.358249971180308" CI_START="-0.3582499711803083" EFFECT_SIZE="0.4999999999999998" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" ORDER="40" SD_1="1.4" SD_2="1.6" SE="0.4378906847013896" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="27.6033141392807"/>
<CONT_DATA CI_END="0.10995021003377525" CI_START="-0.9499502100337751" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.42" ORDER="41" SD_1="0.83" SD_2="0.92" SE="0.27038772865927885" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="72.39668586071929"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0430162364474003" CI_END="-0.2394432234008262" CI_START="-0.783014243679238" DF="1" EFFECT_SIZE="-0.5112287335400321" ESTIMABLE="YES" I2="4.124215419111512" ID="CMP-002.05.02" NO="2" P_CHI2="0.30712135252299266" P_Z="2.271866045241093E-4" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="3.68669361765194">
<NAME>day 3</NAME>
<CONT_DATA CI_END="0.734686133023817" CI_START="-0.9346861330238168" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.2" ORDER="42" SD_1="1.3" SD_2="1.6" SE="0.42586809737715314" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="10.602449230427814"/>
<CONT_DATA CI_END="-0.27254922166216783" CI_START="-0.8474507783378322" EFFECT_SIZE="-0.56" ESTIMABLE="YES" MEAN_1="3.82" MEAN_2="4.38" ORDER="43" SD_1="0.46" SD_2="0.49" SE="0.1466612553114278" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="89.39755076957219"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4203984073795344" CI_END="-0.2660591931412724" CI_START="-0.7270248062364786" DF="1" EFFECT_SIZE="-0.49654199968887547" ESTIMABLE="YES" I2="29.59721759721762" ID="CMP-002.05.03" NO="3" P_CHI2="0.233338081068303" P_Z="2.416502715094272E-5" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="4.222460021115253">
<NAME>day 4</NAME>
<CONT_DATA CI_END="-0.29370543211081246" CI_START="-1.1062945678891873" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.9" ORDER="44" SD_1="0.4" SD_2="0.9" SE="0.20729695601245082" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="32.180666562958535"/>
<CONT_DATA CI_END="-0.120126502469315" CI_START="-0.6798734975306848" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.12" MEAN_2="3.52" ORDER="45" SD_1="0.41" SD_2="0.51" SE="0.14279522467672434" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="67.81933343704146"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6757037223673008" CI_END="-0.0536382311377091" CI_START="-0.5176705227137333" DF="1" EFFECT_SIZE="-0.28565437692572115" ESTIMABLE="YES" I2="40.323579481742776" ID="CMP-002.05.04" NO="4" P_CHI2="0.1954963834728889" P_Z="0.015818577279824275" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="2.4130746974487964">
<NAME>day 5</NAME>
<CONT_DATA CI_END="0.01258913577837506" CI_START="-1.612589135778375" EFFECT_SIZE="-0.7999999999999999" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.2" ORDER="46" SD_1="0.8" SD_2="1.8" SE="0.41459391202490165" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="8.152567308164524"/>
<CONT_DATA CI_END="0.0020943741749525346" CI_START="-0.48209437417495205" EFFECT_SIZE="-0.23999999999999977" ESTIMABLE="YES" MEAN_1="3.66" MEAN_2="3.9" ORDER="47" SD_1="0.48" SD_2="0.3" SE="0.12351980754981307" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="91.84743269183548"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.541734472103624" CI_END="-0.27053190664348287" CI_START="-0.7720598552620439" DF="1" EFFECT_SIZE="-0.5212958809527634" ESTIMABLE="YES" I2="86.74045070535254" ID="CMP-002.05.05" NO="5" P_CHI2="0.006028645522788922" P_Z="4.612647955255205E-5" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="4.0744335575745545">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="0.6094113715945365" CI_START="-0.40941137159453656" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.4" ORDER="48" SD_1="1.0" SD_2="0.8" SE="0.25990853689797794" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="24.232209639906905"/>
<CONT_DATA CI_END="-0.4319135491071403" CI_START="-1.0080864508928595" EFFECT_SIZE="-0.72" ESTIMABLE="YES" MEAN_1="0.76" MEAN_2="1.48" ORDER="49" SD_1="0.44" SD_2="0.51" SE="0.14698558400320047" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="75.7677903600931"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.976892785935946" CI_END="0.352116859477733" CI_START="-0.15697674954566582" DF="1" EFFECT_SIZE="0.0975700549660336" ESTIMABLE="YES" I2="79.90714200583403" ID="CMP-002.05.06" NO="6" P_CHI2="0.02568824315475582" P_Z="0.4524892030249045" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="0.7512716337958582">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="0.7679555352460004" CI_START="0.03204446475399969" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.1" ORDER="50" SD_1="0.9" SD_2="0.3" SE="0.18773586563242317" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="47.85690602862648"/>
<CONT_DATA CI_END="0.1725082219167796" CI_START="-0.5325082219167795" EFFECT_SIZE="-0.17999999999999994" ESTIMABLE="YES" MEAN_1="0.67" MEAN_2="0.85" ORDER="51" SD_1="0.48" SD_2="0.67" SE="0.17985443849852314" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="52.143093971373524"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="40.38527413944602" CI_END="-0.22149799374942997" CI_START="-0.39735360647755896" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30942580011349446" ESTIMABLE="YES" I2="72.76234906313084" I2_Q="20.148559160533864" ID="CMP-002.06" MODIFIED="2010-04-08 13:07:53 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="3.073341927728457E-5" P_Q="0.2815874566201384" P_Z="5.3004570688664325E-12" Q="6.2616277770767255" RANDOM="NO" SCALE="2.34" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="282" TOTAL_2="258" UNITS="" WEIGHT="600.0" Z="6.897288232108068">
<NAME>CIWA-Ar subscore: agitation</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6650900589851556" CI_END="0.02411701426039392" CI_START="-0.8960892653880672" DF="1" EFFECT_SIZE="-0.43598612556383665" ESTIMABLE="YES" I2="62.477815838584014" ID="CMP-002.06.01" NO="1" P_CHI2="0.10257207742323449" P_Z="0.06327851598364959" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="1.8572294555319093">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.8910636516081322" CI_START="-0.691063651608132" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.7" ORDER="52" SD_1="1.1" SD_2="1.6" SE="0.4036113203344251" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="33.82887338718066"/>
<CONT_DATA CI_END="-0.14438498152929402" CI_START="-1.275615018470706" EFFECT_SIZE="-0.71" ESTIMABLE="YES" MEAN_1="4.71" MEAN_2="5.42" ORDER="53" SD_1="0.95" SD_2="0.92" SE="0.28858439386244084" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="66.17112661281935"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0384549202337328" CI_END="-0.06149923740067556" CI_START="-0.39981350255240866" DF="1" EFFECT_SIZE="-0.2306563699765421" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="0.8445325580109856" P_Z="0.007528075882738272" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="2.672533939743939">
<NAME>day 3</NAME>
<CONT_DATA CI_END="0.14999552666836846" CI_START="-0.5499955266683685" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.5" ORDER="54" SD_1="0.5" SD_2="0.7" SE="0.17857242756963318" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="23.359075058645196"/>
<CONT_DATA CI_END="-0.0467764993461286" CI_START="-0.43322350065387183" EFFECT_SIZE="-0.2400000000000002" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="4.19" ORDER="55" SD_1="0.21" SD_2="0.4" SE="0.09858523022769496" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="76.6409249413548"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.09519172431107265" CI_END="-0.30675368321534513" CI_START="-0.8460856167973979" DF="1" EFFECT_SIZE="-0.5764196500063715" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.03" NO="3" P_CHI2="0.757677908928208" P_Z="2.7958720597648746E-5" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="4.189485857031278">
<NAME>day 4</NAME>
<CONT_DATA CI_END="0.05532984756033832" CI_START="-1.0553298475603383" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.6" ORDER="56" SD_1="0.3" SD_2="1.3" SE="0.2833367612572013" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="23.580349993628523"/>
<CONT_DATA CI_END="-0.2915224112080284" CI_START="-0.9084775887919718" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.52" MEAN_2="4.12" ORDER="57" SD_1="0.51" SD_2="0.51" SE="0.15738941696133374" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="76.41965000637147"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2638044947788155" CI_END="-0.16226781838677304" CI_START="-0.5432791037623506" DF="1" EFFECT_SIZE="-0.3527734610745618" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.04" NO="4" P_CHI2="0.6075184261223545" P_Z="2.840686299400475E-4" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="3.6294110171887493">
<NAME>day 5</NAME>
<CONT_DATA CI_END="-0.13775932448427497" CI_START="-0.6622406755157251" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.5" ORDER="58" SD_1="0.2" SD_2="0.6" SE="0.1337987216011345" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="52.773461074561894"/>
<CONT_DATA CI_END="-0.022786239383876306" CI_START="-0.5772137606161234" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="3.52" MEAN_2="3.82" ORDER="59" SD_1="0.51" SD_2="0.4" SE="0.14143819111103587" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="47.226538925438106"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.392797939467393" CI_END="-0.10644128244559847" CI_START="-0.5127951084139075" DF="1" EFFECT_SIZE="-0.309618195429753" ESTIMABLE="YES" I2="93.89976010384174" ID="CMP-002.06.05" NO="5" P_CHI2="5.1480942560244713E-5" P_Z="0.0028195171931895808" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="100.0" Z="2.9867591897506904">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="0.12710708690220976" CI_START="-0.3271070869022098" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.2" ORDER="60" SD_1="0.4" SD_2="0.4" SE="0.11587309190046423" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="80.03636234002353"/>
<CONT_DATA CI_END="-0.6952690460067078" CI_START="-1.604730953993292" EFFECT_SIZE="-1.15" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="2.05" ORDER="61" SD_1="0.3" SD_2="1.02" SE="0.23200985200756333" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="19.963637659976477"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.668307224593125" CI_END="0.006573119832050306" CI_START="-0.4004633278211245" DF="1" EFFECT_SIZE="-0.1969451039945371" ESTIMABLE="YES" I2="93.18258075258075" ID="CMP-002.06.06" NO="6" P_CHI2="1.281859988634393E-4" P_Z="0.05787254301442634" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="43" WEIGHT="99.99999999999997" Z="1.8966621440726281">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="0.22710708690220976" CI_START="-0.22710708690220976" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.2" ORDER="62" SD_1="0.4" SD_2="0.4" SE="0.11587309190046423" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="80.30548960054627"/>
<CONT_DATA CI_END="-0.54140352803093" CI_START="-1.4585964719690698" EFFECT_SIZE="-0.9999999999999999" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="1.14" ORDER="63" SD_1="0.36" SD_2="1.01" SE="0.2339820912967893" STUDY_ID="STD-Nava-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="19.694510399453712"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3202081268062343" CI_END="2.0957835023627105" CI_START="-3.25595651929226" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5800865084647748" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2009-04-03 14:40:29 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9972456554987157" P_Q="0.9972456554987157" P_Z="0.6709173412299367" Q="0.3202081268062343" RANDOM="NO" SCALE="28.74055349336885" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="132" UNITS="" WEIGHT="600.0" Z="0.42488934810288426">
<NAME>STAI-y1 score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.79130185399067" CI_START="-6.79130185399067" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="1.0" P_Z="0.8762160848475896" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.15576775920367092">
<NAME>day 2</NAME>
<CONT_DATA CI_END="5.79130185399067" CI_START="-6.79130185399067" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="62.04" MEAN_2="62.54" ORDER="64" SD_1="12.68" SD_2="9.52" SE="3.209906867481064" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.868331917917882" CI_START="-9.28833191791787" DF="0" EFFECT_SIZE="-2.2099999999999937" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" NO="2" P_CHI2="1.0" P_Z="0.540576900634252" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.6119408436991811">
<NAME>day 3</NAME>
<CONT_DATA CI_END="4.868331917917882" CI_START="-9.28833191791787" EFFECT_SIZE="-2.2099999999999937" ESTIMABLE="YES" MEAN_1="56.27" MEAN_2="58.48" ORDER="65" SD_1="13.66" SD_2="11.36" SE="3.6114601971009948" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.942059683279484E-35" CI_END="7.267157738203379" CI_START="-6.847157738203378" DF="0" EFFECT_SIZE="0.21000000000000088" ESTIMABLE="YES" I2="100.0" ID="CMP-002.07.03" NO="3" P_CHI2="0.0" P_Z="0.9534915927200047" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.05832269194229417">
<NAME>day 4</NAME>
<CONT_DATA CI_END="7.267157738203379" CI_START="-6.847157738203378" EFFECT_SIZE="0.21000000000000085" ESTIMABLE="YES" MEAN_1="56.59" MEAN_2="56.38" ORDER="66" SD_1="13.95" SD_2="10.98" SE="3.6006568456713173" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.55215976906009" CI_START="-7.252159769060093" DF="0" EFFECT_SIZE="-0.8500000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.04" NO="4" P_CHI2="1.0" P_Z="0.7946941537255717" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.26021990186971417">
<NAME>day 5</NAME>
<CONT_DATA CI_END="5.55215976906009" CI_START="-7.252159769060093" EFFECT_SIZE="-0.8500000000000014" ESTIMABLE="YES" MEAN_1="53.5" MEAN_2="54.35" ORDER="67" SD_1="12.35" SD_2="10.28" SE="3.266468067556093" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.763548561483693" CI_START="-6.8035485614836855" DF="0" EFFECT_SIZE="-0.519999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.05" NO="5" P_CHI2="1.0" P_Z="0.871149651249705" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.16219836004898613">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="5.763548561483693" CI_START="-6.8035485614836855" EFFECT_SIZE="-0.519999999999996" ESTIMABLE="YES" MEAN_1="52.09" MEAN_2="52.61" ORDER="68" SD_1="11.04" SD_2="11.09" SE="3.2059510333085295" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.591688306784448" CI_START="-6.151688306784436" DF="0" EFFECT_SIZE="0.22000000000000597" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.06" NO="6" P_CHI2="1.0" P_Z="0.946045841227782" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.0676731277234166">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="6.591688306784448" CI_START="-6.151688306784436" EFFECT_SIZE="0.22000000000000597" ESTIMABLE="YES" MEAN_1="51.45" MEAN_2="51.23" ORDER="69" SD_1="11.68" SD_2="10.82" SE="3.250921117450885" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.751622330513898" CI_END="-0.2920976046559769" CI_START="-5.709939201048489" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.001018402852233" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2009-04-03 14:40:29 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9800158697206868" P_Q="0.9800158697206868" P_Z="0.029908272051859437" Q="0.751622330513898" RANDOM="NO" SCALE="29.49707981168839" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="132" UNITS="" WEIGHT="600.0" Z="2.171303048228197">
<NAME>SDS Zung test score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.219755645717215" CI_START="-7.45975564571721" DF="0" EFFECT_SIZE="-2.1199999999999974" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" NO="1" P_CHI2="1.0" P_Z="0.43648139162063826" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.7781486500337437">
<NAME>day 2</NAME>
<CONT_DATA CI_END="3.219755645717215" CI_START="-7.45975564571721" EFFECT_SIZE="-2.1199999999999974" ESTIMABLE="YES" MEAN_1="59.74" MEAN_2="61.86" ORDER="70" SD_1="3.4" SD_2="12.39" SE="2.7244151871343165" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2745417079419066E-32" CI_END="3.789767585473044" CI_START="-11.629767585473035" DF="0" EFFECT_SIZE="-3.919999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-002.08.02" NO="2" P_CHI2="0.0" P_Z="0.3189899320233711" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.9965357235766275">
<NAME>day 3</NAME>
<CONT_DATA CI_END="3.7897675854730446" CI_START="-11.629767585473033" EFFECT_SIZE="-3.9199999999999946" ESTIMABLE="YES" MEAN_1="56.95" MEAN_2="60.87" ORDER="71" SD_1="14.56" SD_2="12.69" SE="3.9336271718698415" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.069774602677212" CI_START="-9.429774602677226" DF="0" EFFECT_SIZE="-2.180000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.03" NO="3" P_CHI2="1.0" P_Z="0.555620331257755" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.5893592174189096">
<NAME>day 4</NAME>
<CONT_DATA CI_END="5.069774602677212" CI_START="-9.429774602677226" EFFECT_SIZE="-2.180000000000007" ESTIMABLE="YES" MEAN_1="53.91" MEAN_2="56.09" ORDER="72" SD_1="13.58" SD_2="12.04" SE="3.6989325619565028" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5224910369450404" CI_START="-12.642491036945032" DF="0" EFFECT_SIZE="-5.559999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.04" NO="4" P_CHI2="1.0" P_Z="0.12389235436482023" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="1.5386393992166887">
<NAME>day 5</NAME>
<CONT_DATA CI_END="1.5224910369450404" CI_START="-12.642491036945032" EFFECT_SIZE="-5.559999999999995" ESTIMABLE="YES" MEAN_1="50.59" MEAN_2="56.15" ORDER="73" SD_1="11.04" SD_2="13.57" SE="3.6135822355976033" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.078747929309245" CI_START="-8.798747929309243" DF="0" EFFECT_SIZE="-2.3599999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.05" NO="5" P_CHI2="1.0" P_Z="0.472518495396958" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.7183873408771195">
<NAME>day 10-14</NAME>
<CONT_DATA CI_END="4.078747929309245" CI_START="-8.798747929309243" EFFECT_SIZE="-2.3599999999999994" ESTIMABLE="YES" MEAN_1="48.64" MEAN_2="51.0" ORDER="74" SD_1="12.36" SD_2="10.4" SE="3.2851358392793264" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.062825125192546" CI_START="-9.642825125192559" DF="0" EFFECT_SIZE="-2.7900000000000063" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.06" NO="6" P_CHI2="1.0" P_Z="0.42489208578832116" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="0.7979627988410275">
<NAME>day 18-21</NAME>
<CONT_DATA CI_END="4.062825125192545" CI_START="-9.642825125192559" EFFECT_SIZE="-2.7900000000000063" ESTIMABLE="YES" MEAN_1="47.8" MEAN_2="50.59" ORDER="75" SD_1="11.68" SD_2="12.39" SE="3.496403596824616" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3844326582238684" CI_START="0.20201651035643567" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.14127183557956222" LOG_CI_START="-0.6946131351886352" LOG_EFFECT_SIZE="-0.2766706498045365" METHOD="MH" MODIFIED="2009-04-03 14:40:29 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.19447225845809576" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.00000000000001" Z="1.2974620388205613">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>diazepam</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diazepam</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3844326582238684" CI_START="0.20201651035643567" DF="0" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.14127183557956222" LOG_CI_START="-0.6946131351886352" LOG_EFFECT_SIZE="-0.2766706498045365" NO="1" P_CHI2="1.0" P_Z="0.19447225845809576" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.00000000000001" Z="1.2974620388205613">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="1.3844326582238682" CI_START="0.20201651035643567" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.14127183557956216" LOG_CI_START="-0.6946131351886352" LOG_EFFECT_SIZE="-0.2766706498045365" ORDER="76" O_E="0.0" SE="0.49100296952657635" STUDY_ID="STD-Addolorato-1999a" TOTAL_1="26" TOTAL_2="22" VAR="0.24108391608391605" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-04-06 16:44:52 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>GHB 50mg vs clomethiazole: withdrawal syndrome</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3093400177451202" CI_START="0.02121509875304604" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.1170524415508583" LOG_CI_START="-1.6733549423181455" LOG_EFFECT_SIZE="-0.7781512503836436" METHOD="MH" MODIFIED="2009-04-06 16:44:52 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.08843925800963573" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.7036887124325444">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fav. GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fav. clomethiazole</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3093400177451202" CI_START="0.02121509875304604" DF="0" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.1170524415508583" LOG_CI_START="-1.6733549423181455" LOG_EFFECT_SIZE="-0.7781512503836436" NO="1" P_CHI2="1.0" P_Z="0.08843925800963573" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="1.7036887124325444">
<NAME>8 days</NAME>
<DICH_DATA CI_END="1.3093400177451202" CI_START="0.02121509875304604" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1170524415508583" LOG_CI_START="-1.6733549423181455" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="77" O_E="0.0" SE="1.051694159944138" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="33" VAR="1.1060606060606062" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.6410609804696644E-31" CI_END="-1.7063288192594608" CI_START="-5.093671180740538" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.3999999999999995" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2009-04-03 14:43:39 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="8.334378271698852E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="11" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="3.934575744816345">
<NAME>4 points withdrawal scale</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6410609804696644E-31" CI_END="-1.7063288192594608" CI_START="-5.093671180740538" DF="0" EFFECT_SIZE="-3.3999999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.0" P_Z="8.334378271698852E-5" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0" Z="3.934575744816345">
<NAME>7 hours</NAME>
<CONT_DATA CI_END="-1.7063288192594612" CI_START="-5.093671180740539" EFFECT_SIZE="-3.4" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="4.5" ORDER="78" SD_1="1.7" SD_2="2.2" SE="0.8641338280192905" STUDY_ID="STD-Elsing-1996" TOTAL_1="11" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.11162996283511697" CI_END="0.5970456425449129" CI_START="-2.329770887003255" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8663626222291712" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2009-04-03 14:43:39 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7382960646350112" P_Q="0.7382960646350112" P_Z="0.24591365333054183" Q="0.11162996283511697" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="1.1603320672669521">
<NAME>CIWA-Ar score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0331370913987051E-32" CI_END="1.540816010023796" CI_START="-2.7408160100237917" DF="0" EFFECT_SIZE="-0.599999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-003.03.01" MODIFIED="2009-03-26 19:10:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5827905654561097" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0" Z="0.5493131521895515">
<NAME>day 2</NAME>
<CONT_DATA CI_END="1.540816010023796" CI_START="-2.7408160100237917" EFFECT_SIZE="-0.5999999999999979" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="16.9" MODIFIED="2009-03-26 19:10:56 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="3.6" SD_2="4.9" SE="1.0922731371138843" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9049976353427671" CI_START="-3.10499763534277" DF="0" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="1.0" P_Z="0.2822434826758953" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0" Z="1.0752932297725557">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.9049976353427671" CI_START="-3.10499763534277" EFFECT_SIZE="-1.1000000000000014" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="12.8" ORDER="80" SD_1="1.2" SD_2="5.2" SE="1.0229767746539906" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7308008427585477" CI_END="0.17691587646824586" CI_START="-0.42336875495346754" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.12322643924261086" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2009-04-03 14:43:39 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.39262375445999265" P_Q="0.39262375445999265" P_Z="0.4210027089959858" Q="0.7308008427585477" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="0.8046828794754125">
<NAME>CIWA-Ar subscore: tremor</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6933104730132813" CI_START="-0.4933104730132811" DF="0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.7411402497746269" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0" Z="0.3303437363217053">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.6933104730132813" CI_START="-0.4933104730132811" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.6" ORDER="81" SD_1="1.2" SD_2="1.2" SE="0.3027149874657078" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.14794855756618036" CI_START="-0.5479485575661802" DF="0" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.2599190101096188" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0" Z="1.1265826179878706">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.14794855756618036" CI_START="-0.5479485575661802" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.5" ORDER="82" SD_1="0.5" SD_2="0.8" SE="0.1775280363877878" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4640579681839052" CI_END="0.20142797708766275" CI_START="-0.36363342430009243" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08110272360621484" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-04-03 14:43:39 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.49573359076418866" P_Q="0.49573359076418866" P_Z="0.5736912754027266" Q="0.4640579681839052" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="0.5626235199427733">
<NAME>CIWA-Ar subscore: hyperhydrosis</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24367292299599597" CI_START="-0.6436729229959963" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" MODIFIED="2009-03-26 19:14:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3769567348198989" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0" Z="0.8835175116412246">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.24367292299599597" CI_START="-0.6436729229959963" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.2" MODIFIED="2009-03-26 19:14:06 +0100" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="0.6" SD_2="1.1" SE="0.22636789578565297" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3664330954055891" CI_START="-0.3664330954055891" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0" Z="0.0">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.3664330954055891" CI_START="-0.3664330954055891" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.3" ORDER="84" SD_1="0.6" SD_2="0.8" SE="0.18695909633848712" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6782155294356441" CI_END="0.044035121994361826" CI_START="-0.635755970207798" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29586042410671803" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2009-04-03 14:43:39 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4102022311565465" P_Q="0.4102022311565465" P_Z="0.08800042523689976" Q="0.6782155294356441" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="1.7060411127819457">
<NAME>CIWA-Ar subscore: anxiety</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47689689137988334" CI_START="-0.6768968913798835" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="1.0" P_Z="0.7340504453820087" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0" Z="0.3397425109800827">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.47689689137988334" CI_START="-0.6768968913798835" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.2" ORDER="85" SD_1="1.0" SD_2="1.3" SE="0.2943405572400169" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.020661490029705354" CI_START="-0.8206614900297051" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="1.0" P_Z="0.0623642546328353" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0" Z="1.8636970875576462">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.020661490029705354" CI_START="-0.8206614900297051" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.5" ORDER="86" SD_1="0.2" SD_2="1.1" SE="0.21462715302313176" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5857625048261631" CI_END="1.8002938679555764" CI_START="0.6294497854712381" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.064516129032258" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.2553434022225298" LOG_CI_START="-0.20103891013530023" LOG_EFFECT_SIZE="0.027152246043614776" METHOD="MH" MODIFIED="2009-04-03 14:43:39 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.44406256758292606" P_Q="0.0" P_Z="0.8155950582102277" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="66" WEIGHT="200.0" Z="0.23321422808835587">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.897117532359623" CI_START="0.014069831258787349" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.4963113070323152" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.6803050896828817">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="87" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9430384952909134" CI_START="0.6722061617127342" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="0.28848140488532614" LOG_CI_START="-0.17249751092995277" LOG_EFFECT_SIZE="0.05799194697768673" NO="2" P_CHI2="1.0" P_Z="0.6219180968334388" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="100.0" Z="0.49313373592630233">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="1.9430384952909134" CI_START="0.6722061617127343" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.28848140488532614" LOG_CI_START="-0.1724975109299527" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="88" O_E="0.0" SE="0.2707812970323298" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="33" VAR="0.07332251082251082" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-04-06 13:19:02 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>GHB 100mg vs clomethiazole: withdrawal syndrome</NAME>
<DICH_OUTCOME CHI2="7.809722961688017E-32" CI_END="2.2106282701485327" CI_START="0.21381082309611552" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6874999999999999" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.3445157196044756" LOG_CI_START="-0.6699703145998752" LOG_EFFECT_SIZE="-0.16272729749769982" METHOD="MH" MODIFIED="2009-04-06 13:19:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.5294990650844905" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.6287708882008752">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.809722961688017E-32" CI_END="2.2106282701485327" CI_START="0.21381082309611552" DF="0" EFFECT_SIZE="0.6874999999999999" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="100.0" ID="CMP-004.01.01" LOG_CI_END="0.3445157196044756" LOG_CI_START="-0.6699703145998752" LOG_EFFECT_SIZE="-0.16272729749769982" NO="1" P_CHI2="0.0" P_Z="0.5294990650844905" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.6287708882008752">
<NAME>8 days</NAME>
<DICH_DATA CI_END="2.2106282701485327" CI_START="0.21381082309611563" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3445157196044756" LOG_CI_START="-0.669970314599875" LOG_EFFECT_SIZE="-0.16272729749769974" ORDER="89" O_E="0.0" SE="0.5959141182784952" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="33" VAR="0.35511363636363635" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.013677582650095107" CI_END="1.3786437487488976" CI_START="-1.9635076762504722" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29243196375078734" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2009-04-06 13:16:11 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9068987288281581" P_Q="0.9068987288281581" P_Z="0.7316087487875509" Q="0.013677582650095107" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="0.3429863246725716">
<NAME>CIWA-Ar score</NAME>
<GROUP_LABEL_1>GHB 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.078607407548853" CI_START="-2.478607407548852" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2009-03-26 18:00:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8634125761949858" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.17203173991683132">
<NAME>day 2</NAME>
<CONT_DATA CI_END="2.078607407548853" CI_START="-2.478607407548852" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="16.7" MEAN_2="16.9" MODIFIED="2009-03-26 18:00:30 +0100" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="4.2" SD_2="4.9" SE="1.1625761623796238" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.058102763700042" CI_START="-2.858102763700043" DF="0" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" NO="2" P_CHI2="1.0" P_Z="0.749772536860909" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.3189393077431528">
<NAME>day 8</NAME>
<CONT_DATA CI_END="2.058102763700042" CI_START="-2.858102763700043" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="12.8" ORDER="91" SD_1="4.0" SD_2="5.2" SE="1.2541571085434444" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="28" TOTAL_2="27" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.062410094585140144" CI_END="0.34187570027320036" CI_START="-0.4160413470659118" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.037082823396355734" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2009-04-06 13:19:02 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8027264591532655" P_Q="0.8027264591532655" P_Z="0.8479055819685131" Q="0.062410094585140144" RANDOM="NO" SCALE="2.204716903144654" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="0.19179143299938767">
<NAME>CIWA-Ar subscore: tremor</NAME>
<GROUP_LABEL_1>GHB 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5223078557765654" CI_START="-0.7223078557765655" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="1.0" P_Z="0.7527989599408041" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.3149508665761991">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.5223078557765654" CI_START="-0.7223078557765655" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="2.6" ORDER="92" SD_1="1.3" SD_2="1.2" SE="0.3175098423671304" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4777570089047838" CI_START="-0.4777570089047838" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.0">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.47775700890478384" CI_START="-0.47775700890478384" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.5" ORDER="93" SD_1="1.0" SD_2="0.8" SE="0.24375805508329243" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07581835686777899" CI_END="0.4048754232958153" CI_START="-0.27547876090813894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.06469833119383817" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2009-04-06 13:19:02 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.783046337049914" P_Q="0.783046337049914" P_Z="0.7093227309105293" Q="0.07581835686777899" RANDOM="NO" SCALE="1.8095267385696576" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="0.37276583857020434">
<NAME>CIWA-Ar subscore: hyperhydrosis</NAME>
<GROUP_LABEL_1>GHB 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5725421259894904" CI_START="-0.5725421259894904" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.0">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.5725421259894904" CI_START="-0.5725421259894904" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.2" ORDER="94" SD_1="1.2" SD_2="1.1" SE="0.29211869733608864" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5229202935780568" CI_START="-0.322920293578057" DF="0" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.02" NO="2" P_CHI2="1.0" P_Z="0.6430520345258979" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.4634357854899928">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.5229202935780568" CI_START="-0.322920293578057" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.3" ORDER="95" SD_1="0.8" SD_2="0.8" SE="0.2157796249900499" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.891667279876677E-33" CI_END="0.2889017335264366" CI_START="-0.4889017335264368" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2009-04-06 13:19:02 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9999999999999999" P_Q="0.9999999999999999" P_Z="0.6142795842687746" Q="4.891667279876677E-33" RANDOM="NO" SCALE="1.8095267385696576" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="200.0" Z="0.5039740930871479">
<NAME>CIWA-Ar subscore: anxiety</NAME>
<GROUP_LABEL_1>GHB 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5013795323170986" CI_START="-0.7013795323170988" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" MODIFIED="2009-03-26 18:02:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7444914497459036" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.32591132208779516">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.5013795323170986" CI_START="-0.7013795323170988" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.2" ORDER="168" SD_1="1.1" SD_2="1.3" SE="0.3068319301072386" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4098617839302935" CI_START="-0.6098617839302937" DF="0" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" MODIFIED="2009-03-26 18:02:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7006739656772241" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.3844108435489284">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.4098617839302935" CI_START="-0.6098617839302937" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.5" MODIFIED="2009-03-26 18:02:10 +0100" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="0.8" SD_2="1.1" SE="0.260138343332846" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.17385092136957708" CI_END="2.767367365155358" CI_START="1.1545833380240886" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7875" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.44206681511119145" LOG_CI_START="0.06242528583504503" LOG_EFFECT_SIZE="0.25224605047311827" METHOD="MH" MODIFIED="2009-04-06 13:19:02 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6767121055060585" P_Q="0.0" P_Z="0.009200135918734954" Q="0.0" RANDOM="NO" SCALE="820.719542577857" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="66" WEIGHT="200.0" Z="2.604526302021975">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 100mg</GROUP_LABEL_1>
<GROUP_LABEL_2>clomethiazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB100</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clomethiazol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3869864709859272E-32" CI_END="15.793408793243062" CI_START="0.06733673372369049" DF="0" EFFECT_SIZE="1.0312499999999998" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="99.99999999999999" ID="CMP-004.06.01" LOG_CI_END="1.1984758767036463" LOG_CI_START="-1.1717479535876831" LOG_EFFECT_SIZE="0.013363961557981408" MODIFIED="2009-03-26 19:33:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.9823669008556651" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="0.02210161167876025">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="15.793408793243062" CI_START="0.06733673372369049" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1984758767036463" LOG_CI_START="-1.1717479535876831" LOG_EFFECT_SIZE="0.013363961557981502" ORDER="98" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="33" VAR="1.9384469696969697" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8528132974462643" CI_START="1.1887171239743202" DF="0" EFFECT_SIZE="1.8415178571428572" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="0.45527335015618015" LOG_CI_START="0.075078518947382" LOG_EFFECT_SIZE="0.2651759345517811" MODIFIED="2009-03-26 19:33:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.006256110123766098" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="100.0" Z="2.7340470654784346">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="2.8528132974462643" CI_START="1.1887171239743202" EFFECT_SIZE="1.8415178571428572" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.45527335015618015" LOG_CI_START="0.075078518947382" LOG_EFFECT_SIZE="0.2651759345517811" ORDER="99" O_E="0.0" SE="0.2233283258468149" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="33" VAR="0.04987554112554113" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-04-06 13:48:12 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>GHB 50mg vs GHB 100mg: withdrawal syndrome</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0536252567442466" CI_START="0.02861744766819785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.31252119691640895" LOG_CI_START="-1.5433691026882967" LOG_EFFECT_SIZE="-0.6154239528859439" METHOD="MH" MODIFIED="2009-04-06 13:21:32 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.1936452624219264" Q="0.0" RANDOM="NO" SCALE="657.3608898210954" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="1.299870776992197">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>GHB 100mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB100</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0536252567442466" CI_START="0.02861744766819785" DF="0" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.31252119691640895" LOG_CI_START="-1.5433691026882967" LOG_EFFECT_SIZE="-0.6154239528859439" NO="1" P_CHI2="1.0" P_Z="0.1936452624219264" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="1.299870776992197">
<NAME>8 days</NAME>
<DICH_DATA CI_END="2.0536252567442475" CI_START="0.02861744766819785" EFFECT_SIZE="0.24242424242424243" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3125211969164091" LOG_CI_START="-1.5433691026882967" LOG_EFFECT_SIZE="-0.6154239528859439" ORDER="100" O_E="0.0" SE="1.0901591487929503" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" VAR="1.1884469696969697" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.05767730256655769" CI_END="0.6153954560542979" CI_START="-1.7783692078879247" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5814868759168134" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2009-04-06 13:21:32 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8102054540717716" P_Q="0.8102054540717716" P_Z="0.3409862619931542" Q="0.05767730256655769" RANDOM="NO" SCALE="6.000897357573361" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="0.952218362520848">
<NAME>CIWA-Ar score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>GHB 100mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB100</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5042714672159987" CI_START="-2.3042714672159956" DF="0" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" NO="1" P_CHI2="1.0" P_Z="0.6805604690591295" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.41169844074920076">
<NAME>day 2</NAME>
<CONT_DATA CI_END="1.5042714672159987" CI_START="-2.3042714672159956" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="16.7" ORDER="101" SD_1="3.6" SD_2="4.2" SE="0.9715849282112567" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8388258423363448" CI_START="-2.2388258423363467" DF="0" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="1.0" P_Z="0.37262213026952984" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="0.8915724908122276">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.8388258423363448" CI_START="-2.2388258423363467" EFFECT_SIZE="-0.7000000000000011" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="12.4" ORDER="102" SD_1="1.2" SD_2="4.0" SE="0.7851296526234195" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1430559582487687" CI_END="0.26381268961210547" CI_START="-0.4150449308414471" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07561612061467082" ESTIMABLE="YES" I2="12.515219155844228" I2_Q="12.515219155844228" ID="CMP-005.03" MODIFIED="2009-04-06 13:48:12 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.28500755639175657" P_Q="0.28500755639175657" P_Z="0.6623795504514166" Q="1.1430559582487687" RANDOM="NO" SCALE="1.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="0.43663021107835304">
<NAME>CIWA-Ar subscore: tremor</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>GHB 100mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB 50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB100</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8086906751066869" CI_START="-0.40869067510668655" DF="0" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="1.0" P_Z="0.5195796969290621" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.6439934320322972">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.8086906751066869" CI_START="-0.40869067510668655" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.5" ORDER="103" SD_1="1.2" SD_2="1.3" SE="0.310562173543984" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20890873666211385" CI_START="-0.6089087366621138" DF="0" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="1.0" P_Z="0.33774442821727546" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="0.9586315032244448">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.20890873666211385" CI_START="-0.6089087366621138" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.5" ORDER="104" SD_1="0.5" SD_2="1.0" SE="0.20863074009907004" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.11109107303877436" CI_END="0.1473770237235326" CI_START="-0.4231570056892675" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13788999098286744" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2009-04-06 13:21:32 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7389054085557156" P_Q="0.7389054085557156" P_Z="0.3434395623779123" Q="0.11109107303877436" RANDOM="NO" SCALE="1.385458013417937" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="0.9473910484642852">
<NAME>CIWA-Ar subscore: hyperhydrosis</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>GHB 100mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB100</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2634355083824683" CI_START="-0.6634355083824687" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="1.0" P_Z="0.39764140638552936" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.8458410929196725">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.2634355083824683" CI_START="-0.6634355083824687" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.2" ORDER="105" SD_1="0.6" SD_2="1.2" SE="0.23645103279345367" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26196848588965066" CI_START="-0.4619684858896504" DF="0" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" NO="2" P_CHI2="1.0" P_Z="0.5881811549986404" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="0.5414736533548848">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.26196848588965066" CI_START="-0.4619684858896504" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.4" ORDER="106" SD_1="0.6" SD_2="0.8" SE="0.1846811924835414" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9758988426163606" CI_END="0.03995265022434202" CI_START="-0.483111764803855" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.22157955728975648" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2009-04-06 13:21:32 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.32321363101539846" P_Q="0.32321363101539846" P_Z="0.09680336248531746" Q="0.9758988426163606" RANDOM="NO" SCALE="1.446799598007822" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="1.6605524655116946">
<NAME>CIWA-Ar subscore: anxiety</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>GHB 100mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB100</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5115300623705646" CI_START="-0.5115300623705646" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.0">
<NAME>day 2</NAME>
<CONT_DATA CI_END="0.5115300623705646" CI_START="-0.5115300623705646" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.1" ORDER="107" SD_1="1.0" SD_2="1.1" SE="0.2609895214429696" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.004313319738563082" CI_START="-0.6043133197385627" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="1.0" P_Z="0.05333685283113533" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="1.9321835661585907">
<NAME>day 8</NAME>
<CONT_DATA CI_END="0.004313319738563082" CI_START="-0.6043133197385627" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.4" ORDER="108" SD_1="0.2" SD_2="0.8" SE="0.1552647508520297" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1677482023908536" CI_END="0.901969783883839" CI_START="0.40419481866719154" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6037975763782215" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-0.04480801114133639" LOG_CI_START="-0.3934092579624027" LOG_EFFECT_SIZE="-0.21910863455186955" METHOD="MH" MODIFIED="2009-04-06 13:21:32 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6821211101763186" P_Q="0.0" P_Z="0.013746585154778213" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="64" WEIGHT="200.0" Z="2.463818109312976">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>GHB 100mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB50</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB100</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.660704529448924" CI_START="0.01366340130655662" DF="0" EFFECT_SIZE="0.3235294117647059" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.8842687120845497" LOG_CI_START="-1.8644411758526098" LOG_EFFECT_SIZE="-0.49008623188403005" MODIFIED="2009-03-26 19:38:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4846078505802991" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="0.6989106911770272">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="7.660704529448924" CI_START="0.01366340130655662" EFFECT_SIZE="0.3235294117647059" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8842687120845497" LOG_CI_START="-1.8644411758526098" LOG_EFFECT_SIZE="-0.49008623188403005" ORDER="109" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" VAR="2.606951871657754" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9226982321951052" CI_START="0.4174191182145158" DF="0" EFFECT_SIZE="0.6206060606060606" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="-0.034940311456262564" LOG_CI_START="-0.3794276636919261" LOG_EFFECT_SIZE="-0.20718398757409434" MODIFIED="2009-03-26 19:38:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.018395956128152886" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="100.0" Z="2.3575504365154436">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="0.9226982321951052" CI_START="0.4174191182145158" EFFECT_SIZE="0.6206060606060606" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="-0.034940311456262564" LOG_CI_START="-0.3794276636919261" LOG_EFFECT_SIZE="-0.20718398757409434" ORDER="110" O_E="0.0" SE="0.20235357594312411" STUDY_ID="STD-Nimmerrichter-2002" TOTAL_1="33" TOTAL_2="32" VAR="0.040946969696969704" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>GHB 50mg vs placebo: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.0038635863077745147" CI_END="2.149048383568223" CI_START="0.3344778457386409" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8478260869565218" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.33224619328583727" LOG_CI_START="-0.4756326425959869" LOG_EFFECT_SIZE="-0.07169322465507481" METHOD="MH" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9504372545895076" P_Q="0.0" P_Z="0.7279420320723144" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="49" WEIGHT="200.0" Z="0.3478643876246815">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.516158903951463" CI_START="0.27599387437489137" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.40073806480585633" LOG_CI_START="-0.559100556901106" LOG_EFFECT_SIZE="-0.0791812460476248" NO="1" P_CHI2="1.0" P_Z="0.7464136539694628" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="0.3233718397960636">
<NAME>3 months</NAME>
<DICH_DATA CI_END="2.516158903951463" CI_START="0.27599387437489137" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.40073806480585633" LOG_CI_START="-0.559100556901106" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="111" O_E="0.0" SE="0.5638139576684748" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="41" TOTAL_2="41" VAR="0.3178861788617886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.929511710259799" CI_START="0.16028432494553937" DF="0" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.6928039026358092" LOG_CI_START="-0.7951089475305718" LOG_EFFECT_SIZE="-0.05115252244738131" NO="2" P_CHI2="1.0" P_Z="0.8928000024921303" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="0.1347620617753696">
<NAME>6 months</NAME>
<DICH_DATA CI_END="4.929511710259798" CI_START="0.1602843249455394" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.692803902635809" LOG_CI_START="-0.7951089475305718" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="112" O_E="0.0" SE="0.8740073734751262" STUDY_ID="STD-Di-Bello-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.7638888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.198317449741907" CI_START="0.40168255025808897" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.03943284185819055" Q="0.0" RANDOM="NO" SCALE="28.00265585111284" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="9" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="2.059641331865437">
<NAME>average stay in program (weeks)</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.198317449741907" CI_START="0.40168255025808897" DF="0" EFFECT_SIZE="8.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" NO="1" P_CHI2="1.0" P_Z="0.03943284185819055" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="2.059641331865437">
<NAME>6 months</NAME>
<CONT_DATA CI_END="16.198317449741907" CI_START="0.40168255025808897" EFFECT_SIZE="8.299999999999997" ESTIMABLE="YES" MEAN_1="24.9" MEAN_2="16.6" ORDER="113" SD_1="1.5" SD_2="11.31" SE="4.029827849921135" STUDY_ID="STD-Di-Bello-1995" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.5033558775069213" CI_END="5.705080560296882" CI_START="1.2152415979224205" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.633068783068783" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="71.45594010530195" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.7562617813826952" LOG_CI_START="0.0846626270816601" LOG_EFFECT_SIZE="0.4204622042321776" METHOD="MH" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06124473569128097" P_Q="0.0" P_Z="0.014123180970757704" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="43" WEIGHT="200.0" Z="2.4541149936767357">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.41157325777759" CI_START="1.2758044767742696" DF="0" EFFECT_SIZE="5.347222222222222" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="1.350472344406059" LOG_CI_START="0.10578412174840532" LOG_EFFECT_SIZE="0.7281282330772322" NO="1" P_CHI2="1.0" P_Z="0.02184152411164874" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="2.2931125835046653">
<NAME>3 months</NAME>
<DICH_DATA CI_END="22.41157325777759" CI_START="1.2758044767742696" EFFECT_SIZE="5.347222222222222" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.350472344406059" LOG_CI_START="0.10578412174840532" LOG_EFFECT_SIZE="0.7281282330772322" ORDER="114" O_E="0.0" SE="0.7311360232951762" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" VAR="0.5345598845598846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.066407321427068" CI_START="0.5797591746390762" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="0.48662984317937014" LOG_CI_START="-0.2367523699627703" LOG_EFFECT_SIZE="0.12493873660829993" NO="2" P_CHI2="1.0" P_Z="0.4983874612815751" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="0.6770291543734356">
<NAME>6 months</NAME>
<DICH_DATA CI_END="3.066407321427068" CI_START="0.5797591746390763" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.48662984317937014" LOG_CI_START="-0.23675236996277021" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="115" O_E="0.0" SE="0.4249182927993987" STUDY_ID="STD-Di-Bello-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.18055555555555552" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.543724348133044" CI_START="1.0656374555548513" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4305555555555554" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.7438016276172819" LOG_CI_START="0.02760947689277002" LOG_EFFECT_SIZE="0.38570555225502595" METHOD="MH" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.03476554939144428" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.00000000000001" Z="2.111078682703328">
<NAME>controlled drinking</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.543724348133044" CI_START="1.0656374555548513" DF="0" EFFECT_SIZE="2.4305555555555554" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.7438016276172819" LOG_CI_START="0.02760947689277002" LOG_EFFECT_SIZE="0.38570555225502595" NO="1" P_CHI2="1.0" P_Z="0.03476554939144428" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.00000000000001" Z="2.111078682703328">
<NAME>3 months</NAME>
<DICH_DATA CI_END="5.543724348133044" CI_START="1.0656374555548513" EFFECT_SIZE="2.4305555555555554" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" LOG_CI_END="0.7438016276172819" LOG_CI_START="0.02760947689277002" LOG_EFFECT_SIZE="0.38570555225502595" ORDER="116" O_E="0.0" SE="0.4206948145439007" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" VAR="0.17698412698412697" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03316845255029045" CI_END="0.6291158340347575" CI_START="0.21308874073552803" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3661386361083025" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-0.20126938404503236" LOG_CI_START="-0.6714394970976878" LOG_EFFECT_SIZE="-0.43635444057136" METHOD="MH" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8554869698843874" P_Q="0.0" P_Z="2.747654560975699E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="43" WEIGHT="200.0" Z="3.637998095885814">
<NAME>relapse to heavy drinking</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6283342223230258" CI_START="0.20635397759162122" DF="0" EFFECT_SIZE="0.360082304526749" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="-0.20180928572207657" LOG_CI_START="-0.6853871554299212" LOG_EFFECT_SIZE="-0.4435982205759989" NO="1" P_CHI2="1.0" P_Z="3.233351353470473E-4" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="3.5958491502528265">
<NAME>3 months</NAME>
<DICH_DATA CI_END="0.6283342223230258" CI_START="0.20635397759162122" EFFECT_SIZE="0.360082304526749" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" LOG_CI_END="-0.20180928572207657" LOG_CI_START="-0.6853871554299212" LOG_EFFECT_SIZE="-0.4435982205759989" ORDER="117" O_E="0.0" SE="0.2840560344154489" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" VAR="0.0806878306878307" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.0249658627023575" CI_START="0.049076407337504444" DF="0" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="0.604762201299449" LOG_CI_START="-1.309127237522174" LOG_EFFECT_SIZE="-0.35218251811136253" NO="2" P_CHI2="1.0" P_Z="0.4707115758726579" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="0.7213217623562314">
<NAME>6 months</NAME>
<DICH_DATA CI_END="4.0249658627023575" CI_START="0.049076407337504444" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.604762201299449" LOG_CI_START="-1.309127237522174" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="118" O_E="0.0" SE="1.1242281302693367" STUDY_ID="STD-Di-Bello-1995" TOTAL_1="9" TOTAL_2="8" VAR="1.2638888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.0201877417232126" CI_START="-6.1798122582767885" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.1505072528943615E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="5.706902375044522">
<NAME>number of daily drinks</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.0201877417232126" CI_START="-6.1798122582767885" DF="0" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" NO="1" P_CHI2="1.0" P_Z="1.1505072528943615E-8" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="5.706902375044522">
<NAME>3 months</NAME>
<CONT_DATA CI_END="-3.0201877417232126" CI_START="-6.1798122582767885" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="9.3" ORDER="119" SD_1="2.4" SD_2="4.14" SE="0.8060414735873441" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2672375411800574" CI_END="-3.1890607163695606" CI_START="-4.570901829419949" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8799812728947547" ESTIMABLE="YES" I2="38.78620777362756" I2_Q="38.78620777362756" ID="CMP-006.07" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.19522199945147956" P_Q="0.19522199945147956" P_Z="3.5551228564038405E-28" Q="3.2672375411800574" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="108" TOTAL_2="105" UNITS="" WEIGHT="300.0" Z="11.00650933561606">
<NAME>craving score</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.32911246530311E-31" CI_END="-1.8076853797874528" CI_START="-4.192314620212548" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="100.0" ID="CMP-006.07.01" NO="1" P_CHI2="0.0" P_Z="8.160322977923821E-7" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="99.99999999999999" Z="4.931493629233522">
<NAME>1 month</NAME>
<CONT_DATA CI_END="-1.8076853797874524" CI_START="-4.192314620212547" EFFECT_SIZE="-2.9999999999999996" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="5.1" ORDER="120" SD_1="0.6" SD_2="3.55" SE="0.6083349641204495" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.0904407638829356" CI_START="-5.309559236117065" DF="0" EFFECT_SIZE="-4.2" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.02" NO="2" P_CHI2="1.0" P_Z="1.179848215050999E-13" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="7.41902592228949">
<NAME>2 months</NAME>
<CONT_DATA CI_END="-3.0904407638829356" CI_START="-5.309559236117065" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="7.5" ORDER="121" SD_1="2.4" SD_2="2.37" SE="0.5661120535219659" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.1859301227527768" CI_START="-5.814069877247223" DF="0" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.07.03" NO="3" P_CHI2="1.0" P_Z="1.9217417273191714E-11" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.00000000000001" Z="6.711848496905253">
<NAME>3 months</NAME>
<CONT_DATA CI_END="-3.1859301227527768" CI_START="-5.814069877247223" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="7.6" ORDER="122" SD_1="3.6" SD_2="1.77" SE="0.6704561347108613" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1069394063262932" CI_END="4.8812212056226" CI_START="0.7728719950761676" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9423076923076925" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.6885284893210224" LOG_CI_START="-0.11189242902533537" LOG_EFFECT_SIZE="0.28831803014784346" METHOD="MH" MODIFIED="2009-04-06 13:23:25 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5749515684230508" P_Q="0.0" P_Z="0.1579530609426696" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="91" TOTAL_2="90" WEIGHT="200.0" Z="1.411989472615907">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.323248585948573" CI_START="0.3874749277513839" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="1.0138163853669309" LOG_CI_START="-0.41175639403896847" LOG_EFFECT_SIZE="0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.4078128865000237" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="0.8277486190687996">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="10.323248585948573" CI_START="0.3874749277513839" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0138163853669309" LOG_CI_START="-0.41175639403896847" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="123" O_E="0.0" SE="0.8373885073220924" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="41" TOTAL_2="41" VAR="0.7012195121951219" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0970445525892614" CI_END="5.8239662425960805" CI_START="0.6292086257500169" DF="1" EFFECT_SIZE="1.9142857142857146" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="8.845999222202538" ID="CMP-006.08.02" LOG_CI_END="0.7652188490150196" LOG_CI_START="-0.20120533231391768" LOG_EFFECT_SIZE="0.2820067583505509" NO="2" P_CHI2="0.2949161042719103" P_Z="0.25268506232561094" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="49" WEIGHT="100.00000000000001" Z="1.1438519450204905">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="4.929511710259798" CI_START="0.1602843249455394" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.692803902635809" LOG_CI_START="-0.7951089475305718" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="124" O_E="0.0" SE="0.8740073734751262" STUDY_ID="STD-Di-Bello-1995" TOTAL_1="9" TOTAL_2="8" VAR="0.7638888888888888" WEIGHT="51.42857142857144"/>
<DICH_DATA CI_END="14.00278741819194" CI_START="0.6427291746432936" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1462144956670552" LOG_CI_START="-0.19197198622773032" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="125" O_E="0.0" SE="0.7860573635949151" STUDY_ID="STD-Gallimberti-1992" TOTAL_1="41" TOTAL_2="41" VAR="0.6178861788617885" WEIGHT="48.57142857142858"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-11-03 17:57:24 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>GHB 50mg vs NTX: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.7108027461228906" CI_END="1.7084757372021484" CI_START="0.3152247898918906" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7338623203945956" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.2326088155760788" LOG_CI_START="-0.5013796360749001" LOG_EFFECT_SIZE="-0.13438541024941067" METHOD="MH" MODIFIED="2009-04-06 13:26:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7008921717538381" P_Q="0.0" P_Z="0.47294429127445936" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="66" TOTAL_2="61" WEIGHT="200.0" Z="0.7176967527051241">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6250125844651334" CI_END="1.7474204403253424" CI_START="0.2632643403496" DF="1" EFFECT_SIZE="0.6782576866764275" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.2423974115340258" LOG_CI_START="-0.5796079629152207" LOG_EFFECT_SIZE="-0.1686052756905974" NO="1" P_CHI2="0.42919086676880547" P_Z="0.42137715930754127" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="100.0" Z="0.8040343244189371">
<NAME>3 months</NAME>
<DICH_DATA CI_END="3.1897658876284596" CI_START="0.2796366065928258" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.503758809250856" LOG_CI_START="-0.5534059767009203" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="126" O_E="0.0" SE="0.6209838283181613" STUDY_ID="STD-Caputo-2003" TOTAL_1="18" TOTAL_2="17" VAR="0.3856209150326797" WEIGHT="48.75549048316251"/>
<DICH_DATA CI_END="2.0416239924310005" CI_START="0.08847123695138713" EFFECT_SIZE="0.425" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3099757607436378" LOG_CI_START="-1.0531979006430146" LOG_EFFECT_SIZE="-0.37161106994968846" ORDER="127" O_E="0.0" SE="0.8007349565169709" STUDY_ID="STD-Caputo-2007" TOTAL_1="20" TOTAL_2="17" VAR="0.6411764705882352" WEIGHT="51.24450951683748"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.3658974797718875" CI_START="0.14606690442787806" DF="0" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.8038596402026923" LOG_CI_START="-0.8354481745691561" LOG_EFFECT_SIZE="-0.015794267183231903" NO="2" P_CHI2="1.0" P_Z="0.9698731389299916" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.03776739738856886">
<NAME>12 months</NAME>
<DICH_DATA CI_END="6.365897479771887" CI_START="0.1460669044278781" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8038596402026922" LOG_CI_START="-0.835448174569156" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="128" O_E="0.0" SE="0.9629375251015391" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.9272486772486772" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.173207804296512" CI_END="2.623615061178768" CI_START="1.2089039773913304" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.780926355187887" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="20" I2="36.972296699509975" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.41890011535701954" LOG_CI_START="0.08239180644784645" LOG_EFFECT_SIZE="0.250645960902433" METHOD="MH" MODIFIED="2009-04-06 13:26:02 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20461946403158227" P_Q="0.0" P_Z="0.003503324043798694" Q="0.0" RANDOM="NO" SCALE="17.77976552424021" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="57" WEIGHT="200.0" Z="2.9197321030893084">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.003192792743179" CI_END="4.979935509250295" CI_START="1.3457939725081305" DF="1" EFFECT_SIZE="2.588815789473684" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="50.07969259760581" ID="CMP-007.02.01" LOG_CI_END="0.6972237186315884" LOG_CI_START="0.12897857886903322" LOG_EFFECT_SIZE="0.4131011487503108" NO="1" P_CHI2="0.15696862872652073" P_Z="0.004376082898846518" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="2.8496974874648493">
<NAME>3 months</NAME>
<DICH_DATA CI_END="3.4691914766875938" CI_START="0.9941738918169611" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.5402282707195243" LOG_CI_START="-0.002537646134364268" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="129" O_E="0.0" SE="0.3188233862945936" STUDY_ID="STD-Caputo-2003" TOTAL_1="14" TOTAL_2="13" VAR="0.10164835164835165" WEIGHT="85.19736842105263"/>
<DICH_DATA CI_END="49.04193017101238" CI_START="0.9428666416423279" EFFECT_SIZE="6.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.6905675546205463" LOG_CI_START="-0.025549729208073628" LOG_EFFECT_SIZE="0.8325089127062363" ORDER="130" O_E="0.0" SE="1.0080557874384906" STUDY_ID="STD-Caputo-2007" TOTAL_1="20" TOTAL_2="17" VAR="1.0161764705882352" WEIGHT="14.802631578947368"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.155566817308863" CI_START="0.8270052789578222" DF="0" EFFECT_SIZE="1.335164835164835" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="0.33356148946723496" LOG_CI_START="-0.08249171824076024" LOG_EFFECT_SIZE="0.12553488561323736" NO="2" P_CHI2="1.0" P_Z="0.2369075217079779" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="1.1827518694579333">
<NAME>12 months</NAME>
<DICH_DATA CI_END="2.155566817308863" CI_START="0.8270052789578222" EFFECT_SIZE="1.335164835164835" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.33356148946723496" LOG_CI_START="-0.08249171824076024" LOG_EFFECT_SIZE="0.12553488561323736" ORDER="131" O_E="0.0" SE="0.2443917137042697" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.05972730972730973" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9167659180633607" CI_END="2.4743336737839043" CI_START="0.43936609515043873" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0426592561089523" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="31.43090476976171" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.39345826558883307" LOG_CI_START="-0.35717345960757596" LOG_EFFECT_SIZE="0.01814240299062858" METHOD="MH" MODIFIED="2009-04-06 13:26:02 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2326121646692173" P_Q="0.0" P_Z="0.9245191621254317" Q="0.0" RANDOM="NO" SCALE="199.30288363873797" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="57" WEIGHT="200.0" Z="0.09474274870367257">
<NAME>relapses to heavy drinking</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.10559056893623683" CI_END="18.332614823972655" CI_START="0.5708476824407481" DF="1" EFFECT_SIZE="3.234985422740525" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="1.2632244138237396" LOG_CI_START="-0.24347975777882352" LOG_EFFECT_SIZE="0.509872328022458" NO="1" P_CHI2="0.7452211984240862" P_Z="0.18466980376071815" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.00000000000001" Z="1.3265130852789768">
<NAME>3 months</NAME>
<DICH_DATA CI_END="88.95747013494845" CI_START="0.24481111866986432" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.94918242349546" LOG_CI_START="-0.6111688615783089" LOG_EFFECT_SIZE="0.6690067809585756" ORDER="132" O_E="0.0" SE="1.5039630187955957" STUDY_ID="STD-Caputo-2003" TOTAL_1="14" TOTAL_2="13" VAR="2.2619047619047614" WEIGHT="32.36151603498543"/>
<DICH_DATA CI_END="22.30792281769387" CI_START="0.2914883673007172" EFFECT_SIZE="2.55" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3484591332236995" LOG_CI_START="-0.5353787723557891" LOG_EFFECT_SIZE="0.4065401804339551" ORDER="133" O_E="0.0" SE="1.1065757108854182" STUDY_ID="STD-Caputo-2007" TOTAL_1="20" TOTAL_2="17" VAR="1.2245098039215685" WEIGHT="67.63848396501459"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.670165849928687" CI_START="0.1817924191333307" DF="0" EFFECT_SIZE="0.5510204081632653" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="0.22275959937064058" LOG_CI_START="-0.7404242311096935" LOG_EFFECT_SIZE="-0.2588323158695264" NO="2" P_CHI2="1.0" P_Z="0.2921642894842921" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="1.0533856592803856">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.6701658499286869" CI_START="0.18179241913333077" EFFECT_SIZE="0.5510204081632653" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.22275959937064052" LOG_CI_START="-0.7404242311096932" LOG_EFFECT_SIZE="-0.2588323158695264" ORDER="134" O_E="0.0" SE="0.5657789498610036" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.3201058201058201" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6446218472387181" CI_START="-1.044621847238718" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2009-04-06 13:26:02 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6425728820726284" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="18" UNITS="" WEIGHT="100.00000000000001" Z="0.46410449621867383">
<NAME>number of daily drinks</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6446218472387181" CI_START="-1.044621847238718" DF="0" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" NO="1" P_CHI2="1.0" P_Z="0.6425728820726284" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.00000000000001" Z="0.46410449621867383">
<NAME>12 months</NAME>
<CONT_DATA CI_END="0.6446218472387181" CI_START="-1.044621847238718" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.8" ORDER="135" SD_1="1.3" SD_2="1.4" SE="0.4309374324737533" STUDY_ID="STD-Nava-2006" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.571038523407607" CI_START="0.23146368107607707" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="0.41010858398553107" LOG_CI_START="-0.6355171443681077" LOG_EFFECT_SIZE="-0.11270428019128831" METHOD="MH" MODIFIED="2009-11-03 17:57:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6726490818837929" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.4225151009362449">
<NAME>controlled drinking</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.571038523407607" CI_START="0.23146368107607707" DF="0" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-007.05.01" LOG_CI_END="0.41010858398553107" LOG_CI_START="-0.6355171443681077" LOG_EFFECT_SIZE="-0.11270428019128831" MODIFIED="2009-11-03 17:56:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6726490818837929" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="27" WEIGHT="100.0" Z="0.4225151009362449">
<NAME>12 months</NAME>
<DICH_DATA CI_END="2.5710385234076076" CI_START="0.23146368107607704" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4101085839855311" LOG_CI_START="-0.6355171443681078" LOG_EFFECT_SIZE="-0.11270428019128831" MODIFIED="2009-10-12 15:56:57 +0200" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.6142057287657592" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.3772486772486773" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.3532147189525086" CI_START="-2.4467852810474917" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2009-10-12 15:58:17 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="9.71977944935834E-12" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="6.81059220082162">
<NAME>Alcohol Craving Scale</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.3532147189525086" CI_START="-2.4467852810474917" DF="0" EFFECT_SIZE="-1.9000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-007.06.01" NO="1" P_CHI2="1.0" P_Z="9.71977944935834E-12" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="6.81059220082162">
<NAME>12 months</NAME>
<CONT_DATA CI_END="-1.3532147189525086" CI_START="-2.4467852810474917" EFFECT_SIZE="-1.9000000000000001" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="3.6" ORDER="136" SD_1="0.7" SD_2="1.0" SE="0.27897720843875906" STUDY_ID="STD-Nava-2006" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1660521313783598" CI_END="1.0847745374286577" CI_START="0.19533692628892496" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46032219570405725" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-007.07" LOG_CI_END="0.03533948258492446" LOG_CI_START="-0.7092156503751058" LOG_EFFECT_SIZE="-0.33693808389509067" METHOD="MH" MODIFIED="2009-10-12 15:58:10 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8836556711173935" P_Q="0.0" P_Z="0.07607821102586111" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="104" TOTAL_2="95" WEIGHT="200.0" Z="1.7739089564231487">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6394812957360767" CI_END="2.101321386572545" CI_START="0.18369675064850005" DF="2" EFFECT_SIZE="0.621293739531936" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-007.07.01" LOG_CI_END="0.3224924806499856" LOG_CI_START="-0.7358985257187264" LOG_EFFECT_SIZE="-0.20670302253437042" NO="1" P_CHI2="0.7263374410756067" P_Z="0.44393864245853276" STUDIES="3" TAU2="0.0" TOTAL_1="66" TOTAL_2="61" WEIGHT="100.0" Z="0.7655591879090513">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="2.740532518021012" CI_START="0.03616390864737999" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4378349595967986" LOG_CI_START="-1.4417246364861878" LOG_EFFECT_SIZE="-0.5019448384446946" ORDER="137" O_E="0.0" SE="1.1040626107091993" STUDY_ID="STD-Caputo-2003" TOTAL_1="18" TOTAL_2="17" VAR="1.218954248366013" WEIGHT="49.74423973563895"/>
<DICH_DATA CI_END="12.589014410757706" CI_START="0.057391307724820845" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0999917306857576" LOG_CI_START="-1.2411538792571724" LOG_EFFECT_SIZE="-0.07058107428570728" ORDER="138" O_E="0.0" SE="1.375200520138149" STUDY_ID="STD-Caputo-2007" TOTAL_1="20" TOTAL_2="17" VAR="1.8911764705882352" WEIGHT="17.427911819292923"/>
<DICH_DATA CI_END="6.365897479771887" CI_START="0.1460669044278781" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8038596402026922" LOG_CI_START="-0.835448174569156" LOG_EFFECT_SIZE="-0.015794267183231903" ORDER="139" O_E="0.0" SE="0.9629375251015391" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="27" VAR="0.9272486772486772" WEIGHT="32.82784844506812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04590820595948572" CI_END="1.171234425499397" CI_START="0.09942769022370747" DF="1" EFFECT_SIZE="0.3412523020257827" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-007.07.02" LOG_CI_END="0.06864382889934226" LOG_CI_START="-1.002492649439241" LOG_EFFECT_SIZE="-0.46692441026994935" NO="2" P_CHI2="0.8303429018488048" P_Z="0.08749629956521834" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="100.0" Z="1.7087552261336152">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="1.6928785984927668" CI_START="0.08430377081367885" EFFECT_SIZE="0.37777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.22862581463868076" LOG_CI_START="-1.0741529994328203" LOG_EFFECT_SIZE="-0.4227635923970698" ORDER="140" O_E="0.0" SE="0.7652587242447352" STUDY_ID="STD-Caputo-2003" TOTAL_1="18" TOTAL_2="17" VAR="0.5856209150326797" WEIGHT="61.325966850828735"/>
<DICH_DATA CI_END="2.478658090854874" CI_START="0.03238759636674635" EFFECT_SIZE="0.2833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.39421662378437455" LOG_CI_START="-1.489621281795114" LOG_EFFECT_SIZE="-0.5477023290053697" ORDER="141" O_E="0.0" SE="1.1065757108854182" STUDY_ID="STD-Caputo-2007" TOTAL_1="20" TOTAL_2="17" VAR="1.2245098039215685" WEIGHT="38.67403314917127"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-11-03 17:57:51 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>GHB 50mg vs disulfiram: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0430598374664706" CI_START="0.05803273971554425" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24603174603174605" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.018309223417979945" LOG_CI_START="-1.2363269259845604" LOG_EFFECT_SIZE="-0.6090088512832902" METHOD="MH" MODIFIED="2009-04-06 13:29:17 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.05707193646338751" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="1.9027594818621636">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disulfiram</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0430598374664706" CI_START="0.05803273971554425" DF="0" EFFECT_SIZE="0.24603174603174605" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.018309223417979945" LOG_CI_START="-1.2363269259845604" LOG_EFFECT_SIZE="-0.6090088512832902" NO="1" P_CHI2="1.0" P_Z="0.05707193646338751" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="1.9027594818621636">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.0430598374664708" CI_START="0.05803273971554425" EFFECT_SIZE="0.24603174603174602" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.018309223417980035" LOG_CI_START="-1.2363269259845604" LOG_EFFECT_SIZE="-0.6090088512832903" ORDER="142" O_E="0.0" SE="0.7369794847081542" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="31" VAR="0.5431387608806965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7380926758761686E-31" CI_END="2.798796027551121" CI_START="0.9854136963273702" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6607142857142856" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="100.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.44697124882812206" LOG_CI_START="-0.006381405732652676" LOG_EFFECT_SIZE="0.22029492154773467" METHOD="MH" MODIFIED="2009-04-06 13:29:17 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.05680776970318843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="1.904786959410007">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disulfiram</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7380926758761686E-31" CI_END="2.798796027551121" CI_START="0.9854136963273702" DF="0" EFFECT_SIZE="1.6607142857142856" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="100.0" ID="CMP-008.02.01" LOG_CI_END="0.44697124882812206" LOG_CI_START="-0.006381405732652676" LOG_EFFECT_SIZE="0.22029492154773467" NO="1" P_CHI2="0.0" P_Z="0.05680776970318843" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="1.904786959410007">
<NAME>12 months</NAME>
<DICH_DATA CI_END="2.7987960275511212" CI_START="0.9854136963273702" EFFECT_SIZE="1.6607142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.4469712488281221" LOG_CI_START="-0.006381405732652676" LOG_EFFECT_SIZE="0.22029492154773472" ORDER="143" O_E="0.0" SE="0.2663015934208321" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="31" VAR="0.07091653865847415" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.028488958276662" CI_START="0.3614733869593759" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4761904761904763" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.7802084697987806" LOG_CI_START="-0.4419236715980737" LOG_EFFECT_SIZE="0.16914239910035345" METHOD="MH" MODIFIED="2009-04-06 13:29:17 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5874632144910112" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="0.5425158201247944">
<NAME>relapses to heavy drinking</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disulfiram</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.028488958276662" CI_START="0.3614733869593759" DF="0" EFFECT_SIZE="1.4761904761904763" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="0.7802084697987806" LOG_CI_START="-0.4419236715980737" LOG_EFFECT_SIZE="0.16914239910035345" NO="1" P_CHI2="1.0" P_Z="0.5874632144910112" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="0.5425158201247944">
<NAME>12 months</NAME>
<DICH_DATA CI_END="6.028488958276662" CI_START="0.3614733869593759" EFFECT_SIZE="1.4761904761904763" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7802084697987806" LOG_CI_START="-0.4419236715980737" LOG_EFFECT_SIZE="0.16914239910035345" ORDER="144" O_E="0.0" SE="0.7178864695081797" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="31" VAR="0.5153609831029186" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4979859241451082" CI_START="-1.0979859241451084" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2009-04-06 13:29:17 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.46121871028516925" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.7368415627029212">
<NAME>number of daily drinks</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disulfiram</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4979859241451082" CI_START="-1.0979859241451084" DF="0" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.01" NO="1" P_CHI2="1.0" P_Z="0.46121871028516925" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="0.7368415627029212">
<NAME>12 months</NAME>
<CONT_DATA CI_END="0.4979859241451082" CI_START="-1.0979859241451084" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.9" ORDER="145" SD_1="1.3" SD_2="1.3" SE="0.40714315693529035" STUDY_ID="STD-Nava-2006" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9334775708754812" CI_START="0.20701036407445078" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6326530612244898" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.28633913844605813" LOG_CI_START="-0.68400791083454" LOG_EFFECT_SIZE="-0.19883438619424096" METHOD="MH" MODIFIED="2009-11-03 17:57:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.4218390698498745" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="0.803234752180191">
<NAME>controlled drinking</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disulfiram</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9334775708754812" CI_START="0.20701036407445078" DF="0" EFFECT_SIZE="0.6326530612244898" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.28633913844605813" LOG_CI_START="-0.68400791083454" LOG_EFFECT_SIZE="-0.19883438619424096" MODIFIED="2009-11-03 17:57:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4218390698498745" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="0.803234752180191">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.9334775708754812" CI_START="0.20701036407445078" EFFECT_SIZE="0.6326530612244898" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.28633913844605813" LOG_CI_START="-0.68400791083454" LOG_EFFECT_SIZE="-0.19883438619424096" MODIFIED="2009-10-12 16:10:33 +0200" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.5699866600427839" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="31" VAR="0.3248847926267281" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.9363662304284055" CI_START="-1.8636337695715948" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.06" MODIFIED="2009-10-12 16:13:59 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="3.251760539633298E-9" Q="0.0" RANDOM="NO" SCALE="2.4923855848260317" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="19" UNITS="" WEIGHT="100.00000000000001" Z="5.918355733430572">
<NAME>Alcohol Craving Scale</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disulfiram</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9363662304284055" CI_START="-1.8636337695715948" DF="0" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-008.06.01" NO="1" P_CHI2="1.0" P_Z="3.251760539633298E-9" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.00000000000001" Z="5.918355733430572">
<NAME>12 months</NAME>
<CONT_DATA CI_END="-0.9363662304284055" CI_START="-1.8636337695715948" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="3.1" ORDER="146" SD_1="0.7" SD_2="0.8" SE="0.23655218832013172" STUDY_ID="STD-Nava-2006" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7934324004745212" CI_START="0.10970064157577505" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5535714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.4461381661360913" LOG_CI_START="-0.9597908324799466" LOG_EFFECT_SIZE="-0.2568263331719277" METHOD="MH" MODIFIED="2009-10-12 16:13:55 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.47394938439579226" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="0.7160679718449059">
<NAME>side-effects</NAME>
<GROUP_LABEL_1>GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disulfiram</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7934324004745212" CI_START="0.10970064157577505" DF="0" EFFECT_SIZE="0.5535714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-008.07.01" LOG_CI_END="0.4461381661360913" LOG_CI_START="-0.9597908324799466" LOG_EFFECT_SIZE="-0.2568263331719277" NO="1" P_CHI2="1.0" P_Z="0.47394938439579226" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="31" WEIGHT="100.0" Z="0.7160679718449059">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="2.7934324004745212" CI_START="0.10970064157577505" EFFECT_SIZE="0.5535714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4461381661360913" LOG_CI_START="-0.9597908324799466" LOG_EFFECT_SIZE="-0.2568263331719277" ORDER="147" O_E="0.0" SE="0.8258496532478447" STUDY_ID="STD-Nava-2006" TOTAL_1="28" TOTAL_2="31" VAR="0.6820276497695853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-02-17 10:58:38 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>GHB 50mg + NTX vs NTX: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7110809818271893" CI_START="0.18506865507682316" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.43314249044489067" LOG_CI_START="-0.7326671311115548" LOG_EFFECT_SIZE="-0.14976232033333206" METHOD="MH" MODIFIED="2009-04-06 13:43:28 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6145691530480215" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.5035620716572884">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>NTX+GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX+GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7110809818271893" CI_START="0.18506865507682316" DF="0" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.43314249044489067" LOG_CI_START="-0.7326671311115548" LOG_EFFECT_SIZE="-0.14976232033333206" NO="1" P_CHI2="1.0" P_Z="0.6145691530480215" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.5035620716572884">
<NAME>3 months</NAME>
<DICH_DATA CI_END="2.7110809818271884" CI_START="0.18506865507682324" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4331424904448905" LOG_CI_START="-0.7326671311115546" LOG_EFFECT_SIZE="-0.14976232033333206" ORDER="153" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Caputo-2007" TOTAL_1="18" TOTAL_2="17" VAR="0.46895424836601296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="83.99005557530172" CI_START="1.7947818480170405" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.277777777777779" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="1.9242278686281244" LOG_CI_START="0.25401166853548524" LOG_EFFECT_SIZE="1.0891197685818046" METHOD="MH" MODIFIED="2009-04-06 13:43:28 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.01058469722613012" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="2.5561188080351966">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>NTX+GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX+GHB</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="83.99005557530172" CI_START="1.7947818480170405" DF="0" EFFECT_SIZE="12.277777777777779" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="1.9242278686281244" LOG_CI_START="0.25401166853548524" LOG_EFFECT_SIZE="1.0891197685818046" NO="1" P_CHI2="1.0" P_Z="0.01058469722613012" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="2.5561188080351966">
<NAME>3 months</NAME>
<DICH_DATA CI_END="83.99005557530165" CI_START="1.7947818480170414" EFFECT_SIZE="12.277777777777779" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.924227868628124" LOG_CI_START="0.25401166853548546" LOG_EFFECT_SIZE="1.0891197685818046" ORDER="154" O_E="0.0" SE="0.9810932636379461" STUDY_ID="STD-Caputo-2007" TOTAL_1="18" TOTAL_2="17" VAR="0.9625439919557566" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.259648833094586" CI_START="0.013736613709900562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.8609156133257376" LOG_CI_START="-1.8621203144641083" LOG_EFFECT_SIZE="-0.5006023505691853" METHOD="MH" MODIFIED="2009-04-06 13:43:28 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.47113182309383816" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.7206387309682388">
<NAME>relapses to heavy drinking</NAME>
<GROUP_LABEL_1>NTX+GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX+GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.259648833094586" CI_START="0.013736613709900562" DF="0" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="0.8609156133257376" LOG_CI_START="-1.8621203144641083" LOG_EFFECT_SIZE="-0.5006023505691853" NO="1" P_CHI2="1.0" P_Z="0.47113182309383816" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.7206387309682388">
<NAME>3 months</NAME>
<DICH_DATA CI_END="7.259648833094586" CI_START="0.013736613709900562" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8609156133257376" LOG_CI_START="-1.8621203144641083" LOG_EFFECT_SIZE="-0.5006023505691853" ORDER="155" O_E="0.0" SE="1.5995247832289885" STUDY_ID="STD-Caputo-2007" TOTAL_1="18" TOTAL_2="17" VAR="2.5584795321637426" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10387040233852218" CI_END="6.15462296723039" CI_START="0.7336964464018263" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="0.7892014531622662" LOG_CI_START="-0.13448358438960542" LOG_EFFECT_SIZE="0.32735893438633035" METHOD="MH" MODIFIED="2009-04-06 13:43:28 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7472335576729994" P_Q="0.0" P_Z="0.16475871540853382" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="34" WEIGHT="200.0" Z="1.3892435090539985">
<NAME>side effects</NAME>
<GROUP_LABEL_1>NTX+GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX+GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.66479266218911" CI_START="0.32547517782642" DF="0" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-009.04.01" LOG_CI_END="1.3920774690361235" LOG_CI_START="-0.48748212704686283" LOG_EFFECT_SIZE="0.4522976709946303" NO="1" P_CHI2="1.0" P_Z="0.3455313712574465" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.9432924045486686">
<NAME>side-effects causing abandon</NAME>
<DICH_DATA CI_END="24.66479266218911" CI_START="0.32547517782642" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3920774690361235" LOG_CI_START="-0.48748212704686283" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="156" O_E="0.0" SE="1.1040626107091993" STUDY_ID="STD-Caputo-2007" TOTAL_1="18" TOTAL_2="17" VAR="1.218954248366013" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.196390850074545E-32" CI_END="6.37953177525692" CI_START="0.5592732131856514" DF="0" EFFECT_SIZE="1.8888888888888886" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="100.0" ID="CMP-009.04.02" LOG_CI_END="0.8047888049148373" LOG_CI_START="-0.25237598103693926" LOG_EFFECT_SIZE="0.276206411938949" NO="2" P_CHI2="0.0" P_Z="0.3057582252596872" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.024163170951607">
<NAME>tolerated side-effects</NAME>
<DICH_DATA CI_END="6.379531775256918" CI_START="0.5592732131856516" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8047888049148372" LOG_CI_START="-0.2523759810369391" LOG_EFFECT_SIZE="0.27620641193894907" ORDER="157" O_E="0.0" SE="0.6209838283181613" STUDY_ID="STD-Caputo-2007" TOTAL_1="18" TOTAL_2="17" VAR="0.3856209150326797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-02-17 10:58:38 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>GHB 50mg + disulfiram vs disulfiram + placebo: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5623477480712826" CI_START="0.025602494738690536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.19377770576380984" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2009-04-06 13:42:44 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.12489714589710044" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.534538839219438">
<NAME>drop-outs</NAME>
<GROUP_LABEL_1>disulfiram+GHB 50mg</GROUP_LABEL_1>
<GROUP_LABEL_2>disulfiram+placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours disulf+GHB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours disulfiram</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5623477480712826" CI_START="0.025602494738690536" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-010.01.01" LOG_CI_END="0.19377770576380984" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" NO="1" P_CHI2="1.0" P_Z="0.12489714589710044" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.534538839219438">
<NAME>3 months</NAME>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="158" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Ferri-1991" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-02-17 10:58:38 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>GHB 75mg + escitalopram vs escitalopram: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.45201477820129143" CI_END="3.8175052124519855" CI_START="1.0107172492552208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.964285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.5817796387180041" LOG_CI_START="0.004629677586045105" LOG_EFFECT_SIZE="0.29320465815202457" METHOD="MH" MODIFIED="2009-04-06 13:42:22 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5013797458544226" P_Q="0.0" P_Z="0.0464360332556975" Q="0.0" RANDOM="NO" SCALE="132.92788101468818" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="22" WEIGHT="200.00000000000003" Z="1.9914081565569213">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>GHB 75mg+escitalopram</GROUP_LABEL_1>
<GROUP_LABEL_2>escitalopram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours escitalopram</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB+escitalo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4071597334831654" CI_START="0.799052645887185" DF="0" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="0.5323924945142127" LOG_CI_START="-0.09742460608640016" LOG_EFFECT_SIZE="0.21748394421390627" NO="1" P_CHI2="1.0" P_Z="0.17586353613555625" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.00000000000001" Z="1.353601537552662">
<NAME>3 months</NAME>
<DICH_DATA CI_END="3.4071597334831663" CI_START="0.7990526458871849" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.5323924945142128" LOG_CI_START="-0.09742460608640022" LOG_EFFECT_SIZE="0.21748394421390627" ORDER="159" O_E="0.0" SE="0.36995768253772876" STUDY_ID="STD-Stella-2008" TOTAL_1="12" TOTAL_2="11" VAR="0.1368686868686869" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.880425950165131" CI_START="0.6950555092822653" DF="0" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="1.0366458975850708" LOG_CI_START="-0.1579805099245453" LOG_EFFECT_SIZE="0.43933269383026263" NO="2" P_CHI2="1.0" P_Z="0.14942019029668926" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.00000000000001" Z="1.4415824926109317">
<NAME>6 months</NAME>
<DICH_DATA CI_END="10.880425950165126" CI_START="0.6950555092822654" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0366458975850705" LOG_CI_START="-0.15798050992454524" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="160" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Stella-2008" TOTAL_1="12" TOTAL_2="11" VAR="0.4924242424242423" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2011-02-17 11:01:18 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>GHB 75mg + escitalopram vs NTX + escitalopram: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="0.07599409966201738" CI_END="2.287796254112638" CI_START="0.8127927165230218" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.359417344572629" LOG_CI_START="-0.0900201967777167" LOG_EFFECT_SIZE="0.13469857389745618" METHOD="MH" MODIFIED="2009-04-06 13:40:58 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7828013370985207" P_Q="0.0" P_Z="0.2400663168887428" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="24" WEIGHT="200.0" Z="1.174821101124369">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>GHB 75mg+escitalopram</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX+escitalopram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NTX+escital</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GHB+escital</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2942864733872663" CI_START="0.7205121259548855" DF="0" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-012.01.01" LOG_CI_END="0.3606476446217381" LOG_CI_START="-0.142358705771602" LOG_EFFECT_SIZE="0.10914446942506807" NO="1" P_CHI2="1.0" P_Z="0.3950123046077183" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.8505627374985875">
<NAME>3 months</NAME>
<DICH_DATA CI_END="2.2942864733872668" CI_START="0.7205121259548855" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.3606476446217382" LOG_CI_START="-0.142358705771602" LOG_EFFECT_SIZE="0.10914446942506807" ORDER="165" O_E="0.0" SE="0.29546842014263947" STUDY_ID="STD-Stella-2008" TOTAL_1="12" TOTAL_2="12" VAR="0.08730158730158731" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9966123923293475" CI_START="0.5629767861197648" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-012.01.02" LOG_CI_END="0.6016920306631093" LOG_CI_START="-0.2495095125517467" LOG_EFFECT_SIZE="0.17609125905568124" NO="2" P_CHI2="1.0" P_Z="0.41740575426480886" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.8109302162163288">
<NAME>6 months</NAME>
<DICH_DATA CI_END="3.9966123923293475" CI_START="0.5629767861197648" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6016920306631093" LOG_CI_START="-0.2495095125517467" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="166" O_E="0.0" SE="0.5" STUDY_ID="STD-Stella-2008" TOTAL_1="12" TOTAL_2="12" VAR="0.25" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-02-17 11:01:18 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>GHB 75mg + NTX + Escitalopram vs escitalopram: maintaining abstinence</NAME>
<DICH_OUTCOME CHI2="1.4374284290349137" CI_END="5.135945185946678" CI_START="1.4724650918574882" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" I2="30.431318888593445" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.7106203800203137" LOG_CI_START="0.16804500764021155" LOG_EFFECT_SIZE="0.43933269383026263" METHOD="MH" MODIFIED="2009-04-06 13:41:41 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23055619682793504" P_Q="0.0" P_Z="0.0015033623708478301" Q="0.0" RANDOM="NO" SCALE="43.86797569998509" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="22" WEIGHT="200.00000000000003" Z="3.1740336954882973">
<NAME>abstinence</NAME>
<GROUP_LABEL_1>NTX+GHB 75mg+escitalopram</GROUP_LABEL_1>
<GROUP_LABEL_2>escitalopram</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours escitalopram</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NTX+GHB+esc</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.938898563418159" CI_START="1.0325080422774755" DF="0" EFFECT_SIZE="2.0166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-013.01.01" LOG_CI_END="0.5953747967738551" LOG_CI_START="0.013893443091757761" LOG_EFFECT_SIZE="0.3046341199328064" NO="1" P_CHI2="1.0" P_Z="0.04001214014524681" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.00000000000001" Z="2.0536235590343015">
<NAME>3 months</NAME>
<DICH_DATA CI_END="3.938898563418159" CI_START="1.0325080422774755" EFFECT_SIZE="2.0166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.5953747967738551" LOG_CI_START="0.013893443091757761" LOG_EFFECT_SIZE="0.3046341199328064" ORDER="163" O_E="0.0" SE="0.3415650255319866" STUDY_ID="STD-Stella-2008" TOTAL_1="12" TOTAL_2="11" VAR="0.11666666666666667" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.466121480316186" CI_START="1.2757676098501043" DF="0" EFFECT_SIZE="4.583333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-013.01.02" LOG_CI_END="1.2165913151345544" LOG_CI_START="0.10577157175868349" LOG_EFFECT_SIZE="0.661181443446619" NO="2" P_CHI2="1.0" P_Z="0.019636753206512873" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="11" WEIGHT="100.00000000000001" Z="2.3332171112898297">
<NAME>6 months</NAME>
<DICH_DATA CI_END="16.466121480316186" CI_START="1.2757676098501043" EFFECT_SIZE="4.583333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2165913151345544" LOG_CI_START="0.10577157175868349" LOG_EFFECT_SIZE="0.661181443446619" ORDER="164" O_E="0.0" SE="0.6525010159053974" STUDY_ID="STD-Stella-2008" TOTAL_1="12" TOTAL_2="11" VAR="0.42575757575757567" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-04-08 11:04:52 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flow chart_GHB.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-04-21 21:30:52 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-04-08 11:04:52 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-04-08 11:04:52 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-04-29 12:26:32 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-04-29 11:42:44 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-04-29 11:01:09 +0200" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-29 11:42:44 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>sodium oxybate [mesh]</LI>
<LI>ghb [tiab]</LI>
<LI>gamma-hydroxybutyrate [tiab]</LI>
<LI>gamma-aminobutyric acid [tiab]</LI>
<LI>4-hydroxybutyrate [tiab]</LI>
<LI>gamma hydrate [tiab]</LI>
<LI>sodium [tiab]</LI>
<LI>gamma hydroxybutyric acid.mp</LI>
<LI>gamma-OH [tiab]</LI>
<LI>4-Hydroxybutyric Acid [tiab]</LI>
<LI>sodium oxybuty.mp</LI>
<LI>sodium 4-hydroxybutyrate.mp</LI>
<LI>sodium hydroxybutyrate.mp</LI>
<LI>Hydroxybutyric Acid.mp</LI>
<LI>Oxybate Sodium.mp</LI>
<LI>1 or 2 or 3 or 5 or 6 or 7 or 8 or 10 or 11 or 12 or 13 or 14 or 15</LI>
<LI>exp Alcohol-related disorders/</LI>
<LI>exp Drinking behavior/</LI>
<LI>alcohol$.mp</LI>
<LI>withdraw$.mp</LI>
<LI>drinking behav$.mp</LI>
<LI>17 or 18 or 19 or 20 or 21</LI>
<LI>randomized controlled trial[pt] </LI>
<LI>controlled clinical trial[pt]</LI>
<LI>random*[tiab]</LI>
<LI>placebo[tiab]</LI>
<LI>drug therapy[mesh]</LI>
<LI>trial[tiab]</LI>
<LI>groups[tiab]</LI>
<LI>23/29 OR</LI>
<LI>animals [mesh]</LI>
<LI>humans [mesh]</LI>
<LI>31 NOT (31 and 32)</LI>
<LI>30 NOT 33</LI>
<LI>16 and 22 and 34</LI>
<LI>limit 35 to human</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-04-29 11:00:09 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-04-29 10:55:13 +0200" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-29 11:00:09 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Exp Alcohol Withdrawal/</LI>
<LI>Exp Withdrawal Syndrome/</LI>
<LI>((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy)) [tiab]</LI>
<LI>1 OR 2 OR 3</LI>
<LI>sodium oxybate [mesh]</LI>
<LI>ghb [tiab]</LI>
<LI>gamma-hydroxybutyrate [tiab]</LI>
<LI>gamma-aminobutyric acid [tiab]</LI>
<LI>4-hydroxybutyrate [tiab]</LI>
<LI>gamma hydrate [tiab]</LI>
<LI>sodium [tiab]</LI>
<LI>gamma hydroxybutyric acid.mp</LI>
<LI>gamma-OH [tiab]</LI>
<LI>4-Hydroxybutyric Acid</LI>
<LI>5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14</LI>
<LI>random*.ti,ab</LI>
<LI>placebo.ti,ab</LI>
<LI>(singl* or doubl* or trebl* or tripl*) and (blind* or mask*)).ti,ab</LI>
<LI>crossover*.ti,ab</LI>
<LI>exp randomized controlled trial/</LI>
<LI>exp double blind procedure/</LI>
<LI>exp single blind procedure/</LI>
<LI>exp triple blind procedure/</LI>
<LI>exp latin square design</LI>
<LI>exp crossover procedure/</LI>
<LI>exp Latin square design/</LI>
<LI>exp placebos/</LI>
<LI>exp multicenter study/</LI>
<LI>16/28 OR</LI>
<LI>4 AND 15 AND 29</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-04-29 12:15:01 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-04-29 11:21:46 +0200" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-29 12:15:01 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>MESH alcohol related disorders</LI>
<LI>MESH alcohol withdrawal delirium</LI>
<LI>TX ((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy))</LI>
<LI>1 OR 2 OR 3</LI>
<LI>sodium oxybate [mesh]</LI>
<LI>TW ghb </LI>
<LI>TW gamma-hydroxybutyrate </LI>
<LI>TW gamma-aminobutyric acid</LI>
<LI>TW hydroxybutyrate</LI>
<LI>TW gamma hydrate</LI>
<LI>TW sodium</LI>
<LI>TW gamma hydroxybutyric acid</LI>
<LI>TW gamma-OH </LI>
<LI>TW 4-Hydroxybutyric</LI>
<LI>6/14 OR</LI>
<LI>MH Random Assignment/</LI>
<LI>MH Clinical Trials/</LI>
<LI>TW random*</LI>
<LI>TW placebo*</LI>
<LI>TW group*</LI>
<LI>TW (singl* or doubl* or tripl* or trebl*) and (mask* or blind*)</LI>
<LI>MH crossover design</LI>
<LI>TW crossover*</LI>
<LI>TW allocate*</LI>
<LI>TW assign*</LI>
<LI>16/25 OR</LI>
<LI>4 AND 15 AND 26</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-04-29 12:26:32 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-04-29 11:35:20 +0200" MODIFIED_BY="[Empty name]">Cochrane Library search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-29 12:26:32 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Alcohol-related disorders [mesh]</LI>
<LI>Substance withdrawal syndrome [mesh]</LI>
<LI>Alcohol-Induced disorders [mesh]</LI>
<LI>((alcohol*) near/2 (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy)):ti,ab</LI>
<LI>1 or 2 or 3 or 4</LI>
<LI>sodium oxybate [mesh]</LI>
<LI>ghb:ti,ab</LI>
<LI>gamma-hydroxybutyrate:ti,ab</LI>
<LI>gamma-aminobutyric acid:ti,ab</LI>
<LI>4-hydroxybutyrate:ti,ab</LI>
<LI>gamma hydrate:ti,ab</LI>
<LI>sodium:ti,ab</LI>
<LI>gamma hydroxybutyric acid:ti,ab</LI>
<LI>gamma-OH:ti.ab</LI>
<LI>4-Hydroxybutyric Acid:ti,ab</LI>
<LI>sodium oxybuty:ti,ab</LI>
<LI>sodium 4-hydroxybutyrate:ti,ab</LI>
<LI>sodium hydroxybutyrate.ti,ab</LI>
<LI>Hydroxybutyric Acid:ti,ab</LI>
<LI>Oxybate Sodium:ti,ab</LI>
<LI>6/20 OR</LI>
<LI>5 AND 21</LI>
</OL>
<P>For PsycINFO database we considered the differences in controlled vocabulary and syntax rules. For example in the searches the subject headings "ghb" and "alcohol-related disorders" are invalid; also the "limit to human" is not valid in PsycINFO.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>